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Abstract
Psychological and psychosocial interventions for cannabis
cessation in adults: a systematic review short report
Katy Cooper,* Robin Chatters, Eva Kaltenthaler and Ruth Wong
Health Economics and Decision Science, School of Health and Related Research,
University of Sheffield, Sheffield, UK
*Corresponding author k.l.cooper@sheffield.ac.uk
Background: Cannabis is the most commonly used illicit drug worldwide. Cannabis dependence is a
recognised psychiatric diagnosis, often diagnosed via the Diagnostic and Statistical Manual of Mental
Disorders criteria and the International Classification of Diseases, 10th Revision. Cannabis use is associated
with an increased risk of medical and psychological problems. This systematic review evaluates the use of
a wide variety of psychological and psychosocial interventions, such as motivational interviewing (MI),
cognitive–behavioural therapy (CBT) and contingency management.
Objective: To systematically review the clinical effectiveness of psychological and psychosocial interventions
for cannabis cessation in adults who use cannabis regularly.
Data sources: Studies were identified via searches of 11 databases [MEDLINE, EMBASE, Cochrane
Controlled Trials Register, Health Technology Assessment (HTA) database, Database of Abstracts of Reviews
of Effects, Cochrane Database of Systematic Reviews, NHS Economic Evaluation Database, PsycINFO,
Web of Science Conference Proceedings Citation Index, ClinicalTrials.gov and metaRegister of Current
Controlled Trials] from inception to February 2014, searching of existing reviews and reference tracking.
Methods: Randomised controlled trials (RCTs) assessing psychological or psychosocial interventions in
a community setting were eligible. Risk of bias was assessed using adapted Cochrane criteria and narrative
synthesis was undertaken. Outcomes included change in cannabis use, severity of cannabis dependence,
motivation to change and intervention adherence.
Results: The review included 33 RCTs conducted in various countries (mostly the USA and Australia).
General population studies: 26 studies assessed the general population of cannabis users. Across six
studies, CBT (4–14 sessions) significantly improved outcomes (cannabis use, severity of dependence,
cannabis problems) compared with wait list post treatment, maintained at 9 months in the one study with
later follow-up. Studies of briefer MI or motivational enhancement therapy (MET) (one or two sessions)
gave mixed results, with some improvements over wait list, while some comparisons were not significant.
Four studies comparing CBT (6–14 sessions) with MI/MET (1–4 sessions) also gave mixed results: longer
courses of CBT provided some improvements over MI. In one small study, supportive–expressive dynamic
psychotherapy (16 sessions) gave significant improvements over one-session MI. Courses of other types of
therapy (social support group, case management) gave similar improvements to CBT based on limited
data. Limited data indicated that telephone- or internet-based interventions might be effective.
Contingency management (vouchers for abstinence) gave promising results in the short term; however,
at later follow-ups, vouchers in combination with CBT gave better results than vouchers or CBT alone.
Psychiatric population studies: seven studies assessed psychiatric populations (schizophrenia, psychosis,
bipolar disorder or major depression). CBT appeared to have little effect over treatment as usual (TAU)
based on four small studies with design limitations (both groups received TAU and patients were referred).
Other studies reported no significant difference between types of 10-session therapy.
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Limitations: Included studies were heterogeneous, covering a wide range of interventions, comparators,
populations and outcomes. The majority were considered at high risk of bias. Effect sizes were reported in
different formats across studies and outcomes.
Conclusions: Based on the available evidence, courses of CBT and (to a lesser extent) one or two sessions
of MI improved outcomes in a self-selected population of cannabis users. There was some evidence that
contingency management enhanced long-term outcomes in combination with CBT. Results of CBT for
cannabis cessation in psychiatric populations were less promising, but may have been affected by provision
of TAU in both groups and the referred populations. Future research should focus on the number of CBT/MI
sessions required and potential clinical effectiveness and cost-effectiveness of shorter interventions.
CBT plus contingency management and mutual aid therapies warrant further study. Studies should consider
potential effects of recruitment methods and include inactive control groups and long-term follow-up.
TAU arms in psychiatric population studies should aim not to confound the study intervention.
Study registration: This study is registered as PROSPERO CRD42014008952.
Funding: The National Institute for Health Research HTA programme.
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Glossary
Bipolar disorder A mental disorder characterised by episodes of elevated mood alternating with episodes
of depression.
Cannabis withdrawal syndrome Symptoms following cannabis withdrawal, including dysphoric mood,
disturbed sleep and gastrointestinal symptoms.
Case management A strategy to improve the co-ordination and continuity of the delivery of services to
a patient.
Cognitive–behavioural therapy A therapy that aims to change the way the participant thinks
or behaves.
Contingency management Providing clients with tangible rewards (such as monetary vouchers)
to reinforce behaviour change (e.g. a reduction or cessation in drug taking).
Dual diagnosis The condition of suffering from a mental illness and a substance abuse problem.
Hyperemesis syndrome A disorder characterised by nausea, vomiting and abdominal pain, caused by
regular cannabis use.
Key working When a health professional works with the individual to ensure delivery and ongoing
review of care being received.
Major depressive disorder A mental disorder characterised by low mood, low self-esteem and loss of
interest in normally enjoyable activities.
Motivational enhancement therapy A variant of motivational interviewing that is manual based.
Motivational interviewing A person-centred approach that aims to improve motivation to change and
resolve ambivalence to change.
Mutual aid therapy Therapy in which people with similar experiences assist each other to overcome or
manage their issues (e.g. Self-Management and Recovery Training).
Nicotine replacement therapy The remedial administration of nicotine to the body by means other than
tobacco, to aid cessation of smoking tobacco.
Psychosis disorder Generic psychiatric term for a mental state involving a loss of contact with reality.
Relapse prevention Based on cognitive–behavioural therapy; enables clients to cope with high-risk
situations that may lead to drug taking.
Schizophrenia spectrum diagnosis Mental disorders with similar features to schizophrenia; may include
hallucinations, delusions, motivational loss and withdrawal.
Supportive–expressive dynamic psychotherapy Psychotherapy involving supportive techniques to put
patient at ease and expressive techniques to help understand role of drugs in feelings/behaviours and
other means of resolving problems.
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List of abbreviations
AO assessment only
ASI Addiction Severity Index
CBT cognitive–behavioural therapy
CI confidence interval
CPQ Cannabis Problems Questionnaire
DSM Diagnostic and Statistical Manual
of Mental Disorders
DSM-5 Diagnostic and Statistical Manual
of Mental Disorders-Fifth Edition
DSM-III-R Diagnostic and Statistical Manual
of Mental Disorders Three
(revised)
DSM-IV Diagnostic and Statistical Manual
of Mental Disorders-Fourth
Edition
HTA Health Technology Assessment
ICD-10 International Classification of
Diseases, 10th Revision
MET motivational enhancement
therapy
MI motivational interviewing
MPS Marijuana Problems Scale
NICE National Institute for Health and
Care Excellence
NRT nicotine replacement therapy
PCT person-centred therapy
PRISMA Preferred Reporting Items for
Systematic Reviews and
Meta-Analyses
RCQ Readiness to Change
Questionnaire
RCT randomised controlled trial
RR risk ratio
ScHARR School of Health and Related
Research
ScHARR-TAG School of Health and Related
Research Technology Assessment
Group
SD standard deviation
SDS Severity of Dependence Scale
TAU treatment as usual
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Plain English summary
Regular users of cannabis risk become dependent on the drug. Treatments aiming to reduce cannabisuse in regular users have focused on psychosocial and psychological interventions such as
cognitive–behavioural therapy (CBT), which aims to manage cannabis use by managing negative
behaviours through changing the way the participant thinks or behaves; motivational interviewing (MI),
which helps people change behaviour by resolving ambivalence and improving motivation; and
contingency management, voucher incentives for reductions in cannabis use. This systematic review
assesses which treatment (or combination of treatments) is most effective at reducing cannabis use.
Studies were of low quality and differed in the treatments they tested and the participants they recruited.
We divided studies into those assessing ‘general’ cannabis users and those assessing cannabis users who
also had a psychiatric condition. In the ‘general’ studies, CBT was more effective than no treatment in
six studies, but this effect was assessed long term in only one study. Results were mixed when CBT was
compared with brief MI and when brief MI was compared with no treatment. CBT with contingency
management was more effective than CBT alone in the long term. In studies in people with psychiatric
conditions, CBT showed limited benefit when compared with usual treatment; however, results were
difficult to interpret owing to study design. Future research should focus on the number of treatment
sessions required, effect of participant recruitment method on results (i.e. whether or not participants
volunteered), selection of appropriate measures to assess changes in cannabis use, use of no-treatment
control groups and long-term follow-up.
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Scientific summary
Background
Cannabis is the most commonly used illicit drug worldwide. Chronic cannabis use is often defined as use
on most days over a period of years. Cannabis dependence can develop from chronic use and is defined
as impaired control over use and difficulty in ceasing use. Cannabis dependence is a recognised psychiatric
diagnosis, often diagnosed via the Diagnostic and Statistical Manual of Mental Disorders criteria and the
International Classification of Diseases, 10th Revision. Cannabis use is associated with an increased risk
of medical and psychological problems. Research has looked into evaluating the use of a wide variety of
psychological and psychosocial interventions, such as motivational interviewing (MI), cognitive–behavioural
therapy (CBT) and contingency management.
Objectives
To systematically review the evidence for the clinical effectiveness of psychological and psychosocial
interventions for cannabis cessation in adults who use cannabis regularly, in the form of a Health
Technology Assessment (HTA) short report.
Methods
The systematic review included randomised controlled trials (RCTs) evaluating any psychological or
psychosocial intervention for cannabis reduction or cessation in adult regular users. Studies of drug
treatment (as intervention or comparator) were excluded. Studies were included if they involved all or
mostly adult participants (≥ 18 years). Studies involving users of a range of drugs were included if they
reported cannabis-related outcomes for the subgroup of regular cannabis users. Studies were excluded if
they were based within the criminal justice system or within inpatient or emergency department settings or
if the intervention was provided to partners/parents rather than the cannabis user. RCTs were identified
through literature searching of 11 databases in February 2014 and from existing studies and reviews. Data
were extracted by one researcher and checked by a second. Risk of bias was assessed using an adapted
version of Cochrane risk of bias assessment criteria. Narrative synthesis was used to analyse results,
subgrouped by intervention and comparator. Meta-analysis was not undertaken owing to heterogeneity in
interventions, comparators, outcomes and follow-up periods. Key outcomes included change in cannabis
use, severity of cannabis dependence, motivation to change and adherence to or attendance at the
intervention. Patient and public involvement (service user input) was used to refine the protocol (research
priorities and factors around implementation) and elements of the report (e.g. Plain English summary).
Results
The review included 33 RCTs conducted in a range of countries: the USA (13 studies), Australia (7),
Germany (3), Brazil (2), Canada (2), Switzerland (2), Denmark (1), Ireland (1) and multicountry (2).
The mean participant age was 29 years.
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General population studies
Twenty-six studies assessed the general population of cannabis users (7643 randomised participants).
Participants responded to advertisements in 16 studies and were referred for treatment in four studies,
whereas four studies used advertisements and referrals (not reported in two). Participants in 13 studies
were classed as having high baseline use/dependence and in 10 as low use (not reported in three). Risk of
bias was assessed as high in 18 studies and unclear in eight studies.
Six general population studies compared CBT (4–14 sessions) with wait list. CBT appeared significantly
better than wait list post treatment (in all five studies with data) on most outcomes (cannabis use,
severity of dependence, cannabis problems). Improved outcomes for CBT (6 sessions) over wait list
were maintained at 9 months post baseline in the one study reporting later follow-up. Four studies
comparing CBT (6–14 sessions) against shorter MI or motivational enhancement therapy (MET) (1–4 sessions)
gave mixed results, with two studies showing better results for CBT on most outcomes post treatment
and at 9–16 months, whereas two further studies showed few between-group differences. Both CBT and
MI gave significant improvements from baseline (three studies with data). One small study reported that
supportive–expressive dynamic psychotherapy (16 sessions) improved abstinence rates and symptom
severity post treatment significantly more than one-session MI. In addition, one study of CBT compared
with a social support group (10 sessions each) and another study of CBT compared with case management
(nine sessions each) both showed no significant differences between groups but all groups significantly
improved from baseline with changes maintained at 14–15 months. Three studies (one each) assessed
telephone-delivered CBT, internet-delivered CBT and internet counselling; all showed significant improvements
over wait list or education control on some outcomes (varied by study) post treatment and at 3 months.
Effect sizes from one study for post-treatment cannabis use outcomes were 0.4 to 1.1 (CBT vs. wait list),
0.4 to 0.5 (CBT vs. brief MI) and 0.3 to 0.6 (brief MI vs. wait list), and for severity of dependence were
0.9 (CBT vs. wait list), 0.4 to 0.5 (CBT vs. brief MI) and 0.3 (brief MI vs. wait list).
Ten general population studies assessing brief MI/MET (one or two sessions) compared with wait list or
assessment only (AO) gave mixed results. MI appeared significantly better than wait list/AO on some
outcomes but not others (cannabis use and dependence in most studies; cannabis problems in one study),
both post treatment (in all five studies with data) and at 3–9 months (in all seven studies). Similar results
were seen for three studies comparing brief MI against education controls.
Five general population studies assessed contingency management (monetary vouchers for abstinence).
During and immediately post treatment, both vouchers alone and CBT plus voucher incentives (contingency
management) gave better results than CBT or MET alone on some outcomes (in all three studies with data).
In one study, the odds ratios for continuous abstinence for ≥ 6 weeks was 6.0 [95% confidence interval (CI)
1.7 to 21.0] for vouchers alone compared with CBT and 4.1 (95% CI 1.2 to 14.4) for CBT plus voucher
incentives compared with CBT. However, at later follow-ups (14–15 months), positive results were maintained
for CBT plus vouchers but less so for vouchers alone (in two studies with data).
Psychiatric population studies
Seven studies assessed cannabis users with psychiatric conditions (525 randomised participants). Conditions
included schizophrenia, psychosis or bipolar disorder (two studies), schizophrenia spectrum diagnosis
(one study), psychosis (two studies) and major depression (two studies). Patients were referred for treatment
(four studies) or recruited via both referrals and advertisements (three studies). Participants in three studies
were classed as having high baseline use/dependence and in four as having low use. Risk of bias was
assessed as high in six studies and unclear in one study.
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Four studies assessed CBT (6–24 sessions) plus treatment as usual (TAU) compared with TAU alone. TAU
involved psychiatric treatment, including psychosocial interventions, in two studies and a self-help book on
substance abuse in one study. There were few significant between-group differences in any cannabis-related
outcomes post treatment, and none at 10–12 months (within four small studies with limited data), with
little change from baseline in either group (no change in two studies; change in cannabis use in one study).
Two studies reported no significant difference between different types of 10-session therapy: one compared
CBT, computer-delivered CBT and person-centred therapy; the other compared CBT and psychoeducation;
however, the latter reported significant improvements from baseline in both groups (limited data). A further
study reported improvements for 10-session CBT or computer-delivered CBT over single-session MI at
12 months’ follow-up on one outcome (daily cannabis use).
Subgroup analyses
Number of sessions
Longer courses of CBT appeared somewhat more effective than shorter courses of MI, but results were
mixed and this finding is not conclusive. This is based first on four studies directly comparing CBT
(6–14 sessions) with MI (1–4 sessions), in which two favoured CBT and two showed no difference; and,
second, on the fact that studies of CBT (4–14 sessions) compared with wait list showed slightly more
positive effects than studies of MI (one or two sessions) compared with wait list. Clinical effectiveness of
CBT over MI may have been attributable to treatment content, number of sessions, or both. There was
no clear effect of number of sessions on results, either within studies of CBT (4–14 sessions) compared
with wait list or within studies of MI (one or two sessions) compared with wait list.
Group or individual treatment
Twenty-seven studies provided individualised treatments, whereas three provided group treatment and two
compared group treatment with individual treatment. Limited comparisons suggested a slight advantage of
individual over group treatment, but this was based on extremely limited data.
High compared with low baseline cannabis use/dependence and participant age: studies with low baseline
use appeared slightly less likely to show significant differences on all outcomes than studies of high use,
but this difference was not substantial or conclusive. Mean age was similar across studies within most
intervention/comparator categories.
Discussion
Strengths
This review is inclusive in scope, including a wide range of studies, interventions and outcomes. Results
were analysed using narrative synthesis, in order to provide an overview of the direction of effects for each
population group (general vs. psychiatric) and each intervention/comparator category (such as CBT vs.
wait list) at different time points and to minimise loss of data.
Limitations and uncertainties
There was substantial heterogeneity between included studies in terms of their populations, interventions,
comparators, outcome measures and data format, and most studies were considered at high risk. Owing
to this heterogeneity, results were presented as an overview of outcomes reported per study and how
many of these outcomes showed a significant difference. Detailed numerical results per study group were
not presented in the main results section and meta-analysis was not undertaken. However, the narrative
synthesis approach was thought to provide benefits in terms of interpretability. Studies in languages other
than English were not included owing to time constraints.
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Generalisability of findings
The included studies utilised various recruitment methods, involving voluntary recruitment, referral by
a health-care professional, or both. The general population studies mostly used voluntary recruitment via
advertisement and may therefore reflect more motivated populations and may not be generalisable to
all cannabis users. In addition, the included studies recruited cannabis users with varying frequencies of
cannabis use at baseline.
Conclusions
Implications for service provision
Owing to the heterogeneity (of interventions, comparators, outcomes and populations) and high risk of
bias of the included studies, conclusions should be interpreted with caution. Based on the available
evidence, courses of CBT and (to a lesser extent) one or two sessions of MI improved outcomes in a
self-selected population of cannabis users. There is some evidence that CBT (6–14 sessions) may be more
effective than briefer MI interventions, although results were mixed. Contingency management may also
enhance long-term outcomes in combination with CBT. Results of CBT for cannabis cessation in psychiatric
populations were less promising, but may have been affected by provision of TAU in both groups and
the referred populations.
Suggested research priorities
The highest priority research area should be the investigation of the effects of number and frequency of
sessions; in particular, the effectiveness of shorter courses of therapy, either brief motivational interventions
(e.g. 1 or 2 sessions) or shorter courses of CBT (e.g. 4–6 sessions). It may also be useful to assess relative
cost-effectiveness of longer and shorter interventions. If shorter interventions are found to be as effective
as, or more effective than, longer interventions, such treatments could be made more widely available.
Combined CBT plus contingency management (vouchers for abstinence) may be worthy of further study.
In addition, mutual aid therapies and self-help groups (for which no RCTs were identified in this review)
may be worth investigating, as well as interventions such as nicotine replacement therapy in conjunction
with other treatments. Studies should report included interventions in sufficient detail to allow replication.
The effects of recruitment method (i.e. voluntary vs. referral) should be considered. In this review, most
studies used voluntary recruitment, with the psychiatric studies using referral. Future studies may wish to
align outcomes with existing studies when possible. The main classes of outcome in this review were level
of attendance, cannabis use (via a range of measures), severity of dependence and cannabis-related
problems. Trial methodology should be carefully considered. In populations with psychiatric conditions,
TAU arms should not confound the study intervention when possible. Studies should follow up patients
beyond treatment cessation and may wish to include an inactive control arm. Wait list controls with
long-term follow-up are also valuable; however, this needs to be balanced against ethical considerations
and acceptability to trial participants.
Study registration
This study is registered as PROSPERO CRD42014008952.
Funding
The National Institute for Health Research HTA programme.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxiv
Chapter 1 Background
Description of health problem
Overview of cannabis use
Cannabis use may be defined as acute (occasional) or chronic, with chronic use often defined as use
on most days over a period of years.1 Cannabis dependence can develop from chronic use and is
characterised by impaired control over use and difficulty in ceasing use.1 Cannabis dependence is a
recognised psychiatric diagnosis, often diagnosed via the Diagnostic and Statistical Manual of Mental
Disorders (DSM) criteria and the International Classification of Diseases, 10th Revision (ICD-10).2,3
Cannabis use has been found to exacerbate the symptoms of psychiatric disorders.4 In one study,
individuals who used cannabis regularly were found to be six times more likely to have a mood or anxiety
disorder.5 The term ‘dual diagnosis’ is used to describe individuals who have a mental health problem
and also are dependent on drugs (or alcohol).6
Epidemiology and prevalence
Cannabis is the most commonly used illicit drug worldwide.7 In one study reporting cannabis use in
European countries, use for 20 or more days per month ranged from 3.5% to 44.1%, with the figure
for the UK being 3.9%.8 In Australia, the prevalence of Diagnostic and Statistical Manual of Mental
Disorders-Fourth Edition (DSM-IV)-defined cannabis abuse in the general population over a 12-month
period has been estimated at 2.3%, whereas a national survey undertaken in the USA found that 6% of
individuals who used cannabis within a 1-year period met the DSM-IV criteria for cannabis dependence.9,10
This figure, as would be expected, varies by country. In Australia, 31.7% of individuals who used cannabis
more than five times in the past year met the criteria for a cannabis use disorder.11,12
Estimates for the prevalence of patients with a ‘dual diagnosis’ (substance abuse disorder and mental
health problems) vary across sources, but it is frequently reported that over 50% of patients with
mental health problems also have a substance abuse problem.6
Impact of health problem and prognosis
The impact of cannabis use on the individual can be classed as acute or chronic. Acute effects include
hyperemesis syndrome (recurrent nausea, vomiting and abdominal pain), impaired co-ordination and
performance, anxiety, suicidal ideations/tendencies, impaired attention and memory and psychotic
symptoms.2,13 Chronic effects include development of cannabis dependence, cognitive impairment,
pulmonary disease and malignancy of the oropharynx.2,13 There is increasing evidence to suggest the
presence of a cannabis withdrawal syndrome, with symptoms (such as dysphoric mood, disturbed sleep
and gastrointestinal symptoms) beginning during the first week and continuing for several weeks following
the start of abstinence.4 In a study by Budney et al.,14 47% of participants withdrawing from cannabis
reported four or more severe symptoms, including irritability, craving and nervousness; other symptoms
were less severe and included depression, restlessness and headaches.
In a cohort study comparing those seeking treatment with non-treatment seekers, those seeking treatment
reported increased cannabis use and more symptoms of dependence but a more positive attitude to
treatment.15 Even when an individual has sought treatment, recovery from substance dependence is
hampered by poor adherence to psychological and psychosocial treatments, with factors such as cognitive
defects, personality disorder and younger age predicting low treatment adherence.16
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Measurement of disease
Cannabis abuse and dependence is diagnosed using one or more assessment criteria, the most widely
used being DSM-IV and ICD-10. There are DSM-IV criteria for both substance dependence and abuse.3
Dependence is defined as tolerance (a need for increased amounts of the substance to achieve the
desired effect), withdrawal (either having withdrawal symptoms or taking another substance to avoid
withdrawal symptoms), taking substance in larger amounts than intended, and having persistent desire
or unsuccessful efforts to cut down use. Substance abuse is characterised by recurrent use resulting in
failure to fulfil obligations, recurrent use in hazardous situations, recurrent substance-related legal
problems and continued use despite recurrent social or interpersonal problems. For both sets of criteria,
individuals meeting three or more criteria within a 12-month period meet the diagnosis. In 2013,
the updated Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) criteria were
released.17 In the revised criteria, there is no distinction between abuse and dependence, but a spectrum
of substance use disorders.18
Current service provision
Relevant national guidelines
Guidance from the National Institute for Health and Care Excellence (NICE) states that pharmacological
interventions for chronic cannabis users are not well developed, so psychosocial interventions are the
mainstay of effective treatment.19 UK Department of Health guidelines for the treatment of chronic
users recommend that clinicians should consider motivational interventions in mild cases and structured
treatment with key working (when a health professional works with the individual to ensure delivery and
ongoing review of care being received) in more heavy users, whereas cognitive–behavioural therapy (CBT)
is recommended in cases with comorbid depression and anxiety.20 European best practice guidance,
produced by the European Monitoring Centre for Drugs and Drug Addiction, recommends the use of
multidimensional family therapy for regular cannabis users, while individual sessions of CBT are stated to
be possibly advantageous.21
Management of the condition
Providing treatment to chronic users of cannabis to reduce or cease their use is a relatively recent occurrence.
Until the 1980s, it was thought that chronic cannabis use did not lead to dependence and treatment was,
therefore, not required.22 Since then, research has looked into evaluating the use of a wide variety of
psychological and psychosocial interventions, such as motivational interviewing (MI), CBT and contingency
management (voucher incentives).12 There is limited evidence to suggest which of the many psychological
and psychosocial interventions are the most effective at reducing cannabis use.
A number of systematic reviews have been undertaken to assess the benefits of such interventions for regular
cannabis users, many of which included meta-analyses. However, they all had limited scope and, therefore,
did not assess all the available evidence, and several further studies have been published since. A review by
Denis et al.12 that excluded studies in populations dependent on drugs other than cannabis analysed six
randomised controlled trials (RCTs) via narrative synthesis, involving interventions such as CBT and motivational
enhancement therapy (MET), finding that CBT provided improved outcomes over brief interventions, whereas
voucher incentives were found to enhance treatment when used in combination with other therapies.
Dutra et al.23 undertook a meta-analysis, identifying five studies assessing the use of psychological treatments
(including case management, CBT and relapse prevention), finding a significant difference between outcomes
for cannabis use, with a mean effect size of 0.81 [95% confidence interval (CI) 0.25 to 1.36] when comparing
intervention treatments with control [which consisted of motivational enhancement, wait list control and
treatment as usual (TAU)]. Other reviews have focused on specific interventions to treat regular users of
cannabis. Tait et al.24 assessed the use of internet-delivered interventions, finding that such interventions
provided a significant decrease in cannabis use at post treatment [g (Hedges’ bias-corrected effect size)= 0.16,
95% CI 0.09 to 0.22; p-value< 0.001].
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Previous reviews have also sought to investigate the effectiveness of such interventions across the spectrum
of substance misuse, including alcohol and opioids. The review by Dutra et al.23 reported that treatments
incorporating both CBT and contingency management had the greatest effect sizes on substance use across a
range of substances including cocaine, opiates and cannabis (Cohen’s d 1.02), whereas the two treatments
alone had smaller effect sizes on the same group of substances (contingency management, Cohen’s d 0.58,
95% CI 0.25 to 0.90; CBT, Cohen’s d 0.28, 95% CI 0.06 to 0.51). In contrast, a review by Hunt et al.6
included RCTs of patients with a severe mental illness and substance dependence, finding no compelling
evidence to suggest a significant decrease in substance use when comparing CBT over TAU [two studies, risk
ratio (RR) 1.12, 95% CI 0.44 to 2.86] or of CBT plus MI over TAU (one study, mean difference 0.19, 95% CI
–0.22 to 0.60). The use of MI alone compared with usual treatment had positive effects on abstinence from
alcohol (one study, RR 0.36, 95% CI 0.17 to 0.75) but no effect on other substances (one study, RR –0.07,
95% CI –0.56 to 0.42).6 Other reviews have focused on specific interventions for ‘general’ substance misuse.
Magill et al.25 analysed 52 studies assessing the use of CBT (plus pharmacological treatments in a number of
studies) on a range of substance dependences (including alcohol, cannabis, opiates and cocaine), reporting a
small effect on the reduction of substance use for those studies reporting relevant outcomes (34 studies,
g= 0.108, 95% CI 0.051 to 0.165; p-value< 0.005). Wood et al.26 assessed the use of computer-delivered
interventions, finding that drug prevention programmes were effective at reducing use in the mid-term
(12 months) but not at post treatment. Mindfulness-based interventions have also been found to be effective
for substance abuse.27
Description of technology under assessment
Summary of interventions
This review assesses the clinical effectiveness of psychological and psychosocial interventions aimed at
assisting regular cannabis users to reduce or cease their use. Only interventions delivered in an outpatient
or community setting are included. A full list is provided in Chapter 3, Methods for reviewing effectiveness.
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Chapter 2 Definition of the decision problem
Decision problem
The aim of this assessment was to systematically review the evidence for the clinical effectiveness of
psychological and psychosocial interventions for cannabis cessation in adults who use cannabis regularly.
Population and setting
The relevant population included individuals ≥ 18 years of age who were regular users of cannabis and
had participated in a study providing treatment(s) for cannabis use in a community or outpatient setting.
Studies focusing specifically on treating cannabis users within prisons or the criminal justice system or
in inpatient settings were excluded. Inclusion was not restricted according to level of cannabis use
at baseline.
Interventions
Studies involving psychological and psychosocial interventions were included.
Relevant comparators
Comparators included other psychological and psychosocial interventions, waiting list control, TAU or no
treatment (comparisons with drug treatments were excluded).
Key outcomes
The key outcomes for this review were frequency and amount of cannabis use; severity of dependence;
motivation to change; level of cannabis-related problems (including medical and other); and attendance,
retention and dropout rates. The results of the review were also used to formulate recommendations
for future research.
Overall aims and objectives of assessment
The aims and objectives of this assessment were to systematically review the evidence for the clinical
effectiveness of psychological and psychosocial interventions for cannabis cessation in people who use
cannabis regularly.
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Chapter 3 Assessment of clinical effectiveness
A systematic review was undertaken to evaluate the effectiveness of psychological and psychosocialinterventions for cannabis cessation in adults who use cannabis regularly. The review was undertaken
in accordance with the general principles recommended in the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement (www.prisma-statement.org/).28 The completed PRISMA
checklist is presented in Appendix 1.
Methods for reviewing effectiveness
Identification of studies
The following electronic databases were searched to February 2014 for published and unpublished research
evidence: MEDLINE, EMBASE, Cochrane Controlled Trials Register, Health Technology Assessment (HTA)
database, Database of Abstracts of Reviews of Effects, Cochrane Database of Systematic Reviews, NHS
Economic Evaluation Database, PsycINFO and Web of Science Conference Proceedings Citation Index. This
included reference searching within relevant systematic reviews and included studies, contact with experts
and searching clinical trials databases (https://ClinicalTrials.gov and www.controlled-trials.com) and
relevant websites, including United Nations Office on Drugs and Crime (www.unodc.org), DrugScope
(www.drugscope.org.uk), American Society of Addiction Medicine (www.asam.org), National Institute on
Drug Abuse (www.drugabuse.gov), Canadian Centre on Substance Abuse (www.ccsa.ca), and Canadian
Society of Addiction Medicine (www.csam-smca.org).
The protocol for this review is available on request from the authors.
Inclusion and exclusion criteria
Population and setting
The relevant population included participants aged ≥ 18 years, who were regular users of cannabis.
Inclusion was not restricted according to level of cannabis use at baseline. The review focused on studies
in a community or outpatient setting.
Studies focusing on the following subpopulations were excluded:
l Studies in the setting of the criminal justice system, that is prisons, following release (on parole) or
within the court system.
l Studies for which the majority of participants were young people (< 18 years of age). In studies of
mixed age groups, data for subgroups aged ≥ 18 years were extracted if available or, if not, then the
study was included if ≥ 80% of participants were aged ≥ 18 years or, if these data were not available,
where the mean age of participants was ≥ 18 years, at baseline.
l Studies for which participants were treated in an inpatient setting, that is, the patient received
treatment for regular cannabis use while occupying a hospital ward, drug rehabilitation centre or
within an emergency department. Studies for which a subset of the participants were residing in
inpatient psychological treatment centres were included, provided that the cannabis intervention was
delivered as a standalone therapy rather than as an integrated part of psychological treatment.
l Studies in which the intervention, or a component of the intervention, was provided to participants
other than the cannabis user (e.g. parents or partners). An example of such an intervention is
Multidimensional Family Therapy.
l Studies in very specific subpopulations (such as indigenous communities or human immunodeficiency
virus patients).
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For studies covering abuse of more than one substance (i.e. poly-substance abuse, involving other drugs or
alcohol), the following approach was taken:
l Studies were included only if they reported cannabis-use outcomes (rather than any drug use) for the
subpopulation who were cannabis users.
l Studies were excluded if the entire study population was dependent on alcohol, cocaine, opiates,
amphetamines or receiving methadone maintenance (as these are quite specific populations and less
relevant to cannabis cessation).
Included interventions
Relevant interventions included a range of psychological and psychosocial interventions aiming to reduce
or cease cannabis use. Combinations of therapies were included. All possible modes of delivery were
included, including individual face-to-face or group sessions, plus interventions provided via the internet
or telephone. Relevant interventions included:
l CBT – an approach aiming to manage cannabis use by changing the way the participant thinks
or behaves29
l MI – a person-centred approach that aims to improve motivation to change and resolve ambivalence
to change30
l MET – a variant of MI that is manual based31
l relapse prevention therapy – based on CBT, enables clients to cope with high-risk situations that may
lead to drug taking32
l contingency management – providing patients with tangible rewards (such as monetary vouchers) in
return for a reduction or cessation in drug taking20
l case management – a strategy to improve the co-ordination and continuity of the delivery of services
to a patient33
l mutual aid therapy – therapy in which people with similar experiences assist each other to overcome
or manage their issues (e.g. Self-Management and Recovery Training)
l other psychological and psychosocial interventions as identified within the review process.
Comparators
Comparators included other psychological and psychosocial interventions, waiting list control, TAU or no
treatment. Studies comparing a psychosocial intervention with a drug treatment were excluded.
Outcomes
The key outcomes for this review were:
l frequency and intensity of cannabis use, via self-report, with or without confirmation by biological
analysis (urinalysis, hair/saliva analysis)
¢ number (%) of days used, time periods of use per day, amount per day
¢ number (%) reporting abstinence following intervention
l severity of drug-related problems [measured via the Addiction Severity Index (ASI)]34
l severity of dependence [measured via the Severity of Dependence Scale (SDS)]11
l stage of change or motivation/contemplation to change [e.g. as measured by the Readiness to Change
Questionnaire (RCQ)]31
l level of cannabis-related problems – medical problems, legal problems, social and family relations,
employment and support [assessed via questionnaires such as the Cannabis Problems Questionnaire
(CPQ)]35
l attendance, retention and dropout rates, measured as number of sessions attended or number (%)
completing whole treatment period
l recommendations for future research.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Included study types
Only RCTs were included in this review.
Excluded study types
The following study types were excluded:
l non-randomised studies
l narrative reviews, editorials, opinion pieces
l reports written in a language other than English or published as meeting abstracts, if insufficient
methodological details are reported in the abstract to allow critical appraisal of study quality and
extraction of study characteristics and key outcomes.
Data extraction strategy
Titles and abstracts of citations identified by the searches were screened for potentially relevant studies by
one reviewer and a 10% sample checked by a second reviewer (and a check for consistency undertaken).
Full texts were screened by two reviewers. One reviewer performed data extraction for each included
study. All numerical data were checked against the original article by a second reviewer and any
disagreements were resolved through discussion. When studies comprised duplicate reports (parallel
publications), the most recent and relevant report was used as the main source and additional reports
checked for extra information. Excluded studies were tabulated (see Appendix 3).
Methods of data synthesis
Data were analysed via a narrative synthesis. As described by Popay et al.,36 this method is based around
grouping and tabulating the data in meaningful clusters, allowing results to be summarised (in the form
of text and tables) to provide an overview of the direction of effect for each relevant subgroup. Within
this review, studies were first divided into two main population subgroups (general cannabis users and
those with a major psychiatric condition). Second, studies were categorised according to their intervention
and comparison groups (e.g. CBT vs. wait list, CBT vs. MI, etc.). Third, results were tabulated for two key
time points (post treatment and later follow-up). Within each study, outcomes at each time point were
categorised according to whether or not they were significantly different between groups or between
baseline and follow-up. Finally, summary tables were populated for each intervention/comparison.
Outcomes across studies at each time point were summarised as being mainly significant, mainly not
significant or mixed.
There was substantial heterogeneity between studies in terms of populations, interventions, comparators,
outcome measures reported and statistics reported. To increase clarity, the main results of this review
are presented in the form of an overview of the outcomes reported per study and how many showed a
significant difference, as described above. Detailed numerical results per study group are not presented in
the main results section, but are provided in Appendix 4 for reference. Meta-analysis was not undertaken,
as this would have required restricting each analysis to studies reporting the same outcome in a consistent
format with full data and it was felt that the broad results picture might have been lost.
Subgroup analyses were undertaken with regard to number of treatment sessions, group/individual
treatment, high/low cannabis use at baseline, recruitment method (referral vs. voluntary), participant age
and use of other substances (tobacco and alcohol) at baseline.
Quality assessment of included studies
Methodological quality of included RCTs was assessed using an adapted version of the Cochrane risk of
bias assessment criteria. This tool addresses specific domains, namely sequence generation, allocation
concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete
outcome data and selective outcome reporting.37 Outcome assessment was considered to be blinded if the
person assessing or interviewing the participants was blinded to group allocation (although participants
were not blinded and many of the data were self-reported). We made two adaptations to these criteria in
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order to aid quality assessment. First, we utilised the ‘5-and-20 rule’ for incomplete outcome data, as
proposed by Schulz and Grimes.38 Schulz and Grimes38 state that a lower than 5% loss in participants
probably leads to little bias, while a greater than 20% loss potentially poses serious threats to validity. We
therefore defined < 5% attrition as ‘low risk’, between 5% and 20% attrition as ‘intermediate risk’ and
> 20% attrition as ‘high risk’. Attrition was defined as the percentage of patients not followed up at the
final time point reported. The second adaptation we made to the Cochrane criteria was to add an ‘overall
risk’ criterion, aiming to summarise the overall risk of studies. We categorised studies as low risk, high
risk or unclear risk, determined using the following criteria. Low risk was allocated to studies where
randomisation, allocation concealment, blinded outcome assessment and incomplete data were all
determined to be low risk. High risk was allocated to studies deemed to have undertaken inadequate
randomisation (self-selection, sequential patients, odd and even), and/or when allocation was not
concealed, and/or when incomplete data were deemed to be high risk. Unclear risk was allocated to
all other studies.
Patient and public involvement
In order to seek patient and public input into the review, we recruited a service user through liaison with
the project’s clinical advisors, who was currently acting as a ‘service ambassador’ within their treatment
service (an individual who has completed a treatment regime, ceased their primary substance use and
is now involved in supporting patients at the treatment centre).
A short ‘briefing document’ using non-academic language was developed (see Appendix 5) in order to
introduce the individual to the research. The briefing document included sections describing the basic
principles of a systematic review, the general area in which the research is being undertaken (i.e.
psychological/psychosocial treatments for regular users of cannabis) and the input required from the
service user. The service user was compensated for the time spent at meetings and for travel expenses.
The review team met with the service user twice. The first meeting was scheduled once the protocol had
been written. The service user provided valuable input into the following areas of the protocol:
l an additional intervention not already identified in the protocol (mutual aid therapy)
l two additional outcome measures that were felt to be important (daily time periods of cannabis use
and contemplation to change)
l general approval of the focus of the review.
The review team then met with the service user after the draft report had been written, when the service
user had the following inputs:
l suggested amendments to the plain English summary
l reviewed the suggested research priorities
l reviewed the section describing factors relevant to the NHS.
Results
Quantity of research available
The searches identified 1087 citations (1079 via database searches and eight via other sources). Of these,
919 citations were excluded at the title/abstract stage and 168 full-text articles were screened. Of
these, 126 were excluded: 65 did not include relevant outcomes, 41 evaluated irrelevant populations,
nine were not RCTs, five did not involve a relevant intervention, three detailed a non-relevant secondary
analysis or study characteristic and three were not in English (excluded studies are listed in Appendix 3).
In total, 42 articles relating to 33 RCTs were included in this review. The PRISMA flow chart is shown
in Figure 1.
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NIHR Journals Library www.journalslibrary.nihr.ac.uk
10
All titles and abstracts were screened for inclusion by one reviewer and a check for consistency was
undertaken. A second reviewer screened approximately 10% of the references (n= 100) during the initial
screening stage. No discrepancies were found.
Characteristics of included studies
The 33 studies included in this review were undertaken in a range of countries: the USA (13 studies39–51),
Australia (seven studies52–58), Germany (three studies59–61), Brazil (two studies62,63), Canada (two studies64,65),
Switzerland (two studies66,67), Denmark (one study68), Ireland (one study69) and worldwide (two studies,
one utilising internet-based interventions70 and the other undertaken in a number of locations worldwide71)
(Tables 1 and 2).
Records screened –  title
and/or abstract
(n = 1087)
Full-text articles assessed
for eligibility
(n = 168) 
Full-text articles excluded, with reasons
(n = 126)
• No relevant outcomes, n = 65
• Not relevant population, n = 41
• Not RCT, n = 9
• Not relevant intervention, n = 5
• Study characteristics or secondary
   analysis, n = 3
• Not in English, n = 3
Included in narrative synthesis
(n = 42 articles relating to 33 RCTs)
Included in the data synthesis
(n = 33 RCTs)
Records excluded at title/abstract stage
(n = 919)
Records identified
through database
searching
(n = 1079)
Additional records
identified through
other sources
(n = 8)
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o
n
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FIGURE 1 Study selection process: PRISMA flow diagram.
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TABLE 1 Characteristics of included studies: general population studies
Study (country, mode
of recruitment)
Interventions
(number of sessions)
Number of
cannabis
users
Inclusion
criteria:
age (years)
Mean age
at BL (years)
(range)
Level of cannabis
use/dependencea
Babor 200439 and Litt
200572 (USA, voluntary
and referral)
CBT/MET/CaseM (9);
MET (2); wait list
450 ≥ 18 36 (18–62) High use: DSM-IV
cannabis dependence;
cannabis used ≥ 40 out
of 90 days
Budney 201142 and
ClinicalTrials.gov
201373 (USA, voluntary)
CBT/MET/voucher (9);
computer-delivered
CBT/MET+ brief
therapist+ voucher (9);
MET (2)
45 18–65 35 (NR) High use: DSM-IV
cannabis abuse or
dependence and used
cannabis ≥ 40 of
previous 90 days
Budney 200641 (USA,
voluntary and referral)
CBT (14); CBT/
vouchers (14);
vouchers
60 ≥ 18 33 (NR) High use: MET DSM-IV
cannabis dependence
and used cannabis in
past 30 days
Budney 200040 and
Moore 200374 (USA,
voluntary)
CBT/MET (14);
MET (4); CBT/MET/
vouchers (14)
60 ≥ 18 32 (NR) High use: DSM-III-R
classification for
cannabis dependence;
cannabis use in
previous 30 days
Copeland 200153
(Australia, voluntary)
CBT (6); MI (1);
wait list
229 ≥ 18 32 (NR) High use: DSM-IV
cannabis dependence
de Dios 201243
(USA, voluntary)
MI/meditation (2); AO 39 18–29 23 (NR) Low use: ≥ 3 times past
month
Fernandes 201062 (Brazil,
voluntary)
Tele-brief motivational
intervention (1) written
cannabis information
1744 NR 25 (11–NR) NR
Fischer 201275 and
Fischer 201364 (Canada,
voluntary)
Brief MI (1); written
cannabis information;
therapist general
health MI (1); written
general health
information
134 18–28 20 (NR) Low use: used for
> 1 year, at least 12 of
past 30 days
Gates 201255 (Australia,
voluntary)
Tele-CBT/MI (4);
wait list
160 ≥ 16 36 (NR) Low use: ≥ 1 use
cannabis in last month
Gmel 201367
(Switzerland, voluntary)
Brief MI (1); AO 378 19–20 20 (19–20) NR
Grenyer 199756
(Australia, NR)
SEDP (16); MI (1) 40 NR 34 (NR) High use: DSM-IV
cannabis dependence
Hoch 201460 (Germany,
referral)
CBT/MET/PPS (10);
wait list
385 ≥ 16 27 (16–63) Low use: ≥ 9 days/month
Hoch 201259 and
Hoch 200876 (Germany,
voluntary and referral)
CBT/MET/PPS (10);
wait list
122 ≥ 16 24 (16–44) High use: DSM-IV
cannabis dependence/
abuse 89%
Humeniuk 201271
(worldwide, referral)
Brief MI (1); wait list 395 16–62 31 (NR) NR
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Mean cannabis
use at BL
Additional
exclusion
criteria
Mean alcohol and
tobacco use at BL
Key outcomes
Cannabis
use
Severity of
dependence
Cannabis-
related
problems
Session
attendance
27 days/month Psychiatric
conditions;
other drug use
Total drinks in last
90 days: 47–59
Yes Yes Yes Yes
NR Other drug use NR Yes
26 days/month Psychiatric
conditions;
other drug use
Mean days alcohol use in
past 30 days= 6–8 days
Yes Yes Yes
23 days/month Psychiatric
conditions;
other drug use
Days of alcohol use past
30 days: 2.7–7.0 days
Yes Yes Yes Yes
NR Other drug use NR Yes Yes Yes Yes
18 days/month Psychiatric
conditions;
other drug use
NR Yes Yes
NR NR NR Yes
24 days/month NR NR Yes
NR Psychiatric
conditions;
other drug use
Nicotine 90-day use:
57.6–59. Alcohol: 90-day
use: 20.1–25.9
Yes Yes Yes Yes
7–9 days/month NR NR Yes
NR Other drug use NR Yes Yes
20 days/month Psychiatric
conditions;
other drug use
Alcohol: mean
0.2 litres/day. Tobacco:
78–82% used daily
Yes Yes Yes Yes
NR Psychiatric
conditions;
other drug use
Alcohol dependence:
30%
Yes Yes Yes
NR NR NR Yes
continued
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TABLE 1 Characteristics of included studies: general population studies (continued )
Study (country, mode
of recruitment)
Interventions
(number of sessions)
Number of
cannabis
users
Inclusion
criteria:
age (years)
Mean age
at BL (years)
(range)
Level of cannabis
use/dependencea
Jungerman 200763
(Brazil, NR)
CBT/MI/RP (4)
(3 months); CBT/MI/RP
(4) (1 month); wait list
160 ≥ 18 32 (18–58) Low use: ≥ 13 days/
month
Kadden 200744 and Litt
200877 (USA, voluntary)
CBT/MET (9);
CaseM (9); CBT/MET/
vouchers (9); vouchers
240 ≥ 18 33 (NR) High use: DSM-IV
cannabis dependence
Lee 201346 (USA,
referral)
Brief MI (1); AO 212 18–25 20 (NR) Low use: ≥ 5 days/month
Lee 201045 (USA,
referral)
Internet-based
personalised feedback
(1); AO
341 17–19 18 (NR) Low use: any use
Litt 201347 (USA,
voluntary)
CBT/MET/vouchers
(homework) (9);
CBT/MET/vouchers
(abstinence) (9);
CaseM (9)
215 ≥ 18 33 (NR) High use: DSM-IV
cannabis dependence
Rooke 201370
(worldwide, voluntary)
Internet-based CBT/MI
(6); internet-based
written cannabis
information
230 ≥ 18 31 (NR) Low use: ≥ 1 day/month
Sobell 200965 (Canada,
voluntary and referral)
CBT/MI (4) (group);
CBT/MI (4) (individual)
17 ≥ 18 32 (NR) Low use: ‘not severe
dependence’
Stein 201148 (USA,
voluntary)
MI (2); AO 332 18–24 21 (NR) Low use: ≥ 1 day/month
Stephens 200751
(USA, voluntary)
MI/personalised
feedback (1); cannabis
education (1); wait list
188 ≥ 18 32 (18–57) High use: ≥ 15 days/
month
Stephens 2000,50
Lozano 200678 and
DeMarce 200579
(USA, voluntary)
CBT/RP/social support
(14); MI (2); wait list
291 ≥ 18 34 (NR) High use: DSM-III-R
cannabis dependence
Stephens 199449
(USA, voluntary)
CBT/RP (10); social
support group (10)
212 ≥ 18 32 (18–65) High use: ≥ 17 days/
month
Tossmann 201161
(Germany, voluntary)
Internet-based
counselling; wait list
1292 NR 25 (NR) High use: ‘any use’,
92% DSM-IV cannabis
dependent at BL
AO, assessment only; BL, baseline; CaseM, case management; DSM-III-R, Diagnostic and Statistical Manual of Mental
Disorders Three (Revised); MET+brief therapist+ voucher, MET plus brief plus contingency management; NR, not reported;
PPS, psychosocial problem-solving; RP, relapse prevention; SEDP, supportive–expressive dynamic psychotherapy;
tele-CBT, telephone-delivered CBT.
a Level of cannabis use/dependence was classified as follows: ‘high use’: ≥ 80% of participants met DSM or International
Classification of Diseases criteria for cannabis dependence or abuse and/or inclusion criteria specified that all participants
used cannabis on at least 50% days over a specified time period. Anything else defined as ‘low use’.
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Mean cannabis
use at BL
Additional
exclusion
criteria
Mean alcohol and
tobacco use at BL
Key outcomes
Cannabis
use
Severity of
dependence
Cannabis-
related
problems
Session
attendance
26–28 days/month Psychiatric
conditions;
other drug use
Alcohol: 10–11% of
prior 90 days
Yes Yes Yes Yes
NR Psychiatric
conditions;
other drug use
ASI alcohol score 0.10 Yes Yes Yes Yes
16–17 days/month NR NR Yes Yes Yes
3 days/month NR NR Yes Yes
24 days/month Psychiatric
conditions;
other drug use
NR Yes Yes Yes
21 days/month Psychiatric
conditions;
other drug use
NR Yes Yes Yes
27 days/month Psychiatric
conditions;
other drug use
NR Yes
17 days/month Other drug use NR Yes Yes
26 days/month Psychiatric
conditions;
other drug use
Alcohol use on 1.8 days
per week
Yes Yes Yes Yes
25 days/month Psychiatric
conditions;
other drug use
NR Yes Yes Yes Yes
27 days/month Psychiatric
conditions;
other drug use
NR Yes Yes Yes
NR NR NR Yes Yes
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TABLE 2 Characteristics of included studies: psychiatric population studies
Study
(country, mode
of recruitment)
Interventions
(number of sessions)
Number of
cannabis users
Inclusion
criteria:
age (years)
Mean age
at BL (years)
(range)
Level of cannabis
use/dependencea
Baker 200652
(Australia, referral)
CBT/MI+ TAU (10); TAU 73 ≥ 15 29 (15–61) Low use:
≥ 4 days/month
Bonsack 201166
(Switzerland, referral)
CBT/MI+ TAU (6); TAU 62 18–35 26 (18–35) High use: 82%
cannabis dependent
Edwards 200654
(Australia, referral)
CBT/MI+ TAU (10);
psychoeducation
(non-cannabis)+ TAU (10)
47 15–29 21 (NR) Low use: 49% DSM-IV
cannabis dependent
Hjorthoj 201368 and
201280 (Denmark,
referral)
CBT/MI+ TAU (24); TAU 103 17–42 27 (NR) High use: ICD-10
cannabis dependence/
abuse
Kay-Lambkin 201158
(Australia, voluntary
and referral)
CBT/MI (10); computer-
delivered CBT/MI+ brief
therapist (10); PCT (10)
109 ≥ 16 40 (17–70) Low use:
≥ 4 days/month
Kay-Lambkin 200957
(Australia, voluntary
and referral)
CBT/MI (10); computer-
delivered CBT/MI+ brief
therapist (10); brief MI (1)
43 ≥ 16 35 (18–61) Low use:
≥ 4 days/month
Madigan 201369
(Ireland, voluntary and
referral)
CBT/MI (group) (12); TAU 88 16–65 28 (NR) High use: DSM-IV
cannabis dependence
BDI-II, Beck Depression Inventory II; BL, baseline; PCT, person-centred therapy.
a Level of cannabis use/dependence was classified as follows: ‘high use’: ≥ 80% of participants met DSM or International
Classification of Diseases criteria for cannabis dependence or abuse and/or inclusion criteria specified that all participants
used cannabis on at least 50% days over a specified time period.
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Mean cannabis
use at BL
Inclusion criteria:
psychiatric
condition
Additional
exclusion
criteria
Mean alcohol
and tobacco
use at BL
Key outcomes
Cannabis
use
Severity of
dependence
Cannabis-
related
problems
Session
attendance
5–8 days/month ICD-10 psychotic
disorder
NR NR Yes Yes
23 days/month ICD-10 psychotic
disorder
Other drug
use
NR Yes Yes Yes
8 days/month DSM-IV psychotic
disorder
NR 2.2% DSM-IV
diagnosed
alcohol
dependence
Yes Yes Yes
15 days/month ICD-10
schizophrenia
NR NR Yes Yes
NR DSM-IV major
depressive
disorder, BDI-II
≥ 17
Psychotic
conditions
NR Yes Yes
NR DSM-IV major
depressive
disorder, BDI-II
≥ 17
NR NR Yes Yes
NR DSM-IV
schizophrenia,
psychosis, major
depressive or
bipolar disorder
NR NR Yes Yes
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Population
General or psychiatric
The included studies can be broadly categorised into those that sought to treat the ‘general cannabis users
population’ (26 studies;39–51,53,55,56,59–63,65,67,70,71,75 see Table 1) and those that sought to treat patients with a
‘dual diagnosis’ (patients with both a psychiatric condition and cannabis use, seven studies;52,54,57,58,66,68,69
see Table 2). Among the psychiatric studies, two studies52,66 included participants with schizophrenia,
psychosis or bipolar disorder (via ICD-10 criteria), one study68 included those with schizophrenia spectrum
diagnosis (via ICD-10 criteria), two studies54,69 included those with psychosis (via DSM-IV criteria) and
two studies57,58 included those with major depressive disorder (via DSM-IV criteria and a score ≥ 17 on the
Beck Depression Inventory II).
The included studies recruited a total of 8168 participants; 7643 were involved in general population studies,
whereas 525 were recruited into the psychiatric studies (participant numbers were not reported in one study,52
in which the participant numbers at follow-up were used to calculate total number of participants). The studies
of the former grouping tended to restrict the inclusion of patients, with 15 studies39–41,43,44,47,49–51,55,59,60,63,65,70
excluding patients with a psychiatric condition and other drug dependencies and four studies42,48,53,56 excluding
only patients with other drug dependencies. One psychiatric study excluded participants who had other
drug dependences.66
Recruitment
In order to recruit participants, the studies treating the general population most frequently used voluntary
recruitment methods, that is, participants responded to advertisements (16 studies40,42–44,47–51,53,55,61,62,67,70,75),
with fewer studies employing a referral mechanism (four studies45,46,60,71) or a combination of voluntary
recruitment and referrals (four studies39,41,59,65); recruitment methods could not be ascertained for
two studies.56,63 Conversely, the psychiatric studies all employed referral mechanisms (four studies52,54,66,68)
or a combination of referral and voluntary recruitment methods (three studies57,58,69). Therefore, the
‘general population’ studies mostly involved self-selected participants who may have been more motivated
to cease use than the average cannabis user.
Age
The majority of studies employed participant age study inclusion criteria, bar three.56,61,62 Participants were
included if they were aged 18–19 years or over (19 studies39–44,46–51,53,63,65–67,70,75), aged 16–17 years or
over (nine studies45,55,57–60,68,69,71) or aged 15 years or over (two studies52,54). Twelve studies also included
an upper age limit; this was in the twenties (six studies43,46,48,54,67,75), thirties to forties (two studies66,68) or
sixties (three studies42,69,71), while one study used an age range of 17–19 years45 and one used a range of
19–20 years.67 At baseline, the mean age of participants across studies was 29 years (all studies, range for
mean age 18–40 years, median 32 years; general population studies, range 18–36 years, median 32 years;
psychiatric studies, range 21–40 years, median 28 years).
Cannabis use or dependence at baseline
Thirty of the included studies specified criteria for the level of cannabis use at study inclusion.39–61,63,65,66,68,69,70,75
These criteria varied by study, with eight studies44,47,53,56,65,68,69,71 utilising dichotomous criteria [patients
meeting the DSM-IV, Diagnostic and Statistical Manual of Mental Disorders Three (Revised) (DSM-III-R)
or ICD-10 criteria for cannabis dependence or cannabis abuse], 18 studies43,45,46,48–52,54,55,57–60,63,66,70,75 selecting
an inclusion point on a continuous scale of cannabis use (ranging from 1 to 20 or more days of use of
cannabis per month) and four studies39–42 using a combination of both. Therefore, we classified studies into
those for which the inclusion criteria for cannabis use or dependence were deemed to be ‘low’ and those for
which they were deemed to be ‘high’. ‘High use’ was defined as a study inclusion criterion or population
baseline measurement in which ≥ 80% of participants met the DSM or International Classification of Diseases
criteria for cannabis dependence or abuse, and/or an inclusion criterion specifying that all participants used
cannabis on at least 50% of days over a specified time period. Thirteen studies treating the general
population included participants with ‘high’ use39–42,44,47,49–51,53,56,59,61 and 10 with ‘low’ use,43,45,46,48,55,60,63,65,70,75
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and baseline use could not be determined for three studies.62,67,71 Of those treating the psychiatric population,
three studies66,68,69 included only participants with high use, whereas four52,54,57,58 included low-use participants.
Other substance use
Participants’ use of other substances at baseline was seldom reported by the studies; studies that
did report this did not do so in a consistent manner. Overall, 10 studies reported alcohol use at
baseline39–41,44,51,54,55,59,60,63 and two also reported tobacco use;55,60 the remaining 23 studies did not report
this baseline measurement. Of the studies reporting alcohol use, five reported the average proportion of
participants’ drinking days over a specified period,40,41,55,63,66 two reported average drinks per day over a
specified period,51,60 two reported the proportion of participants who were deemed to meet the DSM
criteria for alcohol dependence54,59 and one reported participants’ ASI score.39
Comparators
Of the 26 ‘general population’ studies, 11 tested two or more interventions (with no inactive control arm,
although some included an active control such as education),40–42,44,47,49,56,62,65,70,75 10 tested a single
intervention against an inactive control [wait list or assessment only (AO)]43,45,46,48,55,59–61,67,71 and five
tested more than one active intervention against an inactive control.39,50,51,53,63 The general population
studies utilised wait list (10 studies50,51,53,55,59–61,63,71) or AO (five studies43,45,46,48,67) as inactive controls. Of
the ‘psychiatric’ studies, four tested a single intervention against a TAU control52,66,68,69 and three tested
two or more active interventions with no inactive control.54,57,58 TAU consisted of antipsychotic medication
and psychiatric condition monitoring, plus self-help material in one study and a psychosocial intervention
in two studies.
Interventions
The included interventions varied considerably. Single interventions consisted of multiple and overlapping
components. In the following summary, we have classed studies by their ‘main’ intervention, which we
have defined as either CBT or MI or contingency management. If a study consists of multiple intervention
arms or multicomponent interventions consisting of CBT or MI, we have classed the ‘main’ intervention
as CBT. The majority of general population studies (15 studies39–42,44,47,49,50,53,55,59,60,63,65,70) evaluated CBT
as their main intervention, or a variation thereof. Of the 15 studies, three studies55,59,60 compared CBT with
a wait list control; eight40–42,44,47,49,65,70 compared CBT with MI, a variation of CBT or another intervention;
and four39,50,53,63 compared CBT with both a wait list control arm and another arm consisting of MI, a
variation of CBT or another intervention. Five of the 15 studies also assessed contingency management,
alone and/or in combination with CBT.40–42,44,47 Of the 15 studies, 12 assessed the use of therapist-delivered
CBT, whereas three42,55,70 assessed the use of computer- or telephone-delivered treatment (one42 of
which tested therapist-delivered CBT against computer-delivered). Duration of CBT treatment ranged
considerably, from 4 weeks63 to 1850 weeks. The majority of interventions involved weekly (or near weekly)
sessions, with the notable exceptions of Hoch et al.59 (two sessions per week over 5 weeks), one treatment
arm of Budney et al.40 (four sessions over 14 weeks) and Babor et al.39 (two arms: nine sessions over
12 weeks and two sessions over 5 weeks). Nine studies assessed the use of a motivational intervention
but not CBT;43,45,46,48,51,62,67,71,75 two45,62 of these assessed computer- or telephone-delivered treatment.
Two general population studies did not involve MI or CBT components; Tossman et al.61 provided
internet-based counselling, whereas Grenyer et al.56 provided supportive–expressive dynamic psychotherapy.
The psychiatric population studies evaluated the use of CBT (seven studies).52,54,57,58,66,68,69 Five studies
utilised therapist-delivered interventions,52,54,66,68,69 the remainder (two studies)57,58 assessed the use
of computer-delivered CBT compared with therapist-delivered CBT. Length of treatment varied: in four
studies treatment lasted 10 weeks,52,54,57,58 in one study 12 weeks69 and in two studies 24 weeks.66,68
All CBT sessions were delivered on a weekly basis, with the notable exception of Bonsack et al.66
(four to six sessions over 24 weeks).
No studies were found that assessed the efficacy of mutual aid therapy.
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Outcomes
All of the included RCTs measured the effect of the intervention(s) on participants’ cannabis use; however,
the way in which this was measured varied greatly by study. For example, studies measured point
abstinence rates, abstinence over a specified period, frequency of cannabis use per day over a specified
period and number of cannabis-using days over a specified period. Thirteen studies39,40,44,50,51,53–56,59,60,63,70
measured participants’ severity of cannabis dependence (measured via self-report using various
instruments, most frequently using the SDS or ASI).11,34 Fifteen studies39–41,44–47,49–51,53,55,60,63,66 measured
participants’ number of cannabis-related problems [measured using various instruments, most frequently
the Marijuana Problems Scale (MPS)].35 Twenty-five studies measured participants’ use of the intervention
or session attendance.39–41,43,44,47–55,57–61,63,66,68,69,70,77
Risk of bias in included studies
Table 3 summarises the risk of bias for each of the included studies. Most studies used an appropriately
generated randomisation sequence, with 21 studies being deemed ‘low risk’, 10 ‘unclear risk’ and two
‘high risk’. Allocation concealment followed a similar pattern. No studies blinded study participants to
group allocation and we deemed this form of blinding to be impossible for the interventions under review.
As many of the outcome measures were self-reported, outcomes were deemed to have been blinded if
the outcome assessors were blinded to group allocation. This form of blinding was poorly reported;
in 18 studies, blinding of outcome assessment was unclear or unreported.40,44–46,49,50,52,55,56,58–63,66,75,81
Participant attrition was well reported but high, ranging from 6% to 79% (mean 30.2%, median 25.5%);
22 studies were rated as high risk for this attribute (with attrition of > 20% at the final follow-up time
point). Regarding overall risk, 24 studies40,41,43,48,49,52–55,57–63,65,67–69,70,71,75,81 were deemed to be ‘high risk’,
in nine studies39,44–47,50,51,56,66 the risk was unclear and no studies were deemed to be ‘low risk’. In the
general population subgroup, 18 studies40,41,43,48,49,53,55,59–62,63,65,67,70,71,75,81 were deemed to be at high
risk of bias, whereas in eight studies39,44–47,50,51,56 the risk was unclear. In the psychiatric population studies,
six52,54,57,58,68,69 were deemed to be at high risk and in one study66 the risk was unclear. Twenty-one of the
studies40,41,43,48,49,53–55,57–63,65,67–69,75,81 were deemed to be at high risk owing to incomplete outcome data
(high level of attrition) and three studies52,70,71 were deemed to be at high risk owing to poor random
sequence generation or allocation concealment.
Assessment of effectiveness
Overview of effectiveness section
Results are presented for each intervention/comparator category (e.g. CBT vs. wait list, CBT vs. brief MI, etc.).
An overall summary of results is provided in Tables 4 and 5. This is followed by more detailed results for
each intervention/comparator category (see Tables 6–23). Owing to the large number of studies and the
variability in outcomes and data format, detailed numerical results are not presented here. Instead, this
section provides an overview of the outcomes reported per study and how many showed a significant
difference, both between intervention groups and in terms of changes from baseline, at different follow-up
time points. Full extracted data per study are provided in Appendix 4.
Outcomes reported
Outcomes reported in most studies could be classified into four main groups: cannabis use, severity of
dependence, cannabis-related problems and level of attendance or compliance with the intervention(s).
Cannabis use outcomes included point abstinence rates, abstinence over a specified period, number of
days using cannabis or number of days abstinent (over a specified period), amount of cannabis use per
day and number of periods of use per day (e.g. of four daily periods). For session attendance, seven
studies41,44,47,49,54,57,58 reported significance levels between study groups; this was non-significant in all cases.
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Subgroup analyses: effect of intervention and population characteristics
The effect of intervention and population characteristics on results was also examined to assess whether
or not any patterns could be observed in terms of which studies showed positive results. Findings are
described within each intervention/comparator category and an overview provided in Subgroup analyses:
effect of intervention and population characteristic.
Studies in general population of cannabis users
Cognitive–behavioural therapy compared with wait list control
Description of studies
Six studies39,50,53,59,60,63 (n= 1265 randomised, 997 followed up) compared CBT (4–14 sessions) with wait list
control (Tables 6 and 7). Session attendance ranged from 60% to 72% (not reported in three studies59,60,63).
Five studies39,53,59,60,63 provided individual CBT sessions and one50 provided group sessions. CBT interventions
also incorporated other strategies including case management (one study),39 psychosocial problem-solving
(two studies)59,60 and a social support group (one study).50 Participants were classified as having high baseline
use/dependence in four studies39,50,53,59 and low use/dependence in two studies.60,63 Two studies were
conducted in the USA,39,50 two in Germany,59,60 one in Australia53 and one in Brazil.63
Main results
Five studies39,50,59,60,63 reported post-treatment (5–18 weeks) outcomes. All five reported significantly better
results for CBT (4–14 sessions) than for wait list on most outcomes, including cannabis use (significant in all
five studies), severity of dependence (significant in four39,50,59,60 out of five studies) and cannabis problems
(significant in three39,50,60 out of four studies39,50,59,60 reporting this). In addition, four studies39,50,59,60 reported
change from baseline to post treatment; all four reported significant improvements from baseline on most
outcomes, for the CBT groups (two studies39,59) or for both the CBT and wait list groups (two studies50,60).
Effect sizes at 12 weeks (based on data from two studies39,60) ranged from 0.4 to 1.1 for cannabis use
outcomes and from 0.9 to 1.6 for severity of dependence.
Only one study53 reported between-group data at a later follow-up point than post treatment (because,
in most studies with a wait list comparison, the wait list group began treatment when other groups
completed theirs and so could not be followed for longer). This study reported significantly better results
for CBT (6 sessions) than wait list on most outcomes at 9 months post baseline (7.5 months after end of
treatment), including cannabis use, severity of dependence and cannabis problems. Three studies39,59,60
reported significant improvements from baseline to 6 months (two studies59,60) or 9 months (one study39),
for the CBT group (wait list groups were not followed for this long).
Effects of intervention characteristics
All six studies reported mainly positive findings so there were no clear differences in results according to
population or intervention differences.39,50,53,59,60,63 All durations of CBT (4–14 sessions) appeared effective;
there were slightly fewer significant effects in the study of four-session CBT,63 but this may have been
owing to the smaller number of participants in this study. The one study of group CBT50 (14 sessions)
had similar positive outcomes to the individual CBT studies.
Effects of population characteristics
In terms of baseline cannabis use/dependence, three studies classed as high use39,50,59 all showed significant
effects post treatment, while of the two studies classed as low use, one60 showed significant effects on
all outcomes and the other63 on some but not all outcomes. This may indicate slightly less effectiveness
in participants with lower baseline use, or may be simply a result of the smaller number of participants in
the latter study.63 Two studies50,53 used voluntary recruitment, one60 used referrals, and two39,59 used a
combination (for one63 this was not reported); all studies showed significant effects regardless of
recruitment method. Mean age ranged from 24 years to 36 years and there were no clear differences in
effects according to age.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
TA
B
LE
6
Su
m
m
ar
y
fo
r
C
B
T
co
m
p
ar
ed
w
it
h
w
ai
t
lis
t
(g
en
er
al
p
o
p
u
la
ti
o
n
)
C
o
m
p
ar
is
o
n
N
u
m
b
er
o
f
st
u
d
ie
s,
n
u
m
b
er
ra
n
d
o
m
is
ed
(n
u
m
b
er
fo
llo
w
ed
u
p
),
ca
te
g
o
ri
sa
ti
o
n
h
ig
h
n
,l
o
w
n
In
te
rv
en
ti
o
n
(n
se
ss
io
n
s)
C
o
m
p
u
te
r
(n
se
ss
io
n
s)
In
d
iv
id
u
al
o
r
g
ro
u
p
,
d
u
ra
ti
o
n
Po
st
-t
re
at
m
en
t
d
if
fe
re
n
ce
b
et
w
ee
n
g
ro
u
p
s
Po
st
-t
re
at
m
en
t
ch
an
g
e
fr
o
m
b
as
el
in
e
Fo
llo
w
-u
p
Fo
llo
w
-u
p
d
if
fe
re
n
ce
b
et
w
ee
n
g
ro
u
p
s
Fo
llo
w
-u
p
ch
an
g
e
fr
o
m
b
as
el
in
e
C
BT
vs
.
w
ai
t
lis
t
Si
x
st
ud
ie
s3
9 ,
50
,5
3 ,
59
,6
0 ,
63
(s
ee
Ta
bl
e
7)
,n
=
12
65
(9
97
),
hi
gh
4,
39
,5
0 ,
53
,5
9
lo
w
26
0 ,
63
C
BT
(4
–
14
se
ss
io
ns
),
so
m
e
C
BT
in
cl
ud
ed
:
C
as
eM
(1
),
PP
S
(2
),
so
ci
al
su
pp
or
t(
1)
W
ai
t
lis
t
Fi
ve
in
di
vi
du
al
,
on
e
gr
ou
p,
5–
18
w
ee
ks
Si
gn
ifi
ca
nt
di
ff
er
en
ce
:
fiv
e
st
ud
ie
s:
39
,5
0 ,
59
,6
0 ,
63
C
BT
si
gn
ifi
ca
nt
ly
be
tt
er
th
an
w
ai
t
lis
t
on
m
os
t
ou
tc
om
es
:
l
C
an
na
bi
s
us
e
(f
iv
e
of
fiv
e
st
ud
ie
s)
l
Se
ve
rit
y
of
de
pe
nd
en
ce
(f
ou
r3
9 ,
50
,5
9 ,
60
of
fiv
e
st
ud
ie
s)
l
C
an
na
bi
s
pr
ob
le
m
s
(t
hr
ee
39
,5
0 ,
60
of
fo
ur
st
ud
ie
s)
Si
gn
ifi
ca
nt
ch
an
ge
:
fo
ur
st
ud
ie
s:
39
,5
0 ,
59
,6
0
sig
ni
fic
an
ti
m
pr
ov
em
en
t
ba
se
lin
e
to
po
st
tr
ea
tm
en
to
n
m
os
t
ou
tc
om
es
,C
BT
gr
ou
p
(tw
o
st
ud
ie
s3
9 ,
50
)o
rb
ot
h
gr
ou
ps
(tw
o
st
ud
ie
s5
9 ,
60
)
6–
9
m
on
th
s
Si
gn
ifi
ca
nt
di
ff
er
en
ce
:
on
e
st
ud
y:
53
C
BT
-6
si
gn
ifi
ca
nt
ly
be
tt
er
th
an
w
ai
t
lis
t
on
m
os
t
ou
tc
om
es
at
9
m
on
th
s:
l
C
an
na
bi
s
us
e
l
Se
ve
rit
y
of
de
pe
nd
en
ce
l
C
an
na
bi
s
pr
ob
le
m
s
Si
gn
ifi
ca
nt
ch
an
ge
:
th
re
e
st
ud
ie
s:
39
,5
9 ,
60
si
gn
ifi
ca
nt
im
pr
ov
em
en
ts
on
m
os
to
ut
co
m
es
in
C
BT
gr
ou
p
fr
om
ba
se
lin
e
to
6
m
on
th
s
(tw
o
st
ud
ie
s5
9 ,
60
)
or
to
9
m
on
th
s
(o
ne
st
ud
y3
9 )
C
as
eM
,
ca
se
m
an
ag
em
en
t;
C
BT
-6
,
si
x-
se
ss
io
n
C
BT
;
PP
S,
ps
yc
ho
so
ci
al
pr
ob
le
m
-s
ol
vi
ng
.
DOI: 10.3310/hta19560 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 56
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Cooper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
27
TA
B
LE
7
R
es
u
lt
s
p
er
st
u
d
y
fo
r
C
B
T
vs
.w
ai
t
lis
t
(g
en
er
al
p
o
p
u
la
ti
o
n
)
St
u
d
y,
co
u
n
tr
y,
ca
n
n
ab
is
u
se
,
re
cr
u
it
m
en
t,
m
ea
n
ag
e
(r
an
g
e)
In
te
rv
en
ti
o
n
(n
u
m
b
er
o
f
se
ss
io
n
s)
(m
ea
n
n
u
m
b
er
o
f
se
ss
io
n
s
at
te
n
d
ed
),
n
u
m
b
er
ra
n
d
o
m
is
ed
(f
o
llo
w
ed
u
p
)
C
o
m
p
u
te
r,
n
u
m
b
er
ra
n
d
o
m
is
ed
(f
o
llo
w
ed
u
p
)
In
d
iv
id
u
al
o
r
g
ro
u
p
,
d
u
ra
ti
o
n
Po
st
-t
re
at
m
en
t
d
if
fe
re
n
ce
b
et
w
ee
n
g
ro
u
p
s
Po
st
-t
re
at
m
en
t
ch
an
g
e
fr
o
m
b
as
el
in
e
Fo
llo
w
-u
p
Fo
llo
w
-u
p
d
if
fe
re
n
ce
b
et
w
ee
n
g
ro
u
p
s
Fo
llo
w
-u
p
ch
an
g
e
fr
o
m
b
as
el
in
e
Ba
bo
r
20
04
39
an
d
Li
tt
20
05
72
(M
TP
),
U
SA
,
hi
gh
us
e
(D
SM
-IV
10
0%
),
vo
lu
nt
ar
y
+
re
fe
rr
al
,
36
ye
ar
s
(1
8–
62
ye
ar
s)
C
BT
/M
ET
/C
as
eM
(9
)
(6
.5
),
n
=
15
6
(1
33
)
W
ai
t
lis
t,
n
=
14
8
(1
37
)
In
di
vi
du
al
,
12
w
ee
ks
Si
gn
ifi
ca
nt
di
ff
er
en
ce
:
l
D
ay
s
us
ed
(d
=
1.
14
)
l
%
ab
st
in
en
t
l
Jo
in
ts
pe
r
da
y
(d
=
0.
43
)
l
Pe
rio
ds
us
e
pe
r
da
y
(d
=
0.
91
)
l
D
ep
en
de
nc
e
sy
m
pt
om
s
(D
SM
-IV
)
(d
=
0.
9)
l
A
bu
se
sy
m
pt
om
s
(D
SM
-IV
)
(d
=
0.
63
)
l
C
an
na
bi
s
pr
ob
le
m
s
(M
PS
)
(p
-v
al
ue
s
N
R)
Si
gn
ifi
ca
nt
ch
an
ge
:
l
A
ll
ou
tc
om
es
(C
BT
)
9
m
on
th
s
Si
gn
ifi
ca
nt
ch
an
ge
:
l
A
ll
ou
tc
om
es
(C
BT
)
C
op
el
an
d
20
01
,5
3
A
us
tr
al
ia
,
hi
gh
us
e
(D
SM
-IV
96
%
),
vo
lu
nt
ar
y,
32
ye
ar
s
(≥
18
ye
ar
s)
C
BT
(6
)
(4
.2
),
n
=
78
(5
8)
W
ai
t
lis
t,
n
=
69
(5
1)
In
di
vi
du
al
,
6
w
ee
ks
9
m
on
th
s
Si
gn
ifi
ca
nt
di
ff
er
en
ce
:
l
%
ab
st
in
en
t,
p
=
0.
05
l
A
m
ou
nt
pe
r
da
y,
p
=
0.
02
l
SD
S,
p
<
0.
00
1
l
C
an
na
bi
s
pr
ob
le
m
s
(C
PQ
),
p
<
0.
00
1
N
o
si
gn
ifi
ca
nt
di
ff
er
en
ce
:
l
D
ay
s
ab
st
in
en
t,
p
=
N
S
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
St
u
d
y,
co
u
n
tr
y,
ca
n
n
ab
is
u
se
,
re
cr
u
it
m
en
t,
m
ea
n
ag
e
(r
an
g
e)
In
te
rv
en
ti
o
n
(n
u
m
b
er
o
f
se
ss
io
n
s)
(m
ea
n
n
u
m
b
er
o
f
se
ss
io
n
s
at
te
n
d
ed
),
n
u
m
b
er
ra
n
d
o
m
is
ed
(f
o
llo
w
ed
u
p
)
C
o
m
p
u
te
r,
n
u
m
b
er
ra
n
d
o
m
is
ed
(f
o
llo
w
ed
u
p
)
In
d
iv
id
u
al
o
r
g
ro
u
p
,
d
u
ra
ti
o
n
Po
st
-t
re
at
m
en
t
d
if
fe
re
n
ce
b
et
w
ee
n
g
ro
u
p
s
Po
st
-t
re
at
m
en
t
ch
an
g
e
fr
o
m
b
as
el
in
e
Fo
llo
w
-u
p
Fo
llo
w
-u
p
d
if
fe
re
n
ce
b
et
w
ee
n
g
ro
u
p
s
Fo
llo
w
-u
p
ch
an
g
e
fr
o
m
b
as
el
in
e
H
oc
h
20
14
60
(C
A
N
D
IS
-II
),
G
er
m
an
y,
lo
w
us
e
(IC
D
-1
0
56
%
),
re
fe
rr
al
,
27
ye
ar
s
(1
6–
63
ye
ar
s)
C
BT
/M
ET
/P
PS
(1
0)
(N
R)
,
n
=
25
5
(1
66
)
W
ai
t
lis
t,
n
=
13
0
(1
06
)
In
di
vi
du
al
,
12
w
ee
ks
Si
gn
ifi
ca
nt
di
ff
er
en
ce
:
l
%
ab
st
in
en
t
l
A
m
ou
nt
pe
r
w
ee
k
l
SD
S
(d
=
–
0.
6,
95
%
C
I
–
1.
2
to
0.
2)
l
N
um
be
ro
fd
ep
en
de
nc
e
sy
m
pt
om
s
(d
=
–
0.
9,
95
%
C
I–
1.
1
to
–
0.
5)
l
C
an
na
bi
s
pr
ob
le
m
s
(C
PQ
)
(d
=
–
0.
7,
95
%
C
I–
1.
3
to
0.
2)
l
C
an
na
bi
s
pr
ob
le
m
s
(C
U
PI
T)
(A
ll
p
<
0.
00
1)
(d
=
–
0.
7,
95
%
C
I–
2.
9
to
2.
1)
Si
gn
ifi
ca
nt
ch
an
ge
:
l
%
ab
st
in
en
t
l
A
m
ou
nt
pe
r
w
ee
k
l
Se
ve
rit
y
de
pe
nd
en
ce
l
N
um
be
ro
f
de
pe
nd
en
ce
sy
m
pt
om
s
l
C
an
na
bi
s
pr
ob
le
m
s
6
m
on
th
s
Si
gn
ifi
ca
nt
ch
an
ge
:
l
%
ab
st
in
en
t
l
A
m
ou
nt
pe
r
w
ee
k
l
Se
ve
rit
y
de
pe
nd
en
ce
l
N
um
be
r
of
de
pe
nd
en
ce
sy
m
pt
om
s
l
C
an
na
bi
s
pr
ob
le
m
s
(A
ll
gr
ou
ps
ex
ce
pt
am
ou
nt
/w
ee
k,
C
BT
on
ly
)
(D
at
a
fo
r
C
BT
on
ly
)
H
oc
h
20
12
59
an
d
H
oc
h
20
08
76
(C
A
N
D
IS
),
G
er
m
an
y,
hi
gh
us
e
(D
SM
-IV
89
%
),
vo
lu
nt
ar
y
+
re
fe
rr
al
,
24
ye
ar
s
(1
6–
44
ye
ar
s)
C
BT
/M
ET
/P
PS
(1
0)
(N
R)
,
n
=
90
(7
9)
W
ai
t
lis
t,
n
=
32
(3
1)
In
di
vi
du
al
,
5–
8
w
ee
ks
Si
gn
ifi
ca
nt
di
ff
er
en
ce
:
l
%
ab
st
in
en
t,
p
<
0.
01
l
A
m
ou
nt
pe
r
w
ee
k,
p
=
0.
00
8
l
Se
ve
rit
y
of
de
pe
nd
en
ce
(A
SI
),
p
<
0.
00
1
(d
=
–
1.
58
)
Si
gn
ifi
ca
nt
ch
an
ge
:
l
A
m
ou
nt
pe
r
w
ee
k,
p
=
0.
00
1
(C
BT
),
p
=
0.
51
6
(w
ai
t
lis
t)
l
Se
ve
rit
y
de
pe
nd
en
ce
,
p
<
0.
00
1
(C
BT
),
p
=
0.
00
2
(w
ai
t)
6
m
on
th
s
Si
gn
ifi
ca
nt
ch
an
ge
:
l
A
m
ou
nt
pe
r
w
ee
k,
p
=
0.
01
5
l
Se
ve
rit
y
of
de
pe
nd
en
ce
,
p
<
0.
00
1
(d
at
a
fo
r
C
BT
on
ly
)
co
nt
in
ue
d
DOI: 10.3310/hta19560 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 56
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Cooper et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
29
TA
B
LE
7
R
es
u
lt
s
p
er
st
u
d
y
fo
r
C
B
T
vs
.w
ai
t
lis
t
(g
en
er
al
p
o
p
u
la
ti
o
n
)
(c
o
n
ti
n
u
ed
)
St
u
d
y,
co
u
n
tr
y,
ca
n
n
ab
is
u
se
,
re
cr
u
it
m
en
t,
m
ea
n
ag
e
(r
an
g
e)
In
te
rv
en
ti
o
n
(n
u
m
b
er
o
f
se
ss
io
n
s)
(m
ea
n
n
u
m
b
er
o
f
se
ss
io
n
s
at
te
n
d
ed
),
n
u
m
b
er
ra
n
d
o
m
is
ed
(f
o
llo
w
ed
u
p
)
C
o
m
p
u
te
r,
n
u
m
b
er
ra
n
d
o
m
is
ed
(f
o
llo
w
ed
u
p
)
In
d
iv
id
u
al
o
r
g
ro
u
p
,
d
u
ra
ti
o
n
Po
st
-t
re
at
m
en
t
d
if
fe
re
n
ce
b
et
w
ee
n
g
ro
u
p
s
Po
st
-t
re
at
m
en
t
ch
an
g
e
fr
o
m
b
as
el
in
e
Fo
llo
w
-u
p
Fo
llo
w
-u
p
d
if
fe
re
n
ce
b
et
w
ee
n
g
ro
u
p
s
Fo
llo
w
-u
p
ch
an
g
e
fr
o
m
b
as
el
in
e
Ju
ng
er
m
an
20
07
,
63
Br
az
il,
lo
w
us
e
(≥
13
da
y/
m
on
th
),
N
R,
32
ye
ar
s
(1
8–
58
ye
ar
s)
C
BT
/M
I/R
P
(4
)
(N
R)
,
n
=
52
(2
7)
W
ai
t
lis
t,
n
=
52
(3
5)
In
di
vi
du
al
,
12
w
ee
ks
Si
gn
ifi
ca
nt
di
ff
er
en
ce
:
l
D
ay
s
us
ed
,
p
=
0.
00
02
l
Pe
rio
ds
us
e
pe
r
da
y,
p
=
0.
00
4
l
Jo
in
ts
pe
rd
ay
,p
=
0.
00
5
l
D
ep
en
de
nc
e
sy
m
pt
om
s
(D
SM
-II
I),
p
=
0.
01
8
N
o
si
gn
ifi
ca
nt
di
ff
er
en
ce
:
l
Se
ve
rit
y
of
de
pe
nd
en
ce
(A
SI
),
p
=
0.
29
2
l
C
an
na
bi
s
pr
ob
le
m
s
(M
PS
),
p
=
0.
16
St
ep
he
ns
20
00
,5
0
Lo
za
no
20
06
78
an
d
D
eM
ar
ce
20
05
,7
9
U
SA
,
hi
gh
us
e
(D
SM
-II
I-R
98
%
),
vo
lu
nt
ar
y,
34
ye
ar
s
(≥
18
ye
ar
s)
C
BT
/R
P/
so
ci
al
su
pp
or
t
gr
ou
p
(1
4)
(8
.4
),
n
=
11
7
(9
5)
W
ai
t
lis
t,
n
=
86
(7
9)
G
ro
up
,
18
w
ee
ks
Si
gn
ifi
ca
nt
di
ff
er
en
ce
:
l
D
ay
s
us
ed
,
p
<
0.
00
1
l
Pe
rio
ds
us
e
pe
r
da
y,
p
<
0.
00
1
l
%
ab
st
in
en
t,
p
<
0.
00
1
l
N
um
be
r
of
de
pe
nd
en
ce
sy
m
pt
om
s
(M
D
S)
,
p
<
0.
00
1
l
C
an
na
bi
s
pr
ob
le
m
s,
p
<
0.
00
1
Si
gn
ifi
ca
nt
ch
an
ge
:
l
A
ll
ou
tc
om
es
(p
<
0.
00
1,
al
lg
ro
up
s)
C
A
N
D
IS
,
C
A
N
na
bi
s
D
IS
or
de
rs
;
C
as
eM
,
ca
se
m
an
ag
em
en
t;
C
U
PI
T,
Th
e
C
an
na
bi
s
U
se
Pr
ob
le
m
s
Id
en
tif
ic
at
io
n
Te
st
;
M
TP
,
M
ar
iju
an
a
Tr
ea
tm
en
t
Pr
oj
ec
t;
N
R,
no
t
re
po
rt
ed
;
N
S,
no
t
si
gn
ifi
ca
nt
;
PP
S,
ps
yc
ho
so
ci
al
pr
ob
le
m
-s
ol
vi
ng
;
RP
,
re
la
ps
e
pr
ev
en
tio
n.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
Cognitive–behavioural therapy or psychotherapy compared with brief
motivational interviewing
Description of studies
Four studies39,40,50,53 (n= 707 randomised, 581 followed up) compared CBT (6–14 sessions) with brief MI/MET
(1–4 sessions) (Tables 8 and 9). Three studies39,40,53 provided individual CBT sessions, whereas one50
compared group CBT with individual MET. CBT interventions also included case management (one study)39
and a social support group (one study).50 One further study, reported only in abstract form, compared
supportive–expressive dynamic psychotherapy (16 sessions, not reported whether individual or group) with
brief MI (1 session).56 Attendance within the CBT or psychotherapy arm of the studies ranged from 60%
to 72% (not reported in two studies40,56). Owing to the brief nature of the MI arms, only one study39
reported attendance for this intervention (mean 1.6 sessions attended from a total of 2). Participants were
classified as having high baseline use in all five studies. Three studies were conducted in the USA39,40,50 and
two in Australia.53,56
Main results
Overall, the comparison of longer durations of CBT with brief MI/MET showed mixed results; however,
both interventions provided improvements from baseline. Three CBT studies reported between-group
data post treatment (at 12–18 weeks).39,40,50 Of these, one study39 reported that nine-session CBT was
significantly better than two-session MET on most outcomes (including cannabis use, dependence and
problems). Conversely, two studies40,50 reported no significant difference on any outcomes between CBT
(14 sessions) and MET (2 or 4 sessions), although one study40 involved few participants, which may impact
on significance levels. Three CBT studies39,40,50 reported change from baseline to post treatment; all three
reported significant improvements on most outcomes for both the CBT and MI groups. One study
investigating possible mechanisms for changes in cannabis use reported that participants in both the
9-session CBT and 2-session MET groups increased their coping skills relative to wait list with no significant
difference between CBT and MET, and that this increase in coping skills was associated with reduction in
cannabis use.39 Effect sizes at 12 weeks (based on data from one study39) ranged from 0.4 to 0.5 for both
cannabis use and severity of dependence outcomes.
One further study56 reported that 16-session dynamic psychotherapy was significantly better than one-session
MI; however, limited outcomes were reported (i.e. percentage abstinent, severity of symptoms).
Results for later follow-ups were again mixed. Three studies of CBT reported between-group data at later
follow-ups. Two of these studies39,53 reported that CBT (6 or 9 sessions) was significantly better than MET
(1 or 2 sessions) on some outcomes (some cannabis use, dependence) but not other outcomes (some
cannabis use, cannabis problems) at 9 and 15 months’ follow-up. The third study50 reported no significant
difference on most outcomes for CBT plus social support (14 group sessions) compared with MET
(2 individual sessions) at 16 months’ follow-up. The study of dynamic psychotherapy did not report
later follow-up data. Two studies39,50 reported change from baseline at follow-up (9–16 months), both
finding significant improvements on most outcomes in both the CBT and brief MI groups. Effect sizes at
9 months (based on data from one study39) ranged from 0.3 to 0.5 for both cannabis use and severity of
dependence outcomes.
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Effects of intervention characteristics
In terms of number of sessions, this section compares four studies of CBT (6–14 sessions) with briefer
MI/MET treatments (1–4 sessions). As described above, some studies showed better results for CBT than
MI (one39 post treatment, two at later follow-ups39,53), whereas others showed no significant differences
(two40,50 post treatment, one at later follow-ups50). When CBT gave better outcomes, this may be owing to
the nature of the CBT treatment, or the fact that more sessions were provided, or a combination of the
two. In terms of group compared with individual treatments, one study50 showed little difference between
group CBT plus social support and individual MI (although both groups improved from baseline), whereas
studies of individual CBT compared with MI showed mixed results, as described above.39,40,53
Effects of population characteristics
It was not possible to assess the effects of baseline cannabis use/dependence, as all studies were classified as
high use. In terms of recruitment method, three CBT studies used voluntary recruitment40,50,53 and showed
mixed results, whereas the one study39 using a combination of voluntary recruitment and referrals showed
mostly significant effects; however, no studies used referrals only, so the significance of this is not clear.
It was not possible to assess effects of participant age, as all studies in this grouping had a similar mean age
(32–36 years).
Cognitive–behavioural therapy compared with other interventions
(or different cognitive–behavioural therapy format or duration)
Description of studies
Four studies44,49,63,65 (n= 462 randomised, 365 followed up) compared CBT (4–10 sessions) with another
intervention (social support group,49 case management sessions44) or compared individual with group CBT65
or CBT over different durations (Tables 10 and 11).63 Two studies44,49 reported overall session attendance
(of both interventions), ranging from 58% to 76%, with both studies reporting no significant differences in
attendance between the two interventions (session attendance not reported in two studies63,65). Participants
were classified as having high baseline use in two studies44,49 and low use in two studies.63,65 Two studies were
conducted in the USA,44,49 one in Canada65 and one in Brazil.63
Main results
One study49 reported no significant difference between 10 sessions of group CBT and 10 sessions of group
social support, either post treatment or at 15 months’ follow-up. A further study44 reported no significant
difference between 9 sessions of CBT and 9 sessions of case management (help with problems of daily
living possibly related to cannabis use), either post treatment or at 14 months’ follow-up. However, both
studies reported significant improvements from baseline in both groups, which were maintained after
14–15 months. The other two studies63,65 compared CBT format or duration and are discussed below.
Effects of intervention characteristics
One study65 compared four sessions of individual with group CBT; however, only 17 cannabis users were
analysed and only one relevant outcome reported (days abstinent). Both groups improved from baseline
and this was maintained at 12 months. Results non-significantly favoured individual CBT post treatment
but this effect was not maintained at 12 months. Another study63 compared four sessions of CBT over
either a 12- or a 4-week period. Post-treatment results significantly favoured 12-week treatment on some
outcomes (i.e. dependence, cannabis problems) but not cannabis use outcomes.
Effects of population characteristics
Studies in this category were too heterogeneous in terms of interventions/comparators to allow meaningful
assessment of the effects of population characteristics.
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40
Telephone- or internet-based cognitive–behavioural therapy or counselling
compared with wait list or other interventions
Description of studies
Three studies55,61,70 (n= 1682 randomised, 481 followed up) compared telephone- or internet-based
interventions with wait list or education controls (Tables 12 and 13). Interventions included telephone-delivered
CBT,55 internet-delivered CBT70 and internet-delivered counselling.61 Participants were classified as having high
baseline use in one study61 and low use in two studies.55,70 Two studies reported session attendance for the
CBT arm of the study, reporting mean attendances of 83%55 and 58%.70 Two studies were conducted in
Australia55,70 and one in Germany.61
Main results
One study55 reported significantly better results for four sessions of telephone-delivered CBT than wait
list control on most outcomes post treatment (i.e. dependence, cannabis problems, some cannabis use
outcomes), with some effects maintained at 3 months (i.e. dependence and problems, not cannabis use).
Both the telephone-delivered CBT and wait list groups showed improvements from baseline post treatment
and at 3 months. Another study70 compared six sessions of internet-based CBT with written cannabis
information. Results post treatment significantly favoured internet-delivered CBT on some outcomes
(i.e. some cannabis use) but not others (i.e. abstinence, dependence), while all outcomes (i.e. cannabis
use, dependence) were significant or borderline significant in favour of internet-delivered CBT at 3 months;
both the internet-delivered CBT and control groups showed improvements from baseline post treatment
and at 3 months. Effect sizes of 0.3 were observed for cannabis use outcomes post treatment and at
3 months.70 A further study61 reported better outcomes for 50-day internet-based counselling than for wait
list control at 3-month follow-up, on the limited outcomes reported (i.e. cannabis use, self-efficacy).
Effects of intervention characteristics
The three studies were too heterogeneous in their interventions and comparators to allow meaningful
assessment of the effects of other intervention characteristics.
Effects of population characteristics
In terms of baseline cannabis use/dependence, the study classed as high use61 showed slightly more
positive effects than the two studies classed as low use,55,70 but this comparison is based on limited data.
All three studies used voluntary recruitment and all showed some positive results. Mean age ranged from
25 years to 36 years; however, the effect of age could not be meaningfully assessed owing to the small
number of studies in this category.
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Brief motivational interviewing compared with wait list or assessment only
Description of studies
Ten studies39,43,45,46,48,50,51,53,67,71 (n= 2437 randomised, 2288 followed up) compared a brief intervention
(1 or 2 sessions of MET, MI or personalised feedback) with wait list or AO (Tables 14 and 15). One study
assessed a internet-based intervention (personalised feedback).45 One study provided a group MI session67
and the other nine provided individual sessions. Eight studies39,43,46,48,50,51,53,71 reported session attendance,
ranging from 80% to 100%. Those interventions involving 1 session did not have a markedly increased
attendance compared with those involving more than 1 session [mean attendance across studies: 1-session
interventions (four studies) – 91%; 2 or more session interventions (four studies) – 88%]. Participants were
classified as having high baseline use in four studies39,50,51,53 and low use in six studies.43,45,46,48,67,71 Seven
studies were conducted in the USA,39,43,45,46,48,50,51 one in Australia,53 one in Switzerland67 and one across
four countries.71
Main results
Five studies reported between-group data post treatment and the results showed a mixed picture with
some significant effects.39,43,48,50,51 One study50 (with high baseline use) reported significantly better results
for two-session MET than wait list on all outcomes (cannabis use, dependence, problems), whereas four
studies39,43,48,51 (two high,39,51 two low use43,48) reported that MI/MET (one or two sessions) gave significantly
better results than wait list or AO on some outcomes (i.e. most cannabis use outcomes, dependence) but
not others (i.e. some cannabis use outcomes, problems). Three studies reported change from baseline to
post treatment, all of which reported significant improvements on most outcomes in both groups (two
studies)48,50 or in the MI group (one study).39
Two studies reported effect sizes at post treatment and one at a later follow-up point.39,46 Effect sizes
(Cohen’s d) at post treatment ranged from 0.29 to 0.60 for cannabis use outcomes and were 0.33 for
dependence symptoms.39 Another study reported effect sizes as RRs, where the effect size for cannabis use
outcomes ranged from 0.76 to 0.99 at post treatment (3 months) and was 0.90 for cannabis problems,
whereas at follow-up (6 months) the RR ranged from 1.03 to 1.11 and was 1.15 for cannabis problems.46
At later follow-ups, seven studies reported mixed between-group results, again with some significant
effects.43,45,46,48,53,67,71 At 3 months, two studies48,71 (both low baseline use) reported significantly better
results for MET/MI on the single outcome reported (cannabis use), whereas three studies43,45,46 (all low use)
showed better results for MET/MI on some outcomes (some cannabis use) but not others (some cannabis
use, problems). At 6 months, four studies45,46,48,67 (all low use) reported no significant differences between
MET/MI and wait list/AO, while at 9 months one study53 (high use) reported better results for MET/MI
on some outcomes (some cannabis use, dependence, problems). Three studies reported significant
improvements from baseline to 3–6 months on most outcomes in both groups (two studies)48,71 or in the
MI group (one study),39 whereas one study45 reported no significant change following internet-based
personalised feedback at 3–6 months.
Effects of intervention characteristics
There was no obvious difference in results between studies of one-session or two-session MI/MET, with
most studies showing mixed results both post treatment (a single 1-session study51 compared with four
2-session studies39,43,48,50) and at later follow-ups (five 1-session studies45,46,53,67,71 compared with two
2-session studies43,48). The one study67 using a group intervention (1-session MI) showed no significant
effect at 6 months on the single outcome reported (cannabis days of use); it is unclear whether this reflects
the group delivery or other factors (only a single session was provided and results were not measured
earlier than 6 months).
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Effects of population characteristics
In terms of baseline cannabis use/dependence, at post treatment one study50 with high baseline use
reported better results for MET on all outcomes, whereas four studies39,43,48,51 (two high, two low use)
reported better results for MI/MET on some outcomes but not others. At later follow-ups, results were
mixed, both among the one study53 with high use and the six43,45,46,48,67,71 with low use. Therefore (based
on the post-treatment data) studies with high baseline use/dependence may have been slightly more likely
to show significant effects, but there is little strong evidence for this.
There was no clear difference in results according to recruitment method; the three studies45,46,71
recruiting participants via referral and the one39 recruiting via referral and voluntary methods all showed
mixed results which were not obviously different from the other six studies43,48,50,51,53,67 using voluntary
recruitment. Mean age ranged from 18 years to 36 years. Five studies43,45,46,48,67 assessed relatively young
populations (mean age 18–23 years, upper age range in teens or twenties); these studies were all classed
as low baseline use. There were no clear differences in effects according to age, with the five studies43,45,46,48,67
of younger populations showing mixed results in a similar manner to other studies.
In addition, two studies with low baseline use reported subgroup effects.45,48 One study45 reported no
significant difference between internet-based personalised feedback and control across all participants,
but a significant difference for participants with a higher contemplation to change use or a family history
of drug problems. Another study,48 in which participants were not seeking treatment for their cannabis
use, reported no significant difference between brief MI and AO across all participants, but significant
differences for those with a desire to cease use.
Brief motivational interviewing compared with other interventions
Description of studies
Three studies51,62,75 (n= 2002 randomised, 754 followed up) compared a brief intervention (one session of
MI or telephone MI) with education controls (regarding cannabis or general health) (Tables 16 and 17).
All MI sessions were individual (not group). One study51 reported session attendance, in which 89% of
participants attended a MI session and 94% attended a ‘cannabis education’ session. Participants were
classified as having high baseline use in one study51 and low use in two studies.62,75 Studies were conducted
in the USA,51 Canada75 and Brazil.62
Main results
One study51 of MI (1 session) compared with education control reported significantly better results for
MI on some outcomes (i.e. some cannabis use outcomes, dependence) but not other outcomes (i.e. some
cannabis use outcomes, cannabis problems), both post treatment and at 6 and 12 months’ follow-up.
Another study75 reported no significant differences between 1-session MI and education after 3 and
12 months (only cannabis use outcomes were reported); however, all groups significantly improved from
baseline. A further study62 reported that one-session telephone MI was significantly better than education
control on a single outcome (% abstinent) after 6 months, with an odds ratio of 1.6 (95% CI 1.2 to 2.0).
Effects of intervention and population characteristics
There were too few studies in this category to allow meaningful assessment of the effects of other
study characteristics.
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Contingency management (vouchers for abstinence) versus other interventions
Description of studies
Five studies40–42,44,47 (n= 680 randomised, 581 followed up) compared contingency management (vouchers
for abstinence assessed via urine tests), alone or in combination with CBT, with other interventions
(Tables 18 and 19). One study also assessed computer-based CBT plus contingency management.42
Comparators included CBT40,41,44 (9–14 sessions), MET40,42 (2–4 sessions), case management44,47
(9 sessions) and CBT plus vouchers for completed CBT homework.47 Three studies reported session
attendance; attendance at the CBT plus voucher arms of the studies was reported as 61%47 and 69%41.
Attendance in the ‘other’ arms of the trials was reported as 67% (case management intervention)47 and
63% (CBT intervention without vouchers).41 One study44 reported attendance across both arms (58%).
All interventions were individual (not group). Participants were classified as having high baseline use in all
five studies and all five studies were conducted in the USA.
Main results
Results post treatment differed from those at later follow-up. Four studies40–42,44 reported between-group
data post treatment; results favoured either CBT plus vouchers or vouchers alone over CBT alone. Three
studies40,42,44 reported better results (on some outcomes only) for CBT plus vouchers than for CBT or
MET alone. In addition, two studies reported better results (again on some outcomes only) for vouchers
alone than CBT alone (two studies)41,44 or case management alone (one study).44 One study41 assessed
continuous abstinence for ≥ 6 weeks and reported an odds ratio of 6.0 (95% CI 1.7 to 21.0) for vouchers
alone compared with CBT and an odds ratio of 4.1 (95% CI 1.2 to 14.4) for CBT plus vouchers compared
with CBT alone.
Later follow-ups indicated that positive results were maintained for combined treatment with CBT plus
vouchers. However, the beneficial short-term results for vouchers alone were less likely to be maintained long
term. Three studies41,44,47 reported between-group data at 14–15 months. Two studies41,44 reported better
results for CBT plus vouchers than for either CBT or vouchers alone (on some outcomes) at 14–15 months’
follow-up. Significant improvements from baseline were reported on some or most outcomes in all groups post
treatment (three studies40,41,44) and at 14–15 months’ follow-up (three studies41,44,47).
Two further studies made other comparisons. One study42 reported no significant difference between CBT
plus voucher and computer-based CBT plus voucher post treatment (however, only one outcome – weeks
of continuous abstinence – was reported). Another study47 reported that CBT plus voucher (for abstinence)
gave better results than CBT plus voucher (for CBT homework) on some but not all outcomes at
5–8 months’ follow-up.
Two studies44,47 investigated potential mechanisms for changes in cannabis use and reported that
long-term abstinence was predicted by abstinence during treatment and by increases in coping skills and
self-efficacy. A further analysis of two studies40,74 assessed ability to maintain abstinence, reporting that
54% of participants achieved at least 2 weeks’ continuous abstinence at any point and, of these,
24% lapsed to cannabis use within 1 month, 46% within 3 months and 71% within 6 months.
Effects of intervention and population characteristics
It was difficult to assess the effects of study characteristics within this category as all studies were similar
in many aspects of their design. All five studies40–42,44,47 provided individualised treatment, all were classified
as high baseline use, all used either voluntary recruitment (four studies40,42,44,47) or a combination of
voluntary and referrals (one study41) and the mean age was 32–35 years in all five studies.
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Studies in populations with psychiatric conditions
Cognitive–behavioural therapy plus treatment as usual compared with
treatment as usual
Description of studies
Four studies52,66,68,69 (n= 326 randomised, 254 followed up) compared CBT (6–24 sessions) plus TAU
with TAU alone (Tables 20 and 21). TAU generally consisted of antipsychotic medication and psychiatric
condition monitoring. In addition, in one study52 a self-help book on substance abuse was provided, and
two studies68,69 explicitly stated that a psychosocial intervention was provided to participants receiving
TAU. In terms of the study interventions, two studies52,68 provided individual CBT sessions, one66 individual
plus optional group sessions, and one69 group sessions. Three studies reported session attendance: two
reported percentage of participants attending all sessions (85%66 and 67%68), while one study69 reported
the proportion attending more than 1 session (46%, 12-session intervention). Participants were
classified as having high baseline use in three studies66,68,69 and low use in one study.52 One study was
conducted in Switzerland,66 one in Denmark,68 one in Ireland69 and one in Australia.52
Main results
Results indicated little effect of CBT plus TAU over TAU alone in this population; however, data were
limited in that the numbers of analysed participants per study were relatively low (22–42 per group), which
may affect significance levels. Furthermore, in one study, only 46% of the CBT group attended any
sessions.69 In addition, the provision of psychosocial and other interventions in the control groups as part
of TAU may potentially have reduced any difference in outcomes between groups, although two52,68 of
three52,68,69 studies showed no changes from baseline in either group.
All four studies52,66,68,69 reported between-group data post treatment, each reporting a significantly better
result for CBT plus TAU than TAU on a single outcome only and not on other outcomes. Outcomes with
significant or near-significant effects in one study each were: joints per week, joints per month, number of
days used and quality of life; however, there were no significant differences in days used, days abstinent or
per cent abstinent. Other outcomes (i.e. severity of dependence, cannabis problems) were not reported in
any study. At 10–12 months’ follow-up, these four studies52,66,68,69 reported no significant differences
between CBT plus TAU and TAU alone on any cannabis use outcomes; however, one study69 reported a
significant difference in quality of life. Two studies52,69 reported no significant improvements from baseline
in any group either post treatment or at 12 months, while one study66 reported a significant improvement
in both groups on the single relevant outcome reported (joints per week).
Effects of intervention characteristics
There were no clear differences in results according to number of CBT sessions (6–24) or group compared
with individual treatment.
Effects of population characteristics
There were no clear differences in results for the one study52 classed as low baseline use/dependence
compared with the three66,68,69 with high use. In terms of recruitment method, three studies recruited via
referrals only52,66,68 and one via using a combination of voluntary recruitment and referrals;69 all four
showed little effect of CBT plus TAU over TAU alone. The effect of age on results could not be assessed as
the mean age was similar across studies (26–29 years).
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67
Cognitive–behavioural therapy compared with other interventions
Description of studies
Three studies54,57,58 (n= 199 randomised, 197 followed up) assessed CBT (one study;54 10 sessions) or
computer-based CBT with brief weekly therapist input (two studies;57,58 10 sessions) (Tables 22 and 23).
Comparators included psychoeducation (10 sessions; non-cannabis-based),54 person-centred therapy (PCT;
10 sessions)58 or brief MI (1 session).57 Sessions were individualised (not group). Session attendance was
reported as 76%,54 53%58 and 76%82 for the CBT interventions. For comparators, 84% attended all
psychoeducation sessions,54 54% attended all sessions for PCT58 and 87% participants attended all brief
MI sessions.82 Participants were classified as having low baseline use in all studies and all studies were
conducted in Australia.
Main results
Two studies reported results post treatment. One study54 reported no significant differences between CBT
and psychoeducation (10 sessions each) post treatment or at 9 months’ follow-up, but numbers of
analysed participants were low; however, both groups showed a significant improvement from baseline,
post treatment and at 9 months (based on one relevant outcome, number of days used). Another study58
reported no significant difference between the three types of 10-session therapy (CBT, computer-delivered
CBT with brief therapist input, or PCT) post treatment. Individual group comparisons were not reported,
only the following comparisons: CBT or computer-delivered CBT compared with PCT, and computer-
delivered CBT compared with CBT or PCT. Changes from baseline were not reported for this study.
A further study57 reported that 10 sessions of either CBT or computer-delivered CBT with brief therapist
input (analysed together) was significantly better than 1-session MI at 12 months’ follow-up, and that
there was a significant improvement from baseline across groups at 12 months; however, only one
relevant outcome (mean use per day) was reported for this study.
Effects of intervention and population characteristics
Intervention and comparator groups were too heterogeneous to allow meaningful assessment of the
effects of other study characteristics on results.
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Subgroup analyses: effect of intervention and
population characteristics
This section provides a summary of the possible effects of intervention and population characteristics on results.
These are covered in each of the intervention/comparator categories above and are summarised here.
Number of sessions, and comparison of longer cognitive–behavioural
therapy, compared with shorter motivational interviewing
Two sets of data imply that longer courses of CBT may be somewhat more effective than shorter courses
of MI, but findings were mixed. First, four studies directly compared CBT (6–14 sessions) against brief MI
(1–4 sessions).39,40,50,53 Of these, some showed better results for CBT than MI (one39 post treatment, two at
later follow-ups39,53), whereas others showed no significant differences (two40,50 post treatment, one at later
follow-ups50). Second, studies comparing brief MI with wait list showed some significant effects, but these were
not as positive overall as results for CBT compared with wait list which were significant on nearly all outcomes.
The somewhat better results for CBT than MI could be due to the nature of CBT treatment, the fact that more
sessions were provided, or a combination of the two.
Within six studies of CBT compared with wait list,39,50,53,59,60,63 all durations of CBT (4–14 sessions) appeared
effective. There were slightly fewer significant effects in the study of four-session CBT,63 but this may have
been related to the small number of participants. One study63 compared four sessions of CBT over either
a 4- or 12-week period; post-treatment results significantly favoured 12-week treatment on some but not
all outcomes. Within studies of brief MI compared with wait list, there was no clear difference between
studies of one-session or two-session MI, with both durations showing mixed results.
Group or individual treatment
Of the 33 included studies, 2739–48,51–55,57–63,66,68,70,71,75 provided individualised treatments, whereas three49,67,69
provided group treatment and two50,65 compared group with individual treatment (not reported for one).56
There were insufficient group treatment studies within most intervention/comparator categories to
meaningfully compare group with individual treatment. Within studies of CBT compared with wait list,
the one study of group CBT50 had similar positive outcomes to the five individual CBT studies. Within
studies of CBT compared with brief MI, one study50 showed little benefit of group CBT compared with
individual MI, and studies of individual CBT compared with MI showed mixed results. Within studies of
brief MI compared with wait list, studies of individual MI showed mixed results, whereas the one study67
of group MI showed no significant effect; however only 1 session of MI was provided and results were not
measured until 6 months and then only on one outcome (cannabis days of use). One study65 directly
compared individual with group CBT (4 sessions each), but only 17 cannabis users were analysed and only
one relevant outcome reported (days abstinent); results non-significantly favoured individual CBT post
treatment, but this effect was not maintained at 12 months. Overall, group treatment may possibly be less
effective than individual treatment, but this is based on very limited data.
High compared with low baseline cannabis use/dependence
The impact of high or low baseline cannabis use/dependence could be assessed to some extent within certain
intervention/comparator categories: CBT compared with wait list, computer-delivered/telephone-delivered CBT
compared with other, and brief MI compared with wait list. Within each of these categories, studies with low
baseline use43,45,46,48,55,60,63,67,70,71 appeared slightly less likely to show significant differences on all outcomes
than studies of high use.39,50,51,53,59,61 However, this difference was not substantial or conclusive. This potential
difference could be owing to the interventions having a greater effect on participants with higher baseline use/
dependence, either because a greater effect could be demonstrated or because these participants may have
been more motivated to reduce use; however, this conclusion should be treated with caution.
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In addition, two studies with low baseline use reported subgroup effects.45,48 One study45 reported no
significant difference between internet-based personalised feedback and the control group across all
participants, but a significant difference for participants with a higher contemplation to change use or a
family history of drug problems. Another study,48 in which participants were not seeking treatment for
their cannabis use, reported no significant difference between brief MI and AO across all participants, but
significant differences for those with a desire to cease use.
Recruitment method (voluntary compared with referrals)
Among the 26 general population studies,39–51,53,55,56,59–63,65,67,70,71,75 1640,42–44,47–50,51,53,55,61,62,67,70,75 used
voluntary recruitment via advertisement, while four45,46,60,71 used referrals and four39,41,59,65 used a
combination of voluntary and referrals (not reported for two studies56,63). Results for the general population
studies showed no clear difference in results according to recruitment method, although this comparison
is based on limited data. No clear difference was observed within studies of CBT compared with wait
list (two voluntary,50,53 one referral,60 two combination;39,59 all positive results) or within studies of brief MI
compared with wait list (six voluntary,43,48,50,51,53,67 three referral,45,46,71 one combination;39 all mixed results).
Nevertheless, it should be noted that the majority of the general population studies recruited volunteers
via advertisement and, therefore, may reflect a more motivated group when compared with the
‘average’ cannabis user.
In contrast to the general population studies, all seven studies in psychiatric populations recruited patients
via referral (four studies52,54,66,68) or a combination of referral and voluntary methods (three studies57,58,69).
Across four studies of CBT plus TAU compared with TAU in psychiatric populations, three studies52,66,68
used referrals and one69 used a combination of voluntary and referrals; all four showed little difference
between CBT plus TAU and TAU alone. Comparisons within the other three studies54,57,58 were too
heterogeneous to assess the effects of recruitment method.
Participant age
Within most intervention/comparator categories, mean ages were similar across studies, so the effect of age
could not be meaningfully assessed. This was true for comparisons of CBT compared with wait list (mean
age 24–36 years), CBT compared with brief MI (mean age 32–36 years), telephone-/internet-delivered CBT
(mean age 25–36 years) and CBT plus TAU vs. TAU (mean age 26–29 years). For brief MI compared with wait
list (10 studies39,43,45,46,48,50,51,53,67,71), mean age ranged from 18 years to 36 years. Five studies43,45,46,48,67 assessed
relatively young populations (mean age 18–23 years, upper age range in teens or twenties) and these studies
were all classed as low baseline use/dependence. There were no clear differences in effects according to age,
with the five studies of younger populations showing mixed results in a similar manner to other studies.
Baseline use of other substances
There were insufficient data to assess the effect of baseline alcohol and tobacco use; these were only
reported in ten studies (alcohol)39–41,44,51,54,55,59,60,63 and two studies (tobacco)55,60 and were reported via very
different measures (see Tables 1 and 2).
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Chapter 4 Discussion
Statement of principal findings
General population studies
Of 26 studies39–51,53,55,56,59–63,65,67,70,71,75 assessing the general population of cannabis users (7643 randomised
participants), 1640,42–44,47–50,51,53,55,61,62,67,70,75 recruited via advertisement and eight39,41,45,46,59,60,65,71 via
referrals or both. Baseline use/dependence was high in 13 studies39–42,44,47,49–51,53,56,59,61 and low in
10.43,45,46,48,55,60,63,65,70,75 Across six studies39,50,53,59,60,63 of CBT (4–14 sessions) compared with wait list, CBT
was significantly better on most outcomes (cannabis use, severity of dependence, cannabis problems) post
treatment (in all five studies39,50,59,60,63 with data) and at 9 months (in the one study53 with later follow-up).
Four studies39,40,50,53 comparing CBT (6–14 sessions) with briefer MI/MET (1–4 sessions) gave mixed results,
with two studies40,50 showing better results for CBT post treatment and at 9–16 months, while two further
studies39,53 showed few between-group differences; both CBT and MI gave significant improvements from
baseline. In one small study,56 supportive–expressive dynamic psychotherapy (16 sessions) gave significant
improvements over one-session MI. One study49 of CBT compared with social support group
(10 sessions each) and another44 of CBT compared with case management (nine sessions each) showed no
significant differences between groups but all groups significantly improved from baseline with changes
maintained at 14–15 months. One study each of telephone-delivered CBT, internet-delivered CBT and
internet-delivered counselling all showed significant improvements over wait list or education control post
treatment and at 3 months.55,61,70
Ten studies39,43,45,46,48,50,51,53,67,71 assessing brief MI/MET (one or two sessions) compared with wait list or AO
gave mixed results, with brief MI appearing significantly better on some outcomes but not others, post
treatment and at 3–9 months. Results were similar for three studies51,62,75 comparing brief MI against
education controls. Five studies40–42,44,47 assessed contingency management (monetary vouchers for
abstinence). Vouchers alone and CBT plus vouchers gave better results than CBT or MET alone post
treatment (three studies40,42,44), while at 14–15 months positive results were maintained for CBT plus
vouchers but less so for vouchers alone (two studies41,44).
Psychiatric population studies
Seven studies52,54,57,58,66,68,69 (525 randomised participants) assessed psychiatric populations (schizophrenia,
psychosis, bipolar disorder or major depression); all recruited via referrals or referrals plus advertisements.
Baseline use/dependence was high in three studies66,68,69 and low in four.52,54,57,58 Across four studies52,66,68,69
assessing CBT (6–24 sessions) plus TAU compared with TAU alone, there were few significant between-group
differences post treatment and none at 10–12 months (small studies; limited data), with little change from
baseline in either group. Two studies54,58 reported no significant difference between different types of
10-session therapy (one compared CBT, computer-delivered CBT and PCT; the other compared CBT and
psychoeducation), although the latter reported significant improvements from baseline in both groups
(limited data).54 A further study reported improvements for 10-session CBT or computer-delivered CBT over
single-session MI at 12 months’ follow-up on one outcome (daily cannabis use).57
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Strengths and limitations of the assessment
Strengths
This report systematically reviews the evidence for a range of psychological and psychosocial treatments
for regular users of cannabis. Thirty-three studies were included and the scope of the review is inclusive,
covering a wide range of populations, interventions and outcomes. The majority of previous reviews in
this topic area have restricted their scope to a subtype of intervention or population, or are not specific to
cannabis users.6,33 The present review has included all psychosocial or psychological interventions
undertaken in the adult, community-dwelling population of cannabis users and has only included RCTs,
ensuring that only the highest quality available evidence has been included. Robust methods were used,
including a search methodology with wide scope, grey literature searching and contact with clinical
experts in the area. Data were double-checked for accuracy.
The included studies reported a heterogeneous set of data; in many cases, similar outcome measures
(e.g. cannabis use) were reported in different ways. Narrative synthesis was used to analyse and explore
the data. Results are presented for each intervention/comparator category (e.g. CBT vs. wait list or
CBT vs. MI) and by population (general vs. psychiatric). This allows studies with similar comparisons and
populations to be analysed together, to provide an overview of the direction of effects for each category
at different time points. This approach also minimises loss of data, as any meta-analysis would have
been restricted to studies reporting the same outcome in a consistent format and reporting full data
[including standard deviations (SDs), etc.].
Limitations
There was substantial heterogeneity between studies in terms of their populations, interventions,
comparators, outcome measures and data format, and limited time was available to conduct this
systematic review short report. Therefore, results are presented as an overview of the outcomes reported
per study and how many showed a significant difference, both between intervention groups and in terms
of changes from baseline, at different follow-up time points. Detailed numerical results per group are
not presented in the main results section (these are provided in Appendix 4) and meta-analysis was not
undertaken. This approach has the limitations that (1) it was not possible to present effect sizes for
outcomes and (2) data were not pooled across studies. However, the narrative synthesis approach was
thought to provide benefits in terms of interpretability as described above. In addition, owing to time
constraints, we were unable to include studies written in languages other than English.
Only RCTs were included in this review. Although this ensures that only the highest quality of evidence is
included in the synthesis, it does potentially result in informative studies being rejected. Nine potentially
relevant articles were excluded owing to this;83–91 however, most of these studies would have been
rejected for other exclusion criteria (four of the studies included a population comprising people aged
< 18 years).84,88,90,91
We excluded studies that were undertaken within the criminal justice setting (e.g. studies undertaken
within the court system, prison, or while study participants are on parole). We also excluded studies that
treated individuals other than the cannabis user (e.g. a family member). Although risking the exclusion of
potentially valid trials, excluding these populations reduced the many sources of heterogeneity. This review
focused on community-delivered interventions. Interventions carried out within the criminal justice setting
are unlikely to be replicable when delivered to cannabis users outside that setting, owing to differences
in recruitment, intervention delivery and outcome assessment.
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The studies included in this review utilised a variety of recruitment methods, involving voluntary
recruitment, referral by a health-care professional or a combination of both. Studies in the general
population of cannabis users mostly used voluntary recruitment methods (most often via advertisements);
therefore, these may have reflected more motivated populations and may not be generalisable to all
cannabis users. Conversely, this may reflect practice in that psychological interventions are likely to be
provided to those willing to receive them. In addition, the included studies recruited cannabis users with
varying frequencies of cannabis use at baseline.
Results obtained from the psychiatric population studies may have been affected by provision of TAU to
both groups, which in two studies included psychosocial interventions.68,69 Although these presumably
focused on the psychiatric condition rather than cannabis use, they may indirectly have affected cannabis
outcomes in both groups. Another study provided a self-help book on substance abuse as part of TAU.52
The following topics are outside the scope of this systematic review, but could form aspects of future
work in this area. Although this short report focused on treatment of adult cannabis users, there is a
large amount of literature on treatment of cannabis use in adolescents, including the effects of
preventative strategies as well as interventions involving families or schools. In addition, assessment of
the effects of factors such as therapist type and treatment fidelity, which are important factors when
considering psychosocial interventions, may form a part of future reviews.
Assessment of factors relevant to the National Health Service
and other parties
It would be important to consider the following points relating to implementation of any psychosocial
intervention for cannabis use.
Intervention delivery
l Availability of CBT and other treatments within the NHS, and which type of health professional would
provide these. Department of Health guidance suggests that psychosocial interventions for substance
misuse may be delivered by a key worker (when a health professional works with the individual to
ensure delivery and ongoing review of care being received) with the required competencies or by a
drug worker or psychologist.20
l UK guidelines also emphasise the importance of person-centred care, consideration of family and carer
involvement, links between services to avoid loss of contact and importance of key working.19,20 They
also advise that treatment and information should be accessible to people with disabilities and to
those who do not speak or read English.19
Patient identification
l How cannabis users would be identified/diagnosed and referred for treatment (e.g. via a general
practitioner, social worker or a variety of routes).
l The level of cannabis use or dependence at which treatment is required.
l Whether all patients with a particular level of use or dependence would be referred or, for example,
only those who wished to receive a psychosocial intervention and/or those expressing a desire to
reduce or cease use (note that the majority of data for ‘general population’ studies involved
participants voluntarily responding to advertisements). Existing UK guidelines advise that service users
should be allowed to make informed decisions about their treatment in partnership with their
health professionals.19
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l Other relevant interventions exist that do not explicitly target cannabis users, but are aimed at individuals
with addictive behaviours. Although no relevant RCTs of such therapies were identified in this review,
they may be worthy of further consideration or research. For example, mutual aid therapies (such as
Self-Management and Recovery Training) involve people with similar experiences assisting each other to
overcome or manage their issues. Department of Health guidance advises that self-help and mutual aid
groups should be recommended for all drug misusers seeking to achieve and maintain abstinence.20
Other interventions not within the scope of this review may increase the effectiveness of psychosocial or
psychological interventions for cannabis cessation. For example, nicotine replacement therapy may
increase the ability of regular cannabis users to reduce their use of the drug, although a recently
conducted pilot study found that this was not the case for a group of 12 cannabis-dependent individuals.92
Comparison of results from this review with relevant national guidelines
l Existing UK guidelines from NICE advise that CBT should not be offered routinely for treatment of
cannabis abuse. Department of Health guidance advises that brief motivational interventions may be
considered in mild cases of cannabis use, whereas more heavily dependent users may require structured
treatment with key working.19,20 Our review found that CBT appeared effective for routine treatment of
cannabis abuse, but it was unclear how much more effective it was than briefer interventions.
l In terms of people with co-existing psychiatric conditions, NICE and Department of Health guidelines
suggest that CBT should be considered for treatment of cannabis users with comorbid depression and
anxiety disorders.19,20 Our review found that studies with people suffering from psychological conditions
appeared to show less promising effects of CBT,52,54,57,58,66,68,69 but we focused on studies of CBT aimed
at treating the cannabis abuse rather than the psychological condition and these studies may have
been confounded by both groups receiving TAU for the psychological condition (including psychosocial
treatments in some cases).52,66,68,69
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Chapter 5 Conclusions
Implications for service provision
This systematic review has identified a disparate evidence base that differed most notably in the nature
and length of the interventions, the comparator groups, the populations studied (which differed in
cannabis use at baseline as well as presence or absence of a psychiatric condition) and the outcomes
measured (differing in metrics used, statistics reported and follow-up periods). Studies recruited
participants using either voluntary or direct referral methods – studies utilising voluntary recruitment
methods identified a self-selecting population, which may not be representative of real-world cannabis
users.39–44,47–50,53,55,61,62,67,70,75 In addition, 24 of the studies were deemed to be at high risk of bias, mostly
owing to high attrition rates.40,41,43,48,49,52–55,57–63,65,67–71,75,81 No studies were deemed to be at low risk of bias.
In light of the above, it is difficult to make definite conclusions regarding the effectiveness of the included
psychological and psychosocial interventions. Based on the available evidence, CBT (4–14 sessions) appeared
to significantly improve outcomes post treatment (cannabis use, severity of dependence, cannabis problems)
compared with wait list in the general population of cannabis users, but only one53 of the six39,50,53,59,60,63 studies
reported outcomes at a follow-up time point significantly after the treatment period elapsed. Studies of
brief MI/MET (one or two sessions) gave mixed results, with some improvements over wait list, whereas some
comparisons were not significant. Comparisons of CBT (6–14 sessions) with briefer MI/MET (1–4 sessions)
also gave mixed results, with longer courses of CBT providing some improvements over MI. Significant
effects were maintained in two39,53 of the three39,50,53 studies reporting later follow-ups. Courses of other types
of therapy (social support group, case management, supportive–expressive dynamic psychotherapy) gave
similar improvements to CBT based on limited data. Limited data indicated that telephone- or internet-based
interventions may also be effective. Contingency management (vouchers for abstinence) gave promising results
in the short term; at later follow-ups vouchers in combination with CBT gave better results than either vouchers
or CBT alone. There were insufficient data to assess the effects of group compared with individual treatment.
In populations with psychiatric conditions (schizophrenia, psychosis, bipolar disorder or major depression),
CBT appeared to have little effect over TAU, but this was based on four small studies with limited data.52,66,68,69
Results may potentially have been affected by provision of TAU in both groups and the fact that patients
were referred rather than volunteering for treatment. Other studies reported no significant difference
between 10 sessions of CBT, computer-delivered CBT, PCT or psychoeducation, but improvements for
10-session CBT or computer-delivered CBT over single-session MI.
Included studies were heterogeneous and most were considered at high risk of bias. Based on the
available evidence, courses of CBT and (to a lesser extent) one or two sessions of MI improved outcomes
in a self-selected population of cannabis users. There is some evidence that CBT (6–14 sessions) may be
more effective than briefer MI interventions, although results were mixed. Contingency management
may also enhance long-term outcomes in combination with CBT. Results of CBT for cannabis cessation in
psychiatric populations were less promising, but may have been affected by provision of TAU in both
groups and the referred populations.
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Suggested research priorities
The highest priority area for future research should be to identify the number and frequency of sessions
required to provide reductions in cannabis use, which was unclear from the identified evidence. CBT
(4–14 sessions) gave improved outcomes over wait list in general population studies, whereas briefer
MI-based interventions (one or two sessions) appeared to have some effectiveness, although results were
mixed. CBT also appeared to give somewhat better results than briefer MI-based interventions; however,
it was unclear to what extent CBT outcomes were better. Future studies may wish to assess further the
effectiveness of shorter courses of therapy. This could include brief interventions (e.g. one or two sessions).
Alternatively, because studies of four- or six-session CBT seemed to have similar effectiveness to studies with
10–14 sessions, further assessment of four- to six-session CBT may be worthwhile. Relative cost-effectiveness
of longer and shorter interventions may also be useful to assess. If shorter interventions are as efficacious and
more cost-effective than longer ones, the former could be made more widely available.
The following areas for future research do not have as high priority, but are important nonetheless.
They do not have any order of importance in relation to each other.
Interventions
Future studies may wish to test other interventions in addition to CBT. The use of contingency
management (vouchers for abstinence) improved long-term outcomes when added to CBT. Future
studies assessing CBT (and/or brief interventions) may also wish to include a group receiving CBT and
contingency management. In addition, mutual aid therapies and self-help groups (for which no RCTs
were identified in this review) may be worthy of future study. Other treatments not within the scope of
this review, such as nicotine replacement therapy, could be assessed in conjunction with psychological
and psychosocial interventions in order to increase effectiveness. All studies should aim to report the
included interventions in sufficient detail to allow replication.
The current review has identified that CBT may be effective when delivered to cannabis-dependent
individuals, but effectiveness has not been demonstrated when such treatment is provided to patients
with psychological comorbidities. This lack of effectiveness for the dually diagnosed population confirms
findings from a previous review.6 These findings suggest that patients with a dual diagnosis may require
separate treatments for their substance abuse and psychological problem. Alternatively, if this lack of
effectiveness in the dually diagnosed population was due to the participant themselves being unable to
respond to the CBT treatment owing to their psychological condition, further research may be necessary
to identify interventions that are effective in such populations.
Populations
Future studies may also wish to consider the potential effects of recruitment method. Most existing general
population studies recruited via advertisement. Studies using other methods of recruitment may be more
generalisable to a clinical setting. Conversely, a somewhat selected study population may be reasonable
(e.g. those wishing to cease use and/or willing to receive the intervention) as current guidance suggests
that these populations would be the most relevant to receive psychosocial interventions (as opposed to,
for example, users expressing no desire to cease use).
The included studies did not report the effect of the psychopharmacology of cannabis. Recent findings
indicate that certain strains of cannabis containing high levels of cannabidiol are associated with less
cognitive impairment and positive therapeutic potential in psychosis and other disorders (such as
Parkinson’s disease).93–96 This pharmacological factor could be an important modulating factor in
treatment outcomes and, therefore, should be taken into account in future studies.
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Outcomes
Outcomes reported in most studies could be classified into four main groups: (1) level of attendance,
(2) cannabis use, (3) severity of dependence and (4) cannabis-related problems. Cannabis use covered a
range of specific outcomes including point abstinence rates, abstinence over a specified period, number
of days using cannabis or number of days abstinent (over a specified period), amount of cannabis use per
day, and number of periods of use per day (e.g. of four daily periods). All the above outcomes showed
significant effects in at least some studies. Future studies may wish to consider which outcomes have
been most commonly used in existing studies making similar comparisons, to improve comparability
between studies. In terms of the above outcomes, level of cannabis use can be difficult to measure owing
to the different levels of active ingredients in different cannabis products. Abstinence is a frequently
used outcome but may not be desirable or attainable for all users. Severity of dependence addresses the
impact on a person’s life rather than focusing on quantities of use. Cannabis-related problems may also be
a useful measure but in populations with other issues (such as psychiatric conditions) it may be difficult
to distinguish between the causes of problems. Patient preference for different types of psychological
intervention may also be useful to assess.
Methodology
Future studies should carefully consider trial methodology. The studies included in this review utilised
a range of comparison groups, including active treatments (e.g. a variation of CBT or MI), less specific
controls for time and attention (e.g. cannabis education) and inactive controls (wait list or AO). We
recommend that wait list controls are included as a group in future studies, even those comparing
different types or durations of active treatments, to indicate whether or not active treatments are
effective when compared with no treatment (as well as with each other).
In addition, it would be useful to consider carefully future study designs for populations with psychiatric
conditions. If TAU (for the psychiatric condition) is provided to all groups, this should be reflective of
current clinical practice and consideration should be given to whether or not it may confound the study
intervention (e.g. whether or not it includes psychosocial interventions). It may also be worth considering
whether or not a single psychosocial intervention can be tailored to address jointly both the psychiatric
condition and cannabis use.
The studies included in this review followed up participants over various time periods, ranging, overall,
between 12 weeks and 16 months. Future studies should aim to follow-up patients over the long term;
wait list controls with long-term follow-up are also valuable to assess fully long-term effects of treatment;
however, this needs to be balanced against ethics considerations and acceptability to trial participants.
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Appendix 1 Preferred Reporting Items for
Systematic Reviews and Meta-Analyses checklist
Section/topic Number Checklist item
Reported on page
number
Title
Title 1 Identify the report as a systematic review, meta-analysis, or both 1
Abstract
Structured
summary
2 Provide a structured summary including, as applicable: background;
objectives; data sources; study eligibility criteria, participants, and
interventions; study appraisal and synthesis methods; results;
limitations; conclusions and implications of key findings; systematic
review registration number
xxi–xxiv
Introduction
Rationale 3 Describe the rationale for the review in the context of what is
already known
1–3
Objectives 4 Provide an explicit statement of questions being addressed with
reference to participants, interventions, comparisons, outcomes,
and study design (PICOS)
5
Methods
Protocol and
registration
5 Indicate if a review protocol exists, if and where it can be accessed
(e.g., Web address), and, if available, provide registration
information including registration number
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and
report characteristics (e.g., years considered, language, publication
status) used as criteria for eligibility, giving rationale
7–10
Information
sources
7 Describe all information sources (e.g., databases with dates of
coverage, contact with study authors to identify additional studies)
in the search and date last searched
7
Search 8 Present full electronic search strategy for at least one database,
including any limits used, such that it could be repeated
93, 94
Study selection 9 State the process for selecting studies (i.e., screening, eligibility,
included in systematic review, and, if applicable, included in the
meta-analysis)
9
Data collection
process
10 Describe method of data extraction from reports (e.g., piloted
forms, independently, in duplicate) and any processes for obtaining
and confirming data from investigators
9
Data items 11 List and define all variables for which data were sought
(e.g., PICOS, funding sources) and any assumptions and
simplifications made
8
Risk of bias in
individual studies
12 Describe methods used for assessing risk of bias of individual
studies (including specification of whether this was done at the
study or outcome level), and how this information is to be used in
any data synthesis
9, 10
Summary
measures
13 State the principal summary measures (e.g., RR, difference in
means)
N/A
Synthesis of
results
14 Describe the methods of handling data and combining results of
studies, if done, including measures of consistency (e.g., I2) for
each meta-analysis
9
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Section/topic Number Checklist item
Reported on page
number
Risk of bias
across studies
15 Specify any assessment of risk of bias that may affect the
cumulative evidence (e.g., publication bias, selective reporting
within studies)
N/A
Additional
analyses
16 Describe methods of additional analyses (e.g., sensitivity or
subgroup analyses, meta-regression), if done, indicating which were
pre-specified
9
Results
Study selection 17 Give numbers of studies screened, assessed for eligibility, and
included in the review, with reasons for exclusions at each stage,
ideally with a flow diagram
11
Study
characteristics
18 For each study, present characteristics for which data were
extracted (e.g., study size, PICOS, follow-up period) and provide the
citations
11–20
Risk of bias
within studies
19 Present data on risk of bias of each study and, if available, any
outcome level assessment (see item 12)
20
Results of
individual studies
20 For all outcomes considered (benefits or harms), present, for each
study: (a) simple summary data for each intervention group
(b) effect estimates and confidence intervals, ideally with a forest
plot
26–72
Synthesis of
results
21 Present results of each meta-analysis done, including confidence
intervals and measures of consistency
N/A
Risk of bias
across studies
22 Present results of any assessment of risk of bias across studies
(see Item 15)
21, 22
Additional
analysis
23 Give results of additional analyses, if done (e.g., sensitivity or
subgroup analyses, meta-regression [see Item 16])
71, 72
Discussion
Summary of
evidence
24 Summarise the main findings including the strength of evidence for
each main outcome; consider their relevance to key groups (e.g.,
health-care providers, users, and policy makers)
73
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias),
and at review-level (e.g., incomplete retrieval of identified research,
reporting bias)
74, 75
Conclusions 26 Provide a general interpretation of the results in the context of
other evidence, and implications for future research
77–79
Funding
Funding 27 Describe sources of funding for the systematic review and other
support (e.g., supply of data); role of funders for the systematic
review
iii
N/A, not applicable.
Checklist from www.prisma-statement.org97 (under the terms of the Creative Commons Attribution Licence, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited) and
has been used in other studies.28
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Appendix 2 Literature search strategies
The following strategy was developed for use in MEDLINE. This strategy was subsequently translated inaccordance with the other databases searched.
MEDLINE search strategy
1. Substance-Related Disorders/
2. (cannabis$ or marijuana or marihuana or hashish).ab,ti.
3. 1 and 2
4. exp marijuana abuse/
5. ((cannabis$ or marijuana or marihuana or hashish) adj2 (misuse or abuse$ or addict$ or depend$ or
disorder$ or use$)).ab,ti.
6. or/3-5
7. ((cannabis$ or marijuana or marihuana or hashish) adj3 (therap$ or treatment$)).ab,ti.
8. (cessation adj2 (therap$ or treat$)).ab,ti.
9. exp psychotherapy/
10. psychotherap$.ab,ti.
11. ((psychodynamic or psychosocial) adj2 (therap$ or treatment$ or intervention$ or program$)).ab,ti.
12. exp Behavior Therapy/
13. ((behavio$ or cognitive$) adj3 (therap$ or treatment$ or management or intervention$ or program$)).
ab,ti.
14. cbt.ab,ti.
15. exp Counseling/
16. counsel$.ab,ti.
17. exp Mind-Body Therapies/
18. ((relaxation or imagery) adj2 (therap$ or technique$)).ab,ti.
19. (guided adj2 imagery).ab,ti.
20. biofeedback.ab,ti.
21. (family adj2 therap$).ab,ti.
22. (motivation$ adj3 (therap$ or interview$)).ab,ti.
23. ((case or contingency) adj2 (therap$ or management)).ab,ti.
24. ((coping skill$ or cbst or self control or assertive$) adj2 (training or therap$)).ab,ti.
25. aversi$ therap$.ab,ti.
26. covert sensiti?ation.ab,ti.
27. or/7-26
28. 6 and 27
29. meta-analysis as topic/
30. (meta analy$ or metaanaly$).tw.
31. Meta-Analysis/
32. (systematic adj (review$1 or overview$1)).tw.
33. “Review Literature as Topic”/
34. or/29-33
35. (cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or cinhal or science
citation index or bids or cancerlit).ab.
36. ((reference adj list$) or bibliograph$ or hand-search$ or (relevant adj journals) or (manual adj
search$)).ab.
37. ((selection adj criteria) or (data adj extraction)).ab.
38. “review”/
39. 37 and 38
40. comment/ or editorial/ or letter/
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41. Animals/
42. Humans/
43. 41 not (41 and 42)
44. 40 or 43
45. 34 or 35 or 36 or 39
46. 45 not 44
47. 28 and 46
48. Randomized controlled trials as Topic/
49. Randomized controlled trial/
50. Random allocation/
51. randomized controlled trial.pt.
52. Double blind method/
53. Single blind method/
54. Clinical trial/
55. exp Clinical Trials as Topic/
56. controlled clinical trial.pt.
57. clinical trial$.pt.
58. multicenter study.pt.
59. or/48-58
60. (clinic$ adj25 trial$).ti,ab.
61. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$ or mask$)).tw.
62. Placebos/
63. Placebo$.tw.
64. randomly allocated.tw.
65. (allocated adj2 random).tw.
66. or/60-65
67. 59 or 66
68. Case report.tw.
69. Letter/
70. Historical article/
71. 68 or 69 or 70
72. exp Animals/
73. Humans/
74. 72 not (72 and 73)
75. 71 or 74
76. 67 not 75
77. 28 and 76
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Appendix 3 Table of excluded studies with
rationale
Author and year Reason for exclusion
Azrin NH, McMahon PT, Donohue B, Besalel VA, Lapinski KJ, Kogan ES, et al. Behavior therapy
for drug abuse: a controlled treatment outcome study. Behav Res Ther 1994;32:857–66
No relevant outcomes
Barrowclough C, Haddock G, Beardmore R, Conrod P, Craig T, Davies L, et al. Evaluating
integrated MI and CBT for people with psychosis and substance misuse: Recruitment, retention
and sample characteristics of the MIDAS trial. Addict Behav 2009;34:859–66
No relevant outcomes
Barrowclough C, Haddock G, Wykes T, Beardmore R, Conrod P, Craig T, et al. Integrated
motivational interviewing and cognitive behavioural therapy for people with psychosis and
comorbid substance misuse: randomised controlled trial. BMJ 2010;341:c6325
No relevant outcomes
Barrowclough C, Lobbanl F, Warburton J, Choudhry I, Gregg L, Wood H, et al. HELPER ReCAP:
Rethinking Choices after Psychosis – a phase-specific psychological therapy for people with
problematic cannabis use following a first episode of psychosis. Early Interv Psychiatry
2010;4(Suppl. 1):161
No relevant outcomes
Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y, Bellack AS, et al. A randomized clinical
trial of a new behavioral treatment for drug abuse in people with severe and persistent mental
illness. Arch Gen Psychiatry 2006;63:426–32
No relevant outcomes
Bernstein E, Edwards E, Dorfman D, Heeren T, Bliss C. Screening and brief intervention to reduce
marijuana use among youth and young adults in a pediatric emergency department. Acad Emerg
Med 2009;16:1174–85
Not relevant population
Bond GR, McDonel EC, Miller LD, Pensec M. Assertive community treatment and reference
groups: an evaluation of their effectiveness for young adults with serious mental illness and
substance abuse problems. Psychosoc Rehabil J 1991;15:31–43
No relevant outcomes
Brooks AJ, Penn PE. Comparing treatments for dual diagnosis: twelve-step and self-management
and recovery training. Am J Drug Alcohol Abuse 2003;29:359–83
No relevant outcomes
Brown TG, Seraganian P, Tremblay J, Annis H. Process and outcome changes with relapse
prevention versus 12-step aftercare programs for substance abusers. Addiction 2002;97:677–89
No relevant outcomes
Buckner JD, Carroll KM. Effect of anxiety on treatment presentation and outcome: results from
the Marijuana Treatment Project. Psychiatry Res 2010;178:493–500
No relevant outcomes
Budney AJ, Moore BA, Rocha H. Abstinence-based vouchers delivered without psychotherapy
increase abstinence during treatment for marijuana dependence. Drug Alcohol Depend
2001;63(Suppl. 1):21
No relevant outcomes
Campbell AN, Nunes EV, McClure EA, Hu MC, Turrigiano E, Goldman B, et al. Characteristics of
an outpatient treatment sample by primary substance of abuse. J Addict Med 2013;7:363–71
No relevant outcomes
Carroll KM, Easton CJ, Nich C, Hunkele KA, Neavins TM, Sinha R, et al. The use of contingency
management and motivational/skills-building therapy to treat young adults with marijuana
dependence. J Consult Clin Psychol 2006;74:955–66
Not relevant population
Carroll KM, Ball SA, Martino S, Nich C, Babuscio TA, Nuro KF, et al. Computer-assisted delivery
of cognitive–behavioral therapy for addiction: A randomized trial of CBT4CBT. Am J Psychiatry
2008;165:881–8
No relevant outcomes
Carroll KM, Nich C, Lapaglia DM, Peters EN, Easton CJ, Petry NM, et al. Combining cognitive
behavioral therapy and contingency management to enhance their effects in treating cannabis
dependence: less can be more, more or less. Addiction 2012;107:1650–9
Not relevant population
ClinicalTrials.gov. Effectiveness of a Brief Intervention for Substances Consumption Linked to the
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): A Randomized Control
Trial in Chilean Primary Care. 2013. URL: http://ClinicalTrials.gov/show/NCT01573416 (accessed
6 February 2014)
No relevant outcomes
ClinicalTrials.gov. Study Comparing Two Types of Psychotherapy for Treating Depression
and Substance Abuse. 2009. URL: http://ClinicalTrials.gov/show/NCT00108407 (accessed
6 February 2014)
Not relevant intervention
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Author and year Reason for exclusion
ClinicalTrials.gov. Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders.
2013. URL: https://clinicaltrials.gov/show/NCT01875796 (accessed 6 February 2014)
No relevant outcomes
ClinicalTrials.gov. Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency
Management. 2011. URL: https://clinicaltrials.gov/ct2/show/NCT00350649 (accessed
6 February 2014)
Not relevant population
ClinicalTrials.gov. Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse. 2013.
URL: https://clinicaltrials.gov/show/NCT00798109 (accessed 6 February 2014)
No relevant outcomes
ClinicalTrials.gov. Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia.
2011. URL: https://clinicaltrials.gov/show/NCT01292577 (accessed 6 February 2014)
No relevant outcomes
ClinicalTrials.gov. Screening, Brief Intervention and Referral to Treatment for Substance Abuse in
Mental Health Treatment Settings. 2013. URL: https://clinicaltrials.gov/show/NCT01883791
(accessed 6 February 2014)
No relevant outcomes
ClinicalTrials.gov. CANDIS – Targeted Treatment for Cannabis Disorders. 2007.
URL: http://ClinicalTrials.gov/show/NCT00252980 (accessed 6 February 2014)
No relevant outcomes
ClinicalTrials.gov. CANDIS-II: Evaluation of the Cognitive-behavioural Treatment Programme
CANDIS. 2009. URL: http://ClinicalTrials.gov/show/NCT00673647 (accessed 6 February 2014)
No relevant outcomes
ClinicalTrials.gov. Marijuana Treatment Project – 3. 2014. URL: http://ClinicalTrials.gov/show/
NCT00107588 (accessed 6 February 2014)
No relevant outcomes
ClinicalTrials.gov. Specialized Addiction Treatment Versus Treatment as Usual for Young Patients
With Cannabis Abuse and Psychosis. 2011. URL: https://clinicaltrials.gov/ct2/show/NCT00484302
(accessed 6 February 2014)
No relevant outcomes
ClinicalTrials.gov. INCA – Intervention and Neuropsychology in Cannabis Abuse. 2007.
URL: https://clinicaltrials.gov/ct2/show/NCT00279604 (accessed 6 February 2014)
No relevant outcomes
ClinicalTrials.gov. A Brief Marijuana Intervention for Adolescent Women – 1. 2013.
URL: https://clinicaltrials.gov/ct2/show/NCT00227864 (accessed 6 February 2014)
No relevant outcomes
Copeland J, Swift W, Rees V, Copeland J, Swift W, Rees V. Clinical profile of participants in a
brief intervention program for cannabis use disorder. J Subst Abuse Treat 2001;20:45–52
No relevant outcomes
Diamond GS, Liddle HA, Wintersteen MB, Dennis ML, Godley SH, Tims F, et al. Early therapeutic
alliance as a predictor of treatment outcome for adolescent cannabis users in outpatient
treatment. Am J Addict 2006;15(Suppl. 1):26–33
Not relevant population
Drapkin ML. Tate SR, McQuaid JR, Brown SA. Does initial treatment focus influence outcomes for
depressed substance abusers? J Subst Abuse Treat 2008;35:343–50
No relevant outcomes
Favrod J. Motivational interventions: psychosis and cannabis. Encephale 2009;35:S209–13 Not in English
Fohlmann AH, Hjorthoej C, Larsen A, Nordentoft M. CapOpus. Randomized clinical trial:
specialized addiction treatment (MI & CBT) versus treatment as usual for young patients with
cannabis abuse and psychosis. Early Interv Psychiatry 2010;4:160
No relevant outcomes
Gaudiano BA, Weinstock LM, Miller IW. Improving treatment adherence in patients with bipolar
disorder and substance abuse: rationale and initial development of a novel psychosocial
approach. J Psychiatr Pract 2011;17:5–20
Not a RCT
Godley MD, Godley SH, Dennis ML, Funk RR, Passetti LL, Petry NM, et al. A randomized trial of
assertive continuing care and contingency management for adolescents with substance use
disorders. J Consult Clin Psychol 2014;82:40–51
Not relevant population
Godley MD, Godley SH, Dennis ML, Funk R, Passetti LL, Godley MD, et al. Preliminary outcomes
from the assertive continuing care experiment for adolescents discharged from residential
treatment. J Subst Abuse Treat 2002;23:21–32
Not relevant population
Goti J, Diaz R, Serrano L, Gonzalez L, Calvo R, Gual A, et al. Brief intervention in substance-use
among adolescent psychiatric patients: a randomized controlled trial. Eur Child Adoles Psychiatry
2010;19:503–11
Not relevant population
Granholm E, Tate SR, Link PC, Lydecker KP, Cummins KM, McQuaid J, et al. Neuropsychological
functioning and outcomes of treatment for co-occurring depression and substance use disorders.
Am J Drug Alcohol Abuse 2011;37:240–9
No relevant outcomes
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Author and year Reason for exclusion
Greenfield SF, Trucco EM, McHugh RK, Lincoln M, Gallop RJ, Greenfield SF, et al. The Women’s
Recovery Group Study: a Stage I trial of women-focused group therapy for substance use
disorders versus mixed-gender group drug counseling. Drug Alcohol Depend 2007;90:39–47
No relevant outcomes
Hawkins JD, Catalano RF Jr, Gillmore MR, Wells EA, Hawkins JD, Catalano RFJ, et al. Skills training
for drug abusers: generalization, maintenance, and effects on drug use. J Consult Clin Psychol
1989;57:559–63
Not relevant population
Hendricks PS, Delucchi KL, Humfleet GL, Hall SM, Hendricks PS, Delucchi KL, et al. Alcohol and
marijuana use in the context of tobacco dependence treatment: impact on outcome and mediation
of effect. Nicotine Tob Res 2012;14:942–51
No relevant outcomes
Hendriks V, van der Schee E, Blanken P, Hendriks V, van der Schee E, Blanken P. Treatment of
adolescents with a cannabis use disorder: main findings of a randomized controlled trial comparing
multidimensional family therapy and cognitive behavioral therapy in The Netherlands. Drug Alcohol
Depend 2011;119:64–71
Not relevant population
Hendriks VM, van der Schee E, Blanken P. Multidimensional family therapy and cognitive behavioral
therapy in adolescents with a cannabis use disorder: a randomised controlled study. Tijdschrift voor
Psychiatrie 2013; 55:747–59
Not in English
Henggeler SW, Pickrel SG, Brondino MJ. Multisystemic treatment of substance-abusing and
dependent delinquents: outcomes, treatment fidelity, and transportability. Ment Health Serv Res
1999;1:171–84
Not relevant population
Hides LM, Elkins KS, Scaffidi A, Cotton SM, Carroll S, Lubman DI, et al. Does the addition of
integrated cognitive behaviour therapy and motivational interviewing improve the outcomes of
standard care for young people with comorbid depression and substance misuse? Med J Aust
2011;195:S31–7
Not a RCT
Hides L, Carroll S, Scott R, Cotton S, Baker A, Lubman D, et al. Quik fix: a randomized controlled
trial of an enhanced brief motivational interviewing intervention for alcohol/cannabis and
psychological distress in young people. Psychother Psychosom 2013;82:122–4
No relevant outcomes
Hill KP, Toto LH, Lukas SE, Weiss RD, Trksak GH, Rodolico JM, et al. Cognitive behavioral therapy
and the nicotine transdermal patch for dual nicotine and cannabis dependence: a pilot study.
Am J Addict 2013;22:233–8
Not relevant intervention
Hjorthoj CR, Orlovska S, Fohlmann A, Nordentoft M. Psychiatric treatment following participation
in the CapOpus randomized trial for patients with comorbid cannabis use disorder and psychosis.
Schizophr Res 2013;151:191–6
No relevant outcomes
James W, Preston NJ, Koh G, Spencer C, Kisely SR, Castle DJ. A group intervention which assists
patients with dual diagnosis reduce their drug use: a randomised controlled trial. Psychol Med
2004;34:983–90
No relevant outcomes
Jerrell JM, Ridgely MS. Comparative effectiveness of three approaches to serving people with
severe mental illness and substance abuse disorders. J Nerv Ment Dis 1995;183:566–76
No relevant outcomes
Johnson IS, Craig T, Hinton T, King M, Major B, Marston L. Randomised controlled trial of the
clinical and cost-effectiveness of a contingency management intervention for reduction of
cannabis use and of relapse in early psychosis (Project record). Health Technology Assessment
Database 2012. URL: www.nets.nihr.ac.uk/projects/hta/0914450 (accessed 6 February 2014)
No relevant outcomes
Jonas B, Tossmann P, Tensil M, Leuschner F, Struber E. Efficacy of a single-session
online-intervention on problematic substance use. Sucht 2012;58:173–82
Not in English
Kadden RM, Litt MD, Dion KB. Increased alcohol use following treatment for marijuana
dependence. Alcohol Clin Exp Res 2004;28:146A
No relevant outcomes
Kay-Lambkin FJ, Baker AL, Kelly BJ, Lewin TJ. It’s worth a try: the treatment experiences of rural
and Urban participants in a randomized controlled trial of computerized psychological treatment
for comorbid depression and alcohol/other drug use. J Dual Diagn 2012;8:262–76
No relevant outcomes
Kemp R, Harris A, Vurel E, Sitharthan T. Stop Using Stuff: Trial of a drug and alcohol intervention for
young people with comorbid mental illness and drug and alcohol problems. Australas Psychiatry
2007;15:490–3
No relevant outcomes
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Author and year Reason for exclusion
Killeen TK, Upadhyana H, Mcrae A, Waldrop A, Brown C, Brady K. Contingency management for
community treatment-seeking adolescents with marijuana use disorders. Proceedings of the 70th
Annual Scientific Meeting of the College on Problems of Drug Dependence; 2008 June 14–19;
San Juan, Puerto Rico, USA 2008;95. URL: www.cpdd.vcu.edu/Pages/Meetings/
CPDD08AbstractBook2.pdf (accessed 6 February 2014)
Not relevant population
Kleber HD, Weiss RD, Anton J, George TP, Greenfield SF, Kosten TR, et al. Treatment of patients
with substance use disorders: Second edition. Am J Psychiatry 2006;163(Suppl. 8):1–81
No relevant outcomes
Kuper LE, Gallop R, Greenfield SF. Changes in coping moderate substance abuse outcomes
differentially across behavioral treatment modality. Am J Addict 2010;19:543–9
No relevant outcomes
Latimer WW, Winters KC, D’Zurilla T, Nichols M. Integrated family and cognitive–behavioral therapy
for adolescent substance abusers: a stage I efficacy study. Drug Alcohol Depend 2003;71:303–17
Not relevant population
Lawlor E, Madigan K, Russell V, O’Connor JJ, Turner N, Clarke M, et al. Engagement with a
group-based psychological intervention for those with early phase psychosis and concurrent use
of cannabis. Early Interv Psychiatry 2012;6:28
No relevant outcomes
Lehman AF, Herron JD, Schwartz RP, Myers CP. Rehabilitation for adults with severe mental
illness and substance use disorders. A clinical trial. J Nerv Ment Dis 1993;181:86–90
No relevant outcomes
Liddle HA, Dakof GA, Parker K, Diamond GS, Barrett K, Tejeda M, et al. Multidimensional family
therapy for adolescent drug abuse: results of a randomized clinical trial. Am J Drug Alcohol
Abuse 2001;27:651–88
Not relevant population
Liddle HA, Dakof GA, Turner RM, Henderson CE, Greenbaum PE, Liddle HA, et al. Treating
adolescent drug abuse: a randomized trial comparing multidimensional family therapy and
cognitive behavior therapy. Addiction 2008;103:1660–70
Not relevant population
Lykke J, Oestrich I, Austin SF, Hesse M. The implementation and evaluation of cognitive milieu
therapy for dual diagnosis inpatients: a pragmatic clinical trial. J Dual Diagn 2010;6:58–72
Not a RCT
Madigan K, Lawlor E, Brennan D, Turner N, Kinsella A, O’Connor JJ, et al. A multi-centre,
randomised controlled trial of a group psychological intervention for psychosis with comorbid
cannabis dependence over the early course of illness. Early Interv Psychiatry 2012;6:27
Study characteristics or
secondary analysis
Magill M, Barnett NP, Apodaca TR, Rohsenow DJ, Monti PM. The role of marijuana use in
brief motivational intervention with young adult drinkers treated in an emergency department.
J Stud Alcohol Drugs 2009;70:409–13
Not relevant population
Mariani JJ, Cheng WY, Bisaga A, Sullivan M, Carpenter K, Nunes EV, et al. Comparison of
clinical trial recruitment populations: treatment-seeking characteristics of opioid-, cocaine-, and
cannabis-using participants. J Subst Abuse Treat 2011;40:426–30
No relevant outcomes
Marsden J, Farrell M, Bradbury C, Dale-Perera A, Eastwood B, Roxburgh M, et al. Development of
the Treatment Outcomes Profile. Addiction 2008;103:1450–60
No relevant outcomes
Martin G, Copeland J. The adolescent cannabis check-up: randomized trial of a brief intervention
for young cannabis users. J Subst Abuse Treat 2008;34:407–14
Not relevant population
Martino S, Carroll KM, Nich C, Rounsaville BJ. A randomized controlled pilot study of
motivational interviewing for patients with psychotic and drug use disorders. Addiction
2006;101:1479–92
No relevant outcomes
McCambridge J, Strang J. The efficacy of single-session motivational interviewing in reducing
drug consumption and perceptions of drug-related risk and harm among young people: results
from a multi-site cluster randomized trial. Addiction 2004;99:39–52
Not relevant population
McCambridge J, Strang J. Deterioration over time in effect of Motivational Interviewing in
reducing drug consumption and related risk among young people. Addiction 2005;100:470–8
Not relevant population
McCambridge J, Slym RL, Strang J. Randomized controlled trial of motivational interviewing
compared with drug information and advice for early intervention among young cannabis users.
Addiction 2008;103:1809–18
Not relevant population
McCambridge J, Day M, Thomas BA, Strang J. Fidelity to Motivational Interviewing and subsequent
cannabis cessation among adolescents. Addict Behav 2011;36:749–54
Not relevant population
McCambridge J, Hunt C, Jenkins RJ, Strang J. Cluster randomised trial of the effectiveness of
motivational interviewing for universal prevention. Drug Alcohol Depend 2011;114:177–84
Not relevant population
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Author and year Reason for exclusion
McGillicuddy NB, Rychtarik RG, Duquette JA, Morsheimer ET. Development of a skill training program
for parents of substance-abusing adolescents. J Subst Abuse Treat 2001;20:59–68
Not relevant population
McLellan AT. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis
use disorder. J Subst Abuse Treat 2001;21:65–6
Not a RCT
Miller WR. It all depends. Addiction 2008;103:1819–20 Not a RCT
Miller WR, Yahne CE, Tonigan JS. Motivational interviewing in drug abuse services: a randomized
trial. J Consult Clin Psychol 2003;71:754–63
No relevant outcomes
Montgomery L, Petry NM, Carroll KM. Moderating effects of race in clinical trial participation and
outcomes among marijuana-dependent young adults. Drug Alcohol Depend 2012;126:333–9
No relevant outcomes
Moore BA, Budney AJ. Abstinence at intake for marijuana dependence treatment predicts
response. Drug Alcohol Depend 2002;67:249–57
No relevant outcomes
Morley KC, Sitharthan G, Haber PS, Tucker P, Sitharthan T. The efficacy of an opportunistic
cognitive behavioral intervention package (OCB) on substance use and comorbid suicide risk:
a multisite randomized controlled trial. J Consult Clin Psychol 2014;82:130–40
No relevant outcomes
Murphy DA, Chen X, Naar-King S, Parsons JT, Adolescent TN. Alcohol and marijuana use
outcomes in the Healthy Choices motivational interviewing intervention for HIV-positive youth.
AIDS Patient Care Stds 2012;26:95–100
Not relevant population
Nagel T, Robinson G, Condon J, Trauer T. Approach to treatment of mental illness and substance
dependence in remote Indigenous communities: results of a mixed methods study. Aust J Rural
Health 2009;17:174–82
Not relevant population
Nery FG, Soares JC. Comorbid bipolar disorder and substance abuse: Evidence-based options.
Current Psychiatry 2011;10:57–66
Not a RCT
Nordentoft M, Hjorthoj C, Fohlmann A. Capopus trial: an observer-blinded RCT of specialized
addiction treatment versus standard treatment for young patients with cannabis abuse and
psychosis. Eur Psychiatry 2009;24:S1178
No relevant outcomes
Nyamathi A, Branson C, Kennedy B, Salem B, Khalilifard F, Marfisee M, et al. Impact of nursing
intervention on decreasing substances among homeless youth. Am J Addict 2012;21:558–65
Not relevant intervention
Ondersma SJ, Svikis DS, Schuster CR. Computer-based brief intervention a randomised trial with
postpartum women. Am J Prev Med 2007;32:231–8. [Erratum published in Am J Prev Med
2007;32:549]
Not relevant population
Peters EN, Nich C, Carroll KM. Primary outcomes in two randomized controlled trials of
treatments for cannabis use disorders. Drug Alcohol Depend 2011;118:408–16
No relevant outcomes
Peters EN, Petry NM, Lapaglia DM, Reynolds B, Carroll KM. Delay discounting in adults receiving
treatment for marijuana dependence. Exp Clin Psychopharmacol 2013;21:46–54
No relevant outcomes
Peterson PL, Baer JS, Wells EA, Ginzler JA, Garrett SB. Short-term effects of a brief motivational
intervention to reduce alcohol and drug risk among homeless adolescents. Psychol Addict Behav
2006;20:254–64
Not relevant population
Phan O, Jouanne C, Monge S. A random clinical trial concerning the psychotherapy of adolescents
addicted to cannabis. Ann Med Psychol (Paris) 2010;168:145–51
No relevant outcomes
Pokhrel P, Sussman S, Rohrbach LA, Sun P. Prospective associations of social self-control with
drug use among youth from regular and alternative high schools. Subst Abuse Treat Prev Policy
2007;2:22
Not a RCT
Ramchand R, Griffin BA, Suttorp M, Harris KM, Morral A. Using a cross-study design to assess
the efficacy of motivational enhancement therapy-cognitive behavioral therapy 5 (MET/CBT5) in
treating adolescents with cannabis-related disorders. J Stud Alcohol Drugs 2011;72:380–9
Not relevant population
Rees V, Copeland J, Swift W, Roffman R, Stephens R. Brief cognitive behavioral interventions for
cannabis dependence. NIDA Research Monograph 1999;179:79
No relevant outcomes
Riley KJ, Rieckmann T, McCarty D. Implementation of MET/CBT 5 for adolescents. J Behav Health
Serv Res 2008;35:304–14
Not a RCT
Roffman RA, Stephens RS, Simpson EE, Whitaker DL. Treatment of marijuana dependence:
preliminary results. J Psychoactive Drugs 1988;20:129–37
No relevant outcomes
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Author and year Reason for exclusion
Roffman RA, Klepsch R, Wertz JS, Simpson EE, Stephens RS. Predictors of attrition from an
outpatient marijuana-dependence counseling program. Addict Behav 1993;18:553–66
No relevant outcomes
Rooke SE, Gates PJ, Norberg MM, Copeland J. Applying technology to the treatment of cannabis
use disorder: Comparing telephone versus Internet delivery using data from two completed trials.
J Subst Abuse Treat 2014;46:78–84
No relevant outcomes
Rowe C, Rigter H, Henderson C, Gantner A, Mos K, Nielsen P, et al. Implementation fidelity of
Multidimensional Family Therapy in an international trial. J Subst Abuse Treat 2013;44:391–99
Not relevant population
Ruehlmann A, Hoch E, Noack R, Henker J, Pixa A, Rohrbacher H, et al. Efficacy of the Manualized
Cognitive-Behavioral Treatment Program Cannabis Use Disorders. Reno/Sparks, Nevada, NV:
Proceedings of the 71th Annual Scientific Meeting of the College on Problems of Drug
Dependence; 2009. URL: www.cpdd.org/Pages/Meetings/CPDD09AbstractBook.pdf (accessed
6 February 2014)
Study characteristics or
secondary analysis
Santisteban DA, Coatsworth JD, Perez-Vidal A, Kurtines WM, Schwartz SJ, LaPerriere A, et al.
Efficacy of brief strategic family therapy in modifying Hispanic adolescent behavior problems and
substance use. J Fam Psychol 2003;17:121–33
Not relevant population
Santisteban DA, Mena MP, McCabe BE. Preliminary results for an adaptive family treatment for
drug abuse in Hispanic youth. J Fam Psychol 2011;25:610–14
Not relevant population
Shane P, Diamond GS, Mensinger JL, Shera D, Wintersteen MB. Impact of victimization on
substance abuse treatment outcomes for adolescents in outpatient and residential substance
abuse treatment. Am J Addict 2006;15(Suppl. 1):34–42
Not relevant population
Smeerdijk M, Keet R, Dekker N, van RB, Krikke M, Koeter M, et al. Motivational interviewing and
interaction skills training for parents to change cannabis use in young adults with recent-onset
schizophrenia: a randomized controlled trial. Psychol Med 2012;42:1627–36
Not relevant population
Smeerdijk M, Keet R, de HL, Barrowclough C, Linszen D, Schippers G. Feasibility of teaching
motivational interviewing to parents of young adults with recent-onset schizophrenia and
co-occurring cannabis use. J Subst Abuse Treat 2014;46:340–5
Not relevant population
Spring B, Ferguson MJ. CALM technology-supported intervention: synopsis of evidence for an
emerging class of practice tool. Transl Behav Med 2011;1:8–9
Not relevant population
Stephens RS, Wertz JS, Roffman RA. Self-efficacy and marijuana cessation: a construct validity
analysis. J Consult Clin Psychol 1995;63:1022–31
No relevant outcomes
Stephens RS, Wertz JS, Roffman RA. Predictors of marijuana treatment outcomes: the role of
self-efficacy. J Subst Abuse 1993;5:341–53
No relevant outcomes
Stephens RS, Babor TF, Kadden R, Miller M, Marijuana Treatment Project Research Group.
The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction
2002;97(Suppl. 1):109–24
No relevant outcomes
Strain EC. Single versus multiple drug focus in substance abuse clinical trials research: The devil is
in the details. Drug Alcohol Depend 2003;70:131–4
No relevant outcomes
Strang J, McCambridge J. Can the practitioner correctly predict outcome in motivational
interviewing? J Subst Abuse Treat 2004;27:83–8
No relevant outcomes
Stanger C, Budney AJ, Kamon JL. Contingency management for adolescent marijuana abuse.
Proceedings of the 68th Annual Scientific Meeting of the College on Problems of Drug
Dependence. Scottsdale, AZ; 2006
Not relevant population
Tetzlaff BT, Kahn JH, Godley SH, Godley MD, Diamond GS, Funk RR, et al. Working alliance,
treatment satisfaction, and patterns of posttreatment use among adolescent substance users.
Psychol Addict Behav 2005;19:199–207
Not relevant population
VanScoyoc J, Stanger C, Budney, Thostenson J. Disruptive behavior disorder influence response to
contingency management among adolescent marijuana abusers. Proceedings of the 70th Annual
Scientific Meeting of the College on Problems of Drug Dependence. San Juan, PR; 2008
Not relevant intervention
Vendetti J, McRee B, Miller M, Christiansen K, Herrell J, Marijuana Treatment Project Research
Group. Correlates of pre-treatment drop-out among persons with marijuana dependence.
Addiction 2002;97(Suppl. 1):125–34
No relevant outcomes
Waldron HB, Slesnick N, Brody JL, Turner CW, Peterson TR. Treatment outcomes for adolescent
substance abuse at 4- and 7-month assessments. J Consult Clin Psychol 2001;69:802–13
Not relevant population
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Author and year Reason for exclusion
Waldron HB, Turner CW, Ozechowski TJ. Profiles of drug use behavior change for adolescents in
treatment. Addict Behav 2005;30:1775–96
Not relevant population
Walker D, Stephens R, Rowland J, Roffman R. The influence of client behavior during
motivational interviewing on marijuana treatment outcome. Addict Behav 2011;36:669–73
No relevant outcomes
Werch CE, Bian H, Carlson JM, Moore MJ, Diclemente CC, Huang IC, et al. Brief integrative
multiple behavior intervention effects and mediators for adolescents. J Behav Med 2011;34:3–12
Not relevant population
White HR, Morgan TJ, Pugh LA, Celinska K, Labouvie EW, Pandina R, et al. Evaluating two brief
substance-use interventions for mandated college students. J Stud Alcohol 2006;67:309–17
Not relevant population
Winstock AR, Ford C, Witton J. Assessment and management of cannabis use disorders in
primary care. BMJ 2010;30:800–4
No relevant outcomes
Wittchen HU. Targeted cognitive–behavioral treatment for cannabis use disorders (CANDIS):
efficacy, longterm stability, and efficiency. Eur Neuropsychopharmacol 2010;20:S206
Study characteristics or
secondary analysis
Worley MJ, Tate SR, Brown SA. Mediational relations between 12-Step attendance, depression and
substance use in patients with comorbid substance dependence and major depression. Addiction
2012;107:1974–83
Not relevant intervention
Wykes T. Cannabis use: Defining the targets for psychological treatment. Schizophr Bull
2011;37:285
No relevant outcomes
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Appendix 4 Table of full data from included
studies
Author and
year
Cannabis use (1) outcome measure, (2) absolute values (mean/median, SD/SE), (3) p-values
(groups/baseline), (4) between group difference and CI
4 months (post treatment) 9 months 15 months
Babor 200439
and Litt 200572
1. Mean percentage of days
smoking
2. Wait list=75.59 (SD=30.69), MET-2=
55.86 (SD=36.18), CBT/MET/
CaseM-9=36.17 (SD=38.83)
3. Reduction in days smoked is
significant (p= value NR)
4. NR
1. Periods smoked per day (of 4)
2. Wait list= 1.95 (SD= 1.05),
MET-2= 1.35 (SD= 0.89), CBT/MET/
CaseM-9= 1.02 (SD= 1.07)
3. (Cohen’s d statistic) MET-2 vs. wait
list = 0.6, CBT/MET/CaseM-9 vs.
wait list = 0.91, CBT/MET/CaseM-9
vs. MET-2= 0.4; all between-group
differences significant
4. NR
1. Mean joints per day
2. Wait list= 2.03 (SD= 1.94),
MET-2= 1.50 (SD= 1.62), CBT/MET/
CaseM-9= 1.00 (SD= 1.71)
3. (Cohen’s d statistic) MET-2 vs. wait
list = 0.29, CBT/MET/
CaseM-9 vs. wait list= 0.43, both
significant; CBT/MET/CaseM-9 vs.
MET-2=NS
4. NR
1. Reduction in days smoked
(baseline to 4 month)
2. Wait list= 15.9%,
MET-2= 35.7%, CBT/MET/
CaseM-9 = 58.8%
3. (Cohen’s d statistic) MET-2 vs. wait
list = 0.59, CBT/MET/CaseM-9
vs. wait list= 1.14, CBT/MET/
CaseM-9 vs. MET-2= 0.52; all
between-group differences
significant
4. NR
1. Abstinence over preceding 90 days
2. CBT/MET/CaseM-9 = 22.6%,
MET-2= 8.6%, wait list = 3.6%
3. p< 0.001 (between groups);
CBT/MET/CaseM-9 vs. MET-2 or
wait list = significant; MET-2 vs.
wait list =NR
4. NR
1. Mean percentage of
days smoking
2. MET-2= 59.76
(SD = 36.78), CBT/MET/
CaseM-9 = 43.87
(SD = 37.48)
3. (Cohen’s d statistic)
MET-2 CB VS
MET-2=0.37, significant
4. NR
1. Periods smoked per
day (of 4)
2. MET-2= 1.39
(SD= 0.92), CBT/MET/
CaseM-9= 1.19
(SD= 1.02)
3. Treatment × time
interaction
4. NR
1. Mean joints per day
2. MET-2= 1.59
(SD = 2.28), CBT/MET/
CaseM-9 = 1.48
(SD = 2.53)
3. NR
4. NR
5. 9 month
1. Abstinence over
preceding 90 days
2. CBT/MET/
CaseM-9= 15.6%,
MET-2= 9.5%
3. p> 0.05 (between
groups) (not significant)
4. NR
1. Mean percentage of days
smoking
2. CBT/MET/CaseM-9= 44.86
(SD= 40.52), MET-2= 53.65
(SD= 38.57)
3. (Cohen’s d statistic) 0.22,
significant
4. NR
1. Reduction in days smoked
(baseline to 15 month)
2. CBT/MET/CaseM-9= 48%,
MET-2= 33%
3. NR
4. NR
1. Abstinence over preceding
90 days
2. CBT/MET/CaseM-9= 22.7%,
MET-2= 12.5%
3. p< 0.001 (between groups,
CBT/MET/CaseM-9 vs. MET-2)
4. NR
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Author and
year
Cannabis use (1) outcome measure, (2) absolute values (mean/median, SD/SE), (3) p-values
(groups/baseline), (4) between group difference and CI
15 weeks (post treatment) 12 months
Baker 200652 1. Days used during prior month via OTI (change, baseline to
15 weeks)
2. CBT/MI-10 + TAU mean change= –3.09 (SD NR;
n analysed= 39); TAU mean change=+ 0.86 (SD NR;
n analysed= 34)
3. p= 0.02 (between groups for change)
4. NR
1. % with at least weekly use via OTI
2. CBT/MI-10 + TAU 64.1% (25/39); TAU 73.5% (25/34)
3. p=NS (between groups)
4. NR
1. % abstinence
2. CBT/MI-10 + TAU 23.1% (9/39); TAU 23.5% (8/34)
3. p=NS (between groups)
4. NR
1. Days used during prior
month via OTI (change,
baseline to 12 months)
2. CBT/MI-10+ TAU mean
change= + 0.35 (SD NR;
n analysed= 29); TAU
mean change= –0.68
(SD NR; n analysed = 29)
3. p=NS
4. NR
1. % with at least weekly use
via OTI
2. CBT/MI-10+ TAU 58.6%
(17/29); TAU 55.2% (16/29)
3. p=NS (between groups)
4. NR
1. % abstinence
2. CBT/MI-10+ TAU 37.9%
(11/29); TAU 34.5% (10/29)
3. p=NS (between groups)
4. NR
3 months
6 months
(post treatment) 12 months
Bonsack 201166 1. Cannabis use: reduction in number
of joints per week
2. CBT/MI-6+ TAU median = 6,
range= 62. TAU median= 0.5
3. p= 0.015
4. NR
1. Number days abstinent last month
2. Median values – CBT/MI-6+ TAU=
5.0 (range 28), TAU= 8.5 (range 28)
3. p= 0.48
4. NR
1. Number days of binge use
2. Median values – CBT/MI-6+ TAU=
1.0 (range= 7),
TAU= 1.0 (range= 12)
3. p= 0.94
4. NR
1. Cannabis use:
reduction in number of
joints per week
2. CBT/MI-6+ TAU
median= 10.5, TAU
median 0.5
3. p= 0.015
4. Overall median
decrease five joints/
week
1. Number days abstinent
last month
2. Median values – CBT/
MI-6+ TAU= 7.0
(range 28), TAU= 4.5
(range 28)
3. p= 0.83
4. NR
1. Number days of
binge use
2. Median values – CBT/
MI-6+ TAU= 0.0
(range= 8), TAU= 0.0
(range= 4)
3. p= 0.48
4. NR
1. Cannabis use: reduction in
number of joints per week
2. CBT/MI-6+ TAU median= 10,
TAU median= 3.5
3. NS
4. NR
1. Number days abstinent
last month
2. Median values –CBT/MI-6+
TAU= 5.5 (range 28),
TAU= 8.5 (range 28)
3. p= 0.76
4. NR
1. Number days of binge use
2. Median values – CBT/MI-6+
TAU= 0 (range= 28),
TAU= 0 (range= 20)
3. p= 0.97
4. NR
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Author and
year
Cannabis use (1) outcome measure, (2) absolute values (mean/median, SD/SE), (3) p-values
(groups/baseline), (4) between group difference and CI
14 weeks
Budney 200040 1. Continuous cannabis abstinence (composite measure across all
durations 1–14 weeks)
2. Absolute values NR, effect size w= 0.37
3. p< 0.02 (CBT/MET-14/vouchers vs. CBT/MET-14 and MET-4),
p=NS (CBT/MET-14 vs. MET-4)
4. NR
1. Mean duration continuous abstinence
2. CBT/MET-14CBT/MET-14/vouchers = 4.8 weeks (SD= 4.9),
CBT/MET-14 = 2.3 weeks (SD = 3.0), MET-4= 1.6 weeks
(SD = 2.4)
3. p< 0.05 (CBT/MET-14/vouchers vs. CBT/MET-14 and MET-4),
other comparisons NS
4. NR
1. End-of-treatment abstinence (past 30 days)
2. CBT/MET-14/vouchers = 35%, CBT/MET-14= 10%,
MET-4= 5%
3. p< 0.05 (CBT/MET-14/vouchers vs. CBT/MET-14 and M-4)
4. NR
1. Percentage of cannabis negative urine samples
2. CBT/MET-14/vouchers = 43%, CBT/MET-14= 31%,
MET-4= 19%
3. p= 0.09 (NS)
4. NR
1. Abstinence for at least
7 weeks
2. CBT/MET-14/vouchers= 40%,
CBT/MET-14=5%,MET-4=5%
3. NS
4. NR
1. Self-reported days of
cannabis use prior 30 days
(least square means)
2. CBT/MET-14/vouchers= 6.6
(SE= 2.6), CBT/MET-14= 7.4
(SE= 2.3), MET-4= 13.0
(SE= 2.1)
3. NS (p= 0.12 for CBT/MET-14/
vouchers and CBT/MET-14
vs. MET-4)
4. NR
1. Abstinence for at least
4 weeks
2. CBT/MET-14/vouchers=50%,
CBT/MET-14=30%,
MET-4=10%
3. p< 0.05 (CBT/MET-14/
vouchers vs. CBT/MET-14 and
MET-4)
4. NR
14 weeks (post treatment) 12 months
Budney 200641 1. Days used during prior month
2. CBT-14/vouchers mean= 9.7 (SD = 9.1); CBT-14 mean= 8.6
(SD = 9.2); voucher mean= 11.3 (SD= 9.7)
3. p= 0.71 (between groups); p< 0.01 (for all groups from baseline)
4. NR
1. Number of times used per day on days when used
2. CBT-14/vouchers mean= 2.7 (SD = 3.0); CBT-14 mean= 1.6
(SD = 1.6); voucher mean= 2.6 (SD= 2.5)
3. p< 0.05 (voucher vs. CBT-14); p< 0.01 (for all groups
from baseline)
4. NR
1. Weeks of continuous abstinence
2. CBT-14/vouchers mean= 5.3 (SD = 4.7); CBT-14 mean= 3.5
(SD = 3.2); Voucher mean= 6.9 (SD= 5.4)
3. p= 0.02 (voucher vs. CBT-14); p= 0.20 (CBT-14CBT-14–14/
vouchers vs. CBT-14); p= 0.32 (voucher vs. CBT-14/vouchers)
4. NR
1. Continuous abstinence for ≥ 6 weeks
2. CBT-14/vouchers 40%; CBT-14 17%; voucher 50%
3. p< 0.05 (voucher vs. CBT-14; CBT-14/vouchers vs. CBT-14)
4. voucher vs. CBT-14: odds ratio = 6.0 (95% CI 1.7 to 21.0);
CBT-14/vouchers vs. CBT-14: odds ratio= 4.1 (95% CI 1.2
to 14.4)
5. 14 weeks
1. Days used during prior month
2. CBT-14/vouchers mean= 12.5
(SD= 13.9); CBT-14
mean= 18.3 (SD= 15.7);
voucher mean= 18.1
(SD= 13.6)
3. For repeated measures up
to 12 months: p= 0.15
(between groups); p< 0.01
(all groups over time post
treatment; days of use
increased after treatment
ended)
4. NR
1. Number of times used per
day on days when used
2. NR
3. For repeated measures up to
12 months: p= 0.31
(between groups); p= 0.94
(all groups over time post
treatment; no change after
treatment ended)
4. NR
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Author and
year
Cannabis use (1) outcome measure, (2) absolute values (mean/median, SD/SE), (3) p-values
(groups/baseline), (4) between group difference and CI
1. % abstinence (point prevalence)
2. CBT-14/vouchers 43%; CBT-14 30%; voucher 40%
3. NR
4. NR
1. Abstinence for specific period of time, at least 2, 4, 6,
and 8 weeks
2. NR
3. p= 0.02 (voucher vs. CBT-14, favours voucher), p= 0.01
(CBT14/vouchers vs. CBT-14), NS, value NR (CBT-14/vouchers
vs. voucher)
4. NR
1. % abstinence (point prevalence)
2. CBT-14/vouchers 37%;
CBT-14 23%; voucher 17%
3. p< 0.05 (CBT-14/vouchers
vs. voucher) at 12 months.
For repeated measures up
to 12 months: p= 0.04
(CBT-14/vouchers vs.
CBT-14); p= 0.08 (CBT-14/
vouchers vs. voucher);
p= 0.74 (CBT-14 vs.
voucher); p< 0.01 (all groups
over time post treatment;
abstinence levels decreased
after treatment ended)
4. For repeated measures up to
12 months: CBT-14/vouchers
vs. CBT-14: odds ratio= 2.45
(95% CI 1.01 to 5.93);
CBT-14/vouchers vs. voucher:
odds ratio= 2.17 (95% CI
0.91 to 5.17)
12 weeks (post treatment) 9 months
Budney 201142
(abstract) and
ClinicalTrials.gov
201373
1. Weeks of continuous abstinence
2. CBT/MET-9/voucher mean= 3.55 (SD= 4.39), computer-
delivered CBT/MET-9+ brief therapist+ voucher= 2.82
(SD = 4.21), MET-2 mean= 0.78 (SD= 1.97)
3. p<0.05 (CBT/MET-9/voucher and computer-delivered
CBT /MET-9+brief therapist+ voucher vs. MET-2); p>0.05
(CBT/MET-9/voucher vs. computer-delivered CBT /MET-9+ brief
therapist+ voucher)
4. NR
1. % abstinence (point prevalence)
2. CBT/MET-9/voucher= 3/29
(10.3%), computer-delivered
CBT/MET-9+ brief
therapist+ voucher= 7/30
(23.3%), MET-2= 1/16 (6.3%)
3. Across all time points from
end of treatment to 9 months
post treatment: p< 0.05
(between groups)
4. NR1. % abstinence (point prevalence)
2. CBT/MET-9/voucher = 13/29 (44.8%), computer-delivered
CBT/MET-9+ brief therapist+ voucher= 14/30 (46.7%),
MET-2= 2/16 (12.5%)
3. NR
4. NR
34 weeks (median)
Copeland 200153 1. % days abstinent since last treatment session
2. CBT-6 mean= 35.9% (SD= 34.8), MI-1 mean= 44.8% (SD= 37.7), wait list mean= 29.7%
(SD = 32.6)
3. p= 0.09 (between wait list and CBT-1), not significant (wait list vs. CBT-6 or MI-1 vs. CBT-6)
4. NR
1. Continuous abstinence since last treatment session
2. CBT-6: 15.1%, MI-1: 4.9%; wait list: 0%. (SD/SE NR)
3. NR
4. NR
1. Complete abstinence in prior month
2. CBT-6: 20.8%; 1 CBT: 17.2%; wait list: 3.6% (SDs NR)
3. p= 0.05 (CBT-6+MI-1vs wait list), p= 0.6 (CBT-6 vs. MI-1)
4. NR
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Author and
year
Cannabis use (1) outcome measure, (2) absolute values (mean/median, SD/SE), (3) p-values
(groups/baseline), (4) between group difference and CI
1. Changes in average daily consumption via OTI (baseline to follow-up)
2. Final values: CBT-6 mean= 1.3 (SD= 0.9), MI-1 mean= 1.5 (SD= 1.2), wait list mean= 1.8
(SD = 1.0) change from baseline: CBT-6= –0.8, MI-1= –0.5, wait list = –0.4 (SDs NR)
3. Differences adjusted for baseline: p= 0.02 (between CBT-6 and wait list), p= 0.2 (between MI-1
and wait list), p= 0.3 (between MI-1 and CBT-6)
4. NR
1 month (post treatment) 2 months 3 months
de Dios 201243 1. Frequency of cannabis use
2. NR
3. p= 0.031 (between group, favours
MI/meditation-2
4. NR
1. Number of days of cannabis use
over 30 days
2. NR
3. p< 0.05
4. 6.15 fewer days for MI/meditation-2
than AO (95% CI= –11.00 to −1.09)
1. Number of days of
cannabis use over
30 days
2. NR
3. p< 0.05
4. 7.81 fewer days for MI/
meditation-2 than AO
(95% CI=−13.48
to −1.98)
1. Number of days of cannabis
use over 30 days
2. NR
3. p< 0.05
4. 6.83 fewer days for MI/
meditation-2 than AO
(95% CI=−12.94 to −0.81)
1. Full abstinence (all follow-up
points)
2. NR
3. NS between groups
4. NR
3 months (post treatment) 6 months
Edwards 200654 1. Number using cannabis in past
4 weeks
2. CBT/MI-10 + TAU= 13/23
(56.5%), psychoeducation
(non-cannabis) –10 + TAU=
13/24 (54.2%)
3. p= 0.87 (between group,
not adjusted for baseline
measurement)
4. NR
1. % days using cannabis in past
4 weeks
2. CBT/MI-10 + TAU= 30.4
(SD = 41.8), psychoeducation
(non-cannabis) –10+ TAU= 18.8
(SD = 30.6)
3. p= 0.99 (between groups);
p< 0.001 (change from baseline
in both groups)
4. NR
1. % days using cannabis in past
4 weeks for those using cannabis
at least once per week
2. NR
3. p= 0.53 (between groups);
p= 0.002 (change from baseline
in both groups)
4. NR
1. Number using cannabis in past 4 weeks
2. CBT/MI-10 + TAU= 15 (65.2%), psychoeducation
(non-cannabis) – 10+ TAU= 12 (50%)
3. p= 0.29 (between groups)
4. NR
1. % days using cannabis in past 4 weeks
2. CBT/MI-10 + TAU= 32.4 (SD= 44.9), psychoeducation
(non-cannabis) –10 + TAU= 19.3 (SD = 30.4)
3. p= 0.84
4. NR
1. % days using cannabis in past 4 weeks for those using
cannabis at least once per week
2. NR
3. p= 0.86 (between groups)
4. NR
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Author and
year
Cannabis use (1) outcome measure, (2) absolute values (mean/median, SD/SE), (3) p-values
(groups/baseline), (4) between group difference and CI
6 months
Fernandes 201062 1. Reduction in cannabis use (% abstinent,% decreased use,% relapsed use)
2. Tele-brief MI-1: 73% abstinent, 16% decreased use, 2% relapsed use (n analysed= 262). Written
cannabis information: 59% abstinent, 21% decreased use, 5% relapsed use (n analysed= 262)
3. For abstinence: p< 0.05
4. For abstinence: OR= 1.6 (95% CI 1.2 to 2.0)
3 months (post treatment) 12 months
Fischer 201275
and Fischer
201364
Note: cannabis BI group is combination of brief MI and written cannabis information groups. Control
group is combination of therapist general health MI-1 and written general health information
1. Mean number of days used cannabis
2. Cannabis BI= 22.3 (95% CI 20.3 to 24.4) n= 62, control= 22.5
(95% CI 20.5, 24.6) n= 51. Separate oral and written groups:
brief MI-1= 18.78 (BL= 21.96) n= 23, written cannabis
information = 24.38 (BL= 24.82) n= 39, therapist general health
MI-1 = 21.18 (BL= 21.36) n= 22, written general health
information = 23.55 (BL= 25.35) n= 29
3. NS (between groups), p= 0.024 (all groups baseline to 3 months)
per group from baseline: brief MI-1: p= 0.125, written cannabis
information: p= 0.469, therapist general health MI-1: p= 0.737,
written general health information: p= 0.108
4. NR
1. Mean number cannabis use episodes/day previous 30 days
2. Cannabis BI= 2.4 (95% CI 1.8, 3.0) n= 40, control= 2.4
(95% CI 1.5 to 3.4) n= 32
3. NS
4. NR
1. Mean number of days
used cannabis
2. Cannabis BI= 22.3 (95% CI
19.8 to 24.8) n= 40,
control= 22.1 (95% CI 18.9
to 25.3) n= 32
3. NS
4. NR
1. Mean number cannabis use
episodes/day previous 30 days
2. Cannabis BI= 2.6 (95% CI
1.6, 3.7) n= 40, control= 2.2
(95% CI 1.7, 2.6) n= 32
3. NS
4. NR
4 weeks (post treatment) 12 weeks
Gates 201255 Both groups showed significant improvements from baseline on all
outcomes (p< 0.001) at 4 and 12 weeks
1. Days cannabis use (previous 28 days)
2. Tele-CBT/MI-4 = 8.5 (SD= 10.7), wait list= 13.4 (SD = 11.2)
3. p=NR
4. NR
1. % days abstinent (previous 28 days)
2. Tele-CBT/MI-4 = 69.5 (SD = 38.0), wait list= 51.9 (SD= 40.3)
3. p= 0.054 (all p-values based on treatment × time interactions)
4. NR
1. Cannabis use per typical day (cones/day)
2. Tele-CBT/MI-4 = 3.4 (SD= 8.0), wait list= 6.5 (SD= 9.5)
3. p= 0.017
4. NR
1. Days cannabis use (previous
28 days)
2. Tele-CBT/MI-4 = 7.3
(SD= 10.3), wait list = 12.5
(SD= 11.4)
3. p=NR
4. NR
1. % days abstinent (previous
28 days)
2. Tele-CBT/MI-4 = 73.3
(SD= 36.8), wait list = 55.3
(SD= 40.7)
3. p= 0.057
4. NR
1. Cannabis use per typical day
(cones/day)
2. Tele-CBT/MI-4 = 5.0
(SD= 13.3), wait list = 6.7
(SD= 10.4)
3. p= 0.340
4. NR
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Author and
year
Cannabis use (1) outcome measure, (2) absolute values (mean/median, SD/SE), (3) p-values
(groups/baseline), (4) between group difference and CI
6 months
Gmel 201367 1. Mean number of days of cannabis use per month, consistent
users (at least twice a week)
2. Brief MI-1= 9.3 (BL= 8.5), AO= 12 (BL= 10.6). Change from
baseline: brief MI-1= + 0.8, AO=+ 1.4
3. p= 0.342 (adjusted for baseline)
4. NR
1. Cannabis use (cannabis users)
2. Brief MI-1+ booster= 49/145 (33.8%); brief MI-1 no
booster= 48/143 (33.6%)
3. NR for cannabis users subgroup
4. NR
1. Cannabis use (cannabis users)
2. Brief MI-1= 97/288 (33.7%);
AO= 148/384 (38.5%)
3. NR for cannabis users
subgroup
4. NR
1. Mean number of days of
cannabis use per month,
consistent users (at least twice
a week) – brief MI-1+ booster
vs. brief MI-1 no booster
2. Brief MI-1+ booster= 9.8
(BL= 8.5), brief MI-1 no
booster= 8.7 (BL= 8.6).
Change from baseline: brief
MI-1+ booster=+ 1.3, brief
MI-1 no booster =+ 0.1
3. p= 0.508 (adjusted for
baseline)
4. NR
4 months
Grenyer 199756 1. Number ‘quitting’ cannabis
2. SEDP-16= 17/20, brief MI-1= 3/20
3. NR
4. NR
1. Changes in cannabis use
(not defined)
2. NR
3. p< 0.05, effect sizes:
SEDP-16= 0.74, brief
MI-1= 0.41
4. NR
4 months 6 months (post treatment)
Hjorthoj 201368
Hjorthoj 201280
1. Number of days cannabis use in past month
2. NR
3. p= 0.75 (for RR)
4. RR (CBT/MI-24+ TAU vs. TAU)= 0.80 (95% CI 0.21 to 3.10)
1. Number joints previous month 2) (Hjorthoj 201280):
CBT/MI-24 + TAU= 28.4 (95% CI 13.5 to 43
2. TAU= 41.6 (95% CI 25.2 to 58.0)
3. p= 0.23 (between groups)
4. Mean difference = 13.3 (95% CI –8.5 to 35.1) fewer for
CBT/MI-24 + TAU vs. TAU
1. Abstinence over previous month
2. NR
3. p= 0.61
4. OR = 1.31 (95% CI 0.47 to 3.64)
1. Abstinence over previous month (4 month)
2. NR
3. p= 0.37
4. OR = 0.64 (95% CI 0.25 to 1.68)
1. Number of days cannabis use
in past month
2. NR
3. p= 0.42 (for RR)
4. RR (CBT/MI-24+ TAU vs.
TAU)= 0.76 (95% CI 0.38 to
1.50)
1. Number joints previous
month
2. (Hjorthoj 201280): CBT/MI-
24+ TAU= 27.3 (95% CI 12.6
to 41.9), TAU= 48.2 (95% CI
31.8 to 64.6)
3. p= 0.06 (between groups)
4. Mean difference = 20.9
(95% CI –1.0, 42.9) fewer
for CBT/MI-24 + TAU vs. TAU
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Author and
year
Cannabis use (1) outcome measure, (2) absolute values (mean/median, SD/SE), (3) p-values
(groups/baseline), (4) between group difference and CI
8–12 weeks (post treatment) 3 months 6 months
Hoch 201259
and Hoch 200876
1. Mean cannabis use, past
7 days (number of joints,
bongs, pipes, etc.)
2. CBT/MET/PPS-10 = 8.1
(SD = 18.1), wait
list = 24.9 (SD= 33.4)
3. CBT/MET/PPS-10 BL vs. post
treatment: p= 0.001, effect
size= –0.43. Wait list BL vs.
post treatment: p= 0.516,
effect size= 0.11
4. NR
1. Abstinence past 7 days,
urine screening
2. CBT/MET/PPS-10 = 37/90
(41.1%), wait list= 4/32
(12.5%)
3. NR
4. NR
1. Abstinence CBT/MET/PPS-10
end of treatment
2. CBT/MET/PPS-10: ITT analysis:
49%. Completer analysis:
55%, wait list: 13%
3. NR
4. NR
1. Cannabis use per week
2. CBT/MET/PPS-10:
BL= 27.1%, post
treatment= 7.4%,
follow-up= 14.1%,
wait list ‘did not
improve’
3. p< 0.0001 (BL to
follow-up)
4. NR
1. Mean cannabis use, past
7 days (number of joints,
bongs, pipes, etc.)
2. CBT/MET/PPS-10= 12.1
(SD= 19.1)
3. BL vs. 6 months:
p= 0.015, ES= –0.29
4. NR
1. Abstinence past 7 days, urine
screening (3 and 6 months)
2. CBT/MET/PPS-10= 44.4%
(3 months), 41.1%
(6 months). Wait list no
follow-up data
3. NR
4. NR
12 weeks (post treatment) 6 months
Hoch 201460 1. Change abstinence rates
(% negative urine drug screenings)
(baseline to post assessment)
2. CBT/MET/PPS-10 = 34.6 increase
(BL 11.7, post assessment 46.3),
n= 166, wait list= 8.4% increase
(BL 9.3, post ass 17.7), n= 106
3. p< 0.001
4. NR
1. Mean number cu units per week
(total number of joints, bongs,
pipes, etc.)
2. CBT/MET/PPS-10 = 5.2 (SD= 13.0),
n= 166, wait list= 20.6 (SD= 30.0),
n= 106
3. p< 0.001 (between group)
4. d= –0.9 (95% CI –2.2 to 4.8)
(between groups)
1. Change abstinence rates (% negative urine drug screenings)
2. CBT/MET/PPS-10= 24.0 increase (BL 11.7, 6 months 35.7),
n= 53
3. NR
4. NR
1. Mean number cu units per week (total number of joints,
bongs, pipes, etc.) (6-month assessment)
2. CBT/MET/PPS-10= 20.8 (SD= 26.7) (BL), wait list= 5.3
(SD= 11.5) (6-month assessment)
3. p= 0.002 (from baseline)
4. d= 0.7 [(95% CI –2.6 to 4.4) (from baseline)
3 months
Humeniuk
201271
1. Pooled mean cannabis specific involvement scores via assist (higher=worse)
2. Follow-up: brief MI-1= 14.4 (SD= 8.9), DTC= 15.4 (SD = 7.9). BL: brief MI-1= 17.5 (SD= 7.1),
DTC= 17.1 (6.8)
3. Brief MI-1 significantly lower (p-value NR). Significant improvement over time across
groups (p< 0.001)
4. NR
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
110
Author and
year
Cannabis use (1) outcome measure, (2) absolute values (mean/median, SD/SE), (3) p-values
(groups/baseline), (4) between group difference and CI
4 months
Jungerman
200763
1. Mean % days smoked (past
90 days)
2. Wait list= 86.12 (SE = 4.38),
CBT/MI/RP-4 (1 month)= 64.90
(SE = 4.27), CBT/MI/RP-4
(3 months)= 56.21 (SE= 4.38)
3. p< 0.0001 (between all groups)
4. NR
1. Change in mean % days smoked
(past 90 days) (baseline to
4 months)
2. Wait list= 7.94 (SE= 4.51),
CBT/MI/RP-4 (1 month)= 29.29
(SE = 4.34), CBT/MI/RP-4
(3 months)= 31.95 (SE= 4.51)
3. p= 0.0003 (between all groups),
p= 0.0008 (CBT/MI/RP-4 (1 month)
vs. wait list), p= 0.0002 [CBT/MI/
RP-4 (3 months) vs. wait list],
p= 0.6708 [CBT/MI/RP-4 (1 month)
vs. 3 MIRP]
4. NR
1. Mean periods smoked (of
4 periods)
2. Wait list= 1.93 (SD= 0.13),
CBT/MI/RP-4 (1 month)= 1.19
(SE = 0.13), CBT/MI/RP-4 (3
months) = 1.38 (SD= 0.13)
3. p= 0.0004 (between all groups)
4. NR
1. Mean joints per day
2. Wait list = 1.56 (SD= 0.18), CBT/MI/RP-4 (1 month)= 0.78
(SE = 0.17), CBT/MI/RP-4 (3 months)= 0.77 (SD= 0.18)
3. p= 0.0015 (between all groups)
4. NR
1. Change in mean joints per day (baseline to 4 months)
2. Wait list = 0.28 (SD= 0.26), CBT/MI/RP-4 (1 month)= 1.28
(SE = 0.25), CBT/MI/RP-4 (3 months)= 1.31 (SD= 0.26)
3. p= 0.0060 (between all groups), p= 0.9366 (CBT/MI/RP-4
(3 months) vs. 1 MIRP), p= 0.0051 [wait list vs. CBT/MI/RP-4
(3 months)], p= 0.0056 [wait list vs. CBT/MI/RP-4 (1 month)]
4. NR
1. Abstinence rates
2. MI/RP-4 (3 months)= 3 (6.5%), MI/RP-4 (1 month) = 1
(1.9%), wait list= 1 (3.7%)
3. p= 0.5268
4. NR
1. Urine analysis, % of positive results
2. MI/RP-4 (1 month)= 90%, MI/RP-4 (3 months)= 81.8%,
wait list = 100%
3. NR
4. NR
1. Change in mean periods smoked (baseline to 4 months)
2. Wait list = 0.14 (SD= 0.13), CBT/MI/RP-4 (1 month)= 0.86
(SE = 0.12), CBT/MI/RP-4 (3 months)= 0.67 (SD= 0.13)
3. p= 0.0030 (between all groups), p= 0.3007 (CBT/MI/RP-4
(3 months) vs. 1 MIRP), p= 0.0037 (wait list vs. 3 MIRP),
p< 0.0001 [wait list vs. CBT/MI/RP-4 (1 month)]
4. NR
30 days (first episode of treatment
after 30 days) 14 months
Kadden 200744
Litt 200877
1. Time to first cannabis use
2. 50% smoked cannabis
immediately after baseline session;
18% not relapsed over 14-month
follow-up
3. No significant difference between
groups when excluding first
30 days: no significant difference
between groups except vouchers
vs. CaseM-9 – p< 0.05
(favours vouchers)
4. 0.33 to 0.95
1. Proportion of days abstinent
2. All groups increased days abstinent from baseline at post
treatment (2 months) and up to 14 months (p< 0.001).
Voucher subjects reported more days abstinent than
CaseM-9 at post treatment (2 months, p< 0.05) but
not at later time points (values NR). No other significant
differences between treatment groups. (Litt 200877
reports values at all time points, 14 month extracted:
CaseM-9 = 19.2, MET/CBT= 20.4, vouchers= 12.5,
CBT/MET-9/vouchers = 27.6)
3. [See above in point 2]
4. NR
1. Joints smoked per smoking day
2. Across all groups, decrease from 5 at baseline to 2.4 at post
treatment (2 months), 1.7 at 5 months, 0.5 at 14 months
(p< 0.001) no significant difference between
treatment groups
3. [See above in point 2]
4. NR
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Author and
year
Cannabis use (1) outcome measure, (2) absolute values (mean/median, SD/SE), (3) p-values
(groups/baseline), (4) between group difference and CI
1. Continuous abstinence
2. Longest period of abstinence at any point: CBT/MET-9/vouchers >
vouchers >CBT/MET-9 >CaseM-9 (values NR) (p< 0.05).
CBT/MET-9/vouchers or vouchers >CBT/MET-9 or CaseM-9
(p< 0.05) at each time point: CBT/MET-9/vouchers and
CBT/MET-9 levels of abstinence remained relatively constant at
all time points (27% and 19% at 14 months) while vouchers
levels were high post treatment (2–5 months) but declined
after this
3. [See above in point 2]
4. NR
3 months (post treatment) 12 months
Kay-Lambkin
200957
1. Mean cannabis use per day
over previous 30 days via OTI
2. Brief MI-1= 7.24 (SD= 7.77),
CBT/MI-10 = 8.9 (SD= 11.25),
computer-delivered CBT/MI+ brief
therapist-10= 5.77 (SD = 6.56)
3. NR
4. NR
1. Mean cannabis use per day over previous 30 days via OTI
2. Brief MI-1= 8.61 (SD= 10.16), CBT/MI-10= 5.72 (SD= 6.22),
computer-delivered CBT/MI+ brief therapist-10= 3.34
(SD= 5.52)
3. p< 0.01 (intervention groups vs. brief MI-1 over time)
4. NR
1. Change in mean cannabis use per day over previous 30
days (ITT analysis)
2. Brief MI-1= 0.76, CBT/MI-10= 6.22, computer-delivered
CBT/MI+ brief therapist-10 = 12.15, CBT/MI-10+ computer-
delivered CBT/MI+ brief therapist-10 = 9.31
3. NR
4. NR
1. Percentage with ≥ 50% reduction in cannabis use (ITT analysis)
2. Brief MI-1= 34.8%, CBT/MI-10= 61.5%, computer-delivered
CBT/MI+ brief therapist-10= 78.9%, CBT/MI-10+ computer-
delivered CBT/MI+ brief therapist-10= 71.9%
3. NS
4. Odds ratios: T vs. brief MI-1: OR= 1.56 (95% CI 0.32 to 7.57);
C vs. brief MI-1: OR= 4.55 (95% CI 0.91 to 22.91); T+C vs.
brief MI-1: OR= 2.66 (95% CI 0.68, 10.45)
3 months
Kay-Lambkin
201158
1. Cannabis abstinence (cannabis users only)
2. CBT/MI-10 = 4 (NR%), PCT= 7 (21%), CAC= 4 (10%), therapist-delivered treatment (CBT/MI and
PCT) = 11 (16%), CBT/MI and CAC= 8 (11%)
3. CBT/MI+CAC vs. PCT: p= 0.164, CAC vs. therapist delivered treatment: p= 0.309
4. NR
1. Change in OTI Q score (cannabis users only)
2. CBT/MI+CAC= 3-point reduction, PCT= 0.15 point increase, CAC= 2.7 point reduction,
therapist-delivered treatment = 1.1 point reduction
3. Therapist-delivered treatment vs. CAC therapy: p= 0.347, CBT/MI+CAC vs. PCT: p= 0.140
4. NR
1. At least 50% reduction in cannabis use (cannabis users only)
2. CBT/MI= 8 (NR%), PCT= 11 (32%), CAC= 14 (33%), therapist-delivered treatment (CBT/MI and
PCT) = 19 (28%), CBT/MI and CAC= 22 (29%)
3. CBT/MI+CAC vs. PCT: p= 0.751, CAC vs. therapist-delivered treatment: p= 0.582
4. NR
1. Participants using above harmful threshold (more than once weekly) (cannabis users only)
2. CBT/MI= 14 (NR%), PCT= 14 (41%), CAC= 20 (48%), therapist-delivered treatment (CBT/MI and
PCT) = 28 (42%), CBT/MI and CAC= 34 (45%)
3. CBT/MI+CAC vs. PCT: p= 0.685, CAC vs. therapist delivered treatment: p= 0.551
4. NR
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Author and
year
Cannabis use (1) outcome measure, (2) absolute values (mean/median, SD/SE), (3) p-values
(groups/baseline), (4) between group difference and CI
3 months 6 months
Lee 201045 1. 90-day marijuana use
2. PFI: baseline mean= 9.89,
3-month mean= 9.14 (SD 14.07).
Control: baseline mean= 9.84,
3-month mean= 9.06 (SD 15.78)
3. No time effect; no intervention
effect (F< 1)
4. NR
1. 90-day marijuana use
2. PFI: 6-month mean= 11.05 (SD 18.71). Control: 6-month
mean= 11.94 (SD 19.31)
3. No time effect; no intervention effect (p or F NR)
4. NR
3 months 6 months
Lee 201346 1. Days using cannabis past 30 days
2. brief MI mean= 14.06 (SD 10.1,
n= 86); AO mean= 14.87
(SD 10.8, n= 93)
3. NS (value NR)
4. RR for brief MI brief MI vs.
AO= 0.96 (95% CI 0.80 to 1.15)
1. Number joints smoked in
typical week
2. Brief MI mean= 6.91 (SD 8.2,
n= 89); AO mean= 8.45
(SD 9.8, n= 95)
3. p< 0.05
4. RR for brief MI vs. AO= 0.76
(95% CI 0.60 to 0.96). 24%
fewer for brief MI vs. AO
1. Days using cannabis past 30 days
2. Brief MI mean= 13.21 (SD 10.6, n= 89); AO mean= 11.68
(SD 11.1, n= 84)
3. NS (value NR)
4. RR for brief MI vs. AO= 1.11 (95% CI 0.85 to 1.43)
1. Number joints smoked in typical week
2. Brief MI mean= 7.26 (SD 8.4, n= 90); AO mean= 7.47
(SD 10.7, n= 87)
3. NS (value NR)
4. RR for brief MI vs. AO= 1.03 (95% CI 0.73 to 1.46)
2 months (post treatment) 8 months
Litt 201347 1. Longest period of initial abstinence
2. CBT/MET-9/vouchers
(homework) = 18.65 (SD= 23.74),
CBT/MET-9/vouchers
(abstinence) = 27.95 (SD= 25.17),
CaseM (= 19.45 (SD= 24.13)
3. CBT/MET-9/vouchers (abstinence)
vs. CBT/MET-9/vouchers
(homework): p< 0.03. Overall:
p= 0.06
4. NR
1. Continuous abstinence
2. NR
3. NS (F= 0.97) (treatment effect
overall); p< 0.001 (all groups
from baseline; maintained to
14 months)
4. NR
1. Abstinence in early part of follow-up (months 5–8)
2. NR
3. CaseM (vs. CBT/MET-9/vouchers (homework) and
CBT/MET-9/vouchers (abstinence): χ2= 0.07 (NS).
CBT/MET-9/vouchers (homework) vs. CBT/MET-9/vouchers
(abstinence): χ2= 6.13 (significant, favours CBT/MET-9/
vouchers (abstinence). Over time: p< 0.001 (all groups from
baseline; maintained to 14 months)
4. NR
1. Proportion of days abstinent 90 days prior to follow-up
2. NR
3. CaseM-(vs. CBT/MET-9/vouchers (homework) and
CBT/MET-9/vouchers (abstinence): NS. CBT/MET-9/vouchers
(homework) vs. CBT/MET-9/vouchers (abstinence): p< 0.05,
favours CBT/MET-9/vouchers (abstinence)
4. NR
3 months 1 year
Madigan 201369 1. Cannabis use over past 30 days
2. GPI mean= 9.9 (SD= 4.0) (n= 36
analysed), TAU mean= 10.1
(SD = 4.2) (n= 18 analysed)
3. p= 0.86 (between groups); also NS
from baseline
4. NR
1. Cannabis use over past 30 days
2. GPI mean= 9.8 (SD= 3.9) (n= 28 analysed, TAU
mean= 10.1 (SD= 4.0) (n= 14 analysed)
3. p= 0.39 (between groups); also NS from baseline
4. NR
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Author and
year
Cannabis use (1) outcome measure, (2) absolute values (mean/median, SD/SE), (3) p-values
(groups/baseline), (4) between group difference and CI
6 weeks (post treatment) 3 months
Rooke 201370 1. Days of cannabis use per month
2. Internet-based CBT/MI-6= 12.90
(SD = 8.47), internet-based written
cannabis information = 14.87
(SD = 8.88)
3. p= 0.02 (between groups),
d= 0.30, both groups p< 0.001
from baseline
4. NR
1. Quantity cannabis per month
(SCUs – standard cannabis
units = 1 joint or 3 cones)
2. Internet-based CBT/MI-6= 39.78
(SD = 44.97), internet-based
written cannabis information= 46.16
(SD= 49.31)
3. p= 0.01 (between groups),
d= 0.34, both groups p< 0.001
from baseline
4. NR
1. Abstinence
2. Internet-based CBT/MI-6= 7/76
(9.3%), internet-based written
cannabis information = 3/73
(4.7%)
3. p= 0.10
4. NR
1. Days of cannabis use per month
2. Internet-based CBT/MI-6= 12.05 (SD= 8.99), internet-based
written cannabis information = 14.11 (SD= 8.79)
3. p= 0.02 (between groups), d= 0.33, both groups p< 0.001
from baseline
4. NR
1. Quantity cannabis per month (SCUs – standard cannabis
units= 1 joint or 3 cones)
2. Internet-based CBT/MI-6= 36.65 (SD= 44.85), internet-based
written cannabis information= 39.25 (SD= 39.21)
3. p= 0.06 (between groups), d= 0.25, both groups p< 0.001
from baseline
4. NR
1. Abstinence
2. Internet-based CBT/MI-6= 8/64 (12.4%), Internet-based
written cannabis information = 4/58 (6.6%)
3. p= 0.06
4. NR
Post treatment (unknown time
point) 12 months
Sobell 200965 1. Percentage days abstinent from
cannabis (cannabis users only,
at end of session four)
2. CBT/MI-4 (individual)
mean= 58.79 (SD= 35.59), n= 9,
CBT/MI-4 (group) mean= 29.47
(SD = 29.94), n= 8
3. NR (between groups); p< 0.05
(from baseline)
4. NR
1. Percentage days abstinent from cannabis (cannabis users only)
2. CBT/MI-4 (individual) mean= 37.78 (SD= 34.02), n= 7,
CBT/MI-4 (group) mean= 41.51 (SD= 43.10), n= 7
3. NR (between groups); p=NS (from end of treatment to
12-month follow-up)
4. NR
1 month (post treatment) 3 months 6 months
Stein 201148 1. Cannabis use
2. NR
3. OR = 0.77, p= 0.174
(treatment × time interaction
to estimate effect of MI vs. AO)
4. NR
1. Cannabis use
2. NR
3. OR= 0.53, p= 0.010
4. NR
1. Change in cannabis
use per 30 days for
average users
2. MI-2= 6.58-day
reduction, AO= 2.07
day/reduction (baseline
to 3 months)
3. Reports that change
from baseline in
cannabis use was
significant at 1, 3 and
6 months
4. NR
1. Cannabis use
2. NR
3. OR= 0.74, p= 0.202
4. NR
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Author and
year
Cannabis use (1) outcome measure, (2) absolute values (mean/median, SD/SE), (3) p-values
(groups/baseline), (4) between group difference and CI
3 months 12 months
Stephens 199449 1. Mean days of cannabis use per
month (3 month)
2. CBT/RP-10= 9.99 (SD= 11.50),
social support group-10= 10.71
(SD = 12.06)
3. NS (between group), both groups
improved from baseline (p< 0.001)
4. NR
1. Percentage abstinent (3 month)
2. CBT/RP-10= 32.5%, social support
group-10= 40.2%
3. p< 0.10 (between group)
4. NR
1. Days of cannabis use per month (12 month)
2. CBT/RP-10= 14.78 (SD= 11.96), social support
group-10 = 14.30 (SD = 12.29)
3. NS (between group), both groups improved from
baseline (p< 0.001)
4. NR
1. Percentage abstinent (12 month)
2. CBT/RP-10= 15.2, social support group-10= 18.1
3. NS
4. NR
1 month (post treatment) 4 months 16 months
Stephens 200050
Lozano 200678
DeMarce 200579
1. Mean days of use per week during
previous 90 days
2. MI-2 = 1.6 (SD= 2.07), CBT/RP/
social support-14= 2.49
(SD = 2.32)
3. p< 0.02 (between groups)
4. NR
1. Use per day
2. CBT/RP/social support-14= 2.00
(SD = 2.98), MI-2= 0.89
(SD = 1.43)
3. p< 0.01
4. NR
1. Abstinence rates for past 4 weeks
2. MI-2 42%, CBT/RP/social
support-14 27%
3. p< 0.04
4. NR
1. Days of use per month
during last 90 days
2. CBT/RP/social support-14
mean=6.68 (SD= 9.87),
MI-2 mean= 7.88
(SD= 10.98), wait list
mean=17.09
(SD= 10.73)
3. p< 0.001 (wait list vs.
CBT/RP/social support-14
and MI-2), p=NS (CBT/
RP/social support-14 vs.
MI-2)
4. NR
1. Times of use per day
during last 90 days on
4-point scale
2. CBT/RP/social support-14
mean=1.15 (SD= 1.10),
MI-2 mean= 1.19
(SD= 1.18), wait list
mean=1.97 (SD= 1.09)
3. p< 0.001 (wait list vs.
CBT/RP/social support-14
and MI-2), p=NS (CBT/
RP/social support-14 vs.
MI-2)
4. NR
1. Days of use per month
during last 90 days
2. CBT/RP/social support-14
mean= 12.29 (SD = 12.34),
MI-2 mean= 12.99
(SD= 11.61)
3. NS
4. NR
1. Times of use per day during
last 90 days on 4-point scale
2. CBT/RP/social support-14
mean= 1.39 (SD= 1.15),
MI-2 mean= 1.41 (SD= 1.20)
3. NS
4. NR
1. Abstinence rates for past
90 days
2. CBT/RP/social support-14
mean= 37%, MI-2
mean= 37%, wait
list mean= 9%
3. p< 0.001 (wait list vs. CBT/
RP/social support-14 and
MI-2), p=NS (CBT/RP/social
support-14 vs. MI-2)
4. NR
1. Abstinence rates for past
90 days (16 months)
2. CBT/RP/social support-14
mean=29%,MI-2 mean=28%
3. NS
4. NR
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Author and
year
Cannabis use (1) outcome measure, (2) absolute values (mean/median, SD/SE), (3) p-values
(groups/baseline), (4) between group difference and CI
7 weeks (post treatment) 6 months 12 months
Stephens 200751 1. Days of marijuana use per week
2. MI/personalised feedback-1
mean= 4.74 (SE= 0.24), cannabis
education-1 mean= 5.44
(SE = 0.24), wait list mean= 5.75
(SE = 0.24) (95% CIs also reported)
3. p< 0.05 (MI/personalised
feedback-1 vs. cannabis education-1
and wait list); no significant
difference between cannabis
education-1 and wait list
(p-value NR)
4. NR
1. Periods smoked per day
(scale of 0–4)
2. MI/personalised feedback-1
mean= 1.66 (SE= 0.11), cannabis
education-1 mean= 1.90
(SE = 0.11), wait list
mean= 2.20 (SE= 0.10)
3. p< 0.05 (MI/personalised
feedback-1 vs. cannabis education-1
and wait list)
4. NR
1. Days of marijuana use
per week
2. MI/personalised
feedback-1 mean=4.90
(SE=0.27), cannabis
education-1 mean=5.22
(SE=0.27)
3. NS (p= 0.408)
4. NR
1. Periods smoked
per day (scale of 0–4)
2. MI/personalised
feedback-1 mean= 1.84
(SE= 0.11), cannabis
education-1
mean= 2.02 (SE= 0.11)
3. NS (p> 0.05)
4. NR
1. Days of marijuana use
per week
2. MI/personalised feedback-1
mean= 4.65 (SE= 0.28),
cannabis education-1
mean= 5.58 (SE= 0.28)
3. p= 0.019 (MI/personalised
feedback-1 vs. cannabis
education-1)
4. NR
1. Periods smoked per day
(scale of 0–4)
2. MI/personalised feedback-1
mean= 1.79 (SE= 0.12),
Cannabis education-1
mean= 1.97 (SE= 0.12)
3. NS (p > 0.05)
4. NR
3 months
Tossmann 201161 1. Frequency of cannabis use over previous 30 days
2. Internet-based counselling= 16.5 (SD= 20.9), wait list = 21.0 (SD= 17.1)
3. p< 0.001 (between group)
4. NR
1. Quantity of grams used over previous 30 days (3 month)
2. Internet-based counselling= 13.1 (SD= 29.7), wait list = 16.5 (SD= 26.8)
3. p= 0.003 (between group)
4. NR
ASSIST, Alcohol Smoking and Substance Involvement Screening Test; BI, brief intervention; BL, baseline; C, computer-delivered;
CAC, clinician-assisted computerised tomography; CaseM, case management; cu, cannabis use; DTC, delayed treatment
control; ES, effect size; GPI, group-based psychological intervention; MET-2, two-session; MIRP, motivational interviewing
and relapse prevention; NR, not reported; NS, not significant; OR, odds ratio; OTI, opiate treatment index; PFI, individual
personalised feedback; SEDP, Supportive–expressive dynamic psychotherapy; SE, standard error; T, therapist-delivered;
tele-CBT, telephone-delivered CBT.
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Author and year
Severity of dependence (1) outcome measure, (2) absolute values (mean/median, SD/SE),
(3) p-values (groups/baseline), (4) between group difference and CI
4 months 9 months
Babor 200439 and Litt
200572 (secondary)
1. Dependence symptoms
2. Wait list= 4.36 (SD= 1.92), MET-2= 3.70
(SD= 2.26), CBT/MET/CaseM-9= 2.47
(SD= 2.34)
3. (Cohen’s d statistic) MET-2 vs. wait list= 0.33,
CBT/MET/CaseM-9 vs. wait list= 0.9, MET-2 vs.
CBT/MET/CaseM-9= 0.52; all between-group
differences significant
4. NR
1. Mean abuse symptoms
2. wait list= 1.63 (SD= 0.91), MET-2= 1.38
(SD= 1.10), CBT/MET/CaseM-9= 1.03
(SD= 1.02)
3. (Cohen’s d statistic) CBT/MET/CaseM-9 vs. wait
list=0.63, MET-2 vs. CBT/MET/CaseM-9=0.38,
both significant; MET-2 vs. wait list=NS
4. NR
1. Dependence symptoms
2. MET-2= 3.63 (SD= 2.08), CBT/MET/
CaseM-9= 2.81 (SD= 2.40)
3. CBT/MET/CaseM-9 vs. MET-2= 0.31,
p< 0.01
4. NR
1. Mean abuse symptoms
2. MET-2= 1.59 (SD= 1.04), CBT/MET/
CaseM-9= 1.11 (SD= 1.07)
3. CBT/MET/CaseM-9 vs. MET-2= 0.45,
p< 0.01
4. NR
14 weeks
Budney 200040 1. Drug ASI composite scores (least square means)
2. CBT/MET-14/vouchers= 0.01 (SE= 0.02), CBT/MET-14= 0.07 (SE= 0.02), MET-4= 0.11
(SE= 0.02)
3. p< 0.05 (change from baseline, all treatment groups), significant difference between
MBT/MET-14 vs. MBT and MET-4 (p-values NR)
4. NR
34 weeks (median)
Copeland 200153 1. SDS scores
2. Final values: wait list mean= 9.2 (SD 3.2), MI-1 mean= 7.6 (SD 4.4), CBT-6 mean= 5.8
(SD 4.3) changes from baseline: DTC mean= –0.1, MI-1 mean= –2.2, CBT-6 mean= –3.4
(SDs for changes NR)
3. Adjusting for baseline: MI-1 vs. wait list: p= 0.008 (MI-1 significantly lower). CBT-6 vs. wait list:
p< 0.0001 (MI-1 significantly lower). CBT-6 vs. MI-1: p= 0.04 (CBT-6 significantly lower)
4. NR
3 months 6 months
Edwards 200654 1. Severity of cannabis dependence (via CASUAS,
0–4 scale)
2. CBT/MET-10+ TAU= 1.4 (SD= 1.4),
psychoeducation (non-cannabis)
–10+ TAU= 1.3 (SD= 1.4)
3. p= 0.99 (between group)
4. NR
1. Severity of cannabis dependence
2. CBT/MET-10+ TAU= 1.4 (SD= 1.4),
psychoeducation (non-cannabis)
–10+ TAU= 1.3 (SD= 1.5)
3. p= 0.99 (between group)
4. NR
4 weeks 12 weeks
Gates 201255 1. Cannabis dependence via SDS, 15-point scale
2. Tele-CBT/MI-4= 4.2 (SD= 4.2), wait list= 7.1
(SD= 3.8)
3. p< 0.001
4. NR
1. Cannabis dependence
2. Tele-CBT/MI-4= 3.2 (SD= 3.8), wait
list= 5.8 (SD= 4.3)
3. p= 0.001
4. NR
4 months
Grenyer 199756 1. Index of severity of symptoms
2. NR
3. p< 0.05, F= 8.52
4. NR
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Author and year
Severity of dependence (1) outcome measure, (2) absolute values (mean/median, SD/SE),
(3) p-values (groups/baseline), (4) between group difference and CI
Post treatment 6 months
Hoch 201259 and
Hoch 200876
1. Mean ASI (drug use) (post treatment)
2. CBT/MET/PPS-10= 3.0 (SD= 4.0), wait
list= 8.3 (SD= 3.5)
3. CBT/MET/PPS-10: p< 0.001, effect
size= –1.58, wait list: p= 0.002, effect
size= –0.41 (vs. baseline)
4. NR
1. Mean ASI (drug use)
2. CBT/MET/PPS-10= 2.5 (SD= 3.6)
3. p< 0.001, effect size= –1.61
(vs. baseline)
4. NR
Post assessment 6 months
Hoch 201460 1. Mean SDS score
2. CBT/MET/PPS-10= 4.7 (SD= 4.2), wait
list= 7.0 (SD= 4.1)
3. p< 0.001 (between groups)
4. d= –0.6, 95% CI –1.2 to 0.2
(between groups)
1. Mean SDS score
2. CBT/MET/PPS-10= –6.1 improvement
(BL 9.0,6 months 2.9), n= 53
3. p< 0.001 (from baseline)
4. d= 1.8, 95% CI 1.4 to 2.9
(from baseline)
4 months
Jungerman 200763 1. Cannabis dependence symptoms via DSM-III
2. Wait list= 5.10 (SE= 0.33), CBT/MI/RP-4 (1 month)= 4.86 (SE= 0.32), CBT/MI/RP-4
(3 months)= 4.20 (SE= 0.33)
3. p= 0.1387 (between all groups)
4. NR
1. Change in cannabis dependence symptoms
2. Wait list= 0.61 (SE= 0.29), CBT/MI/RP-4 (1 month)= 0.73 (SE= 0.28), CBT/MI/RP-4
(3 months)= 1.58 (SE= 0.29)
3. p= 0.0360 (between all groups), p= 0.0349 [CBT/MI/RP-4 (3 months) vs. 1 MIRP], p= 0.0184
[wait list vs. CBT/MI/RP-4 (3 months)], p= 0.7577 [wait list vs. CBT/MI/RP-4 (1 month)]
4. NR
All follow-up points (2, 8 and 14 months)
Kadden 200744 and
Litt 200877
1. ASI (drug, alcohol, psychiatric subscales)
2. NR
3. No significant difference between groups, but scores on all subscales decreased over time in all
groups (p-values NR)
4. NR
6 weeks 3 months
Rooke 201370 1. Severity of dependence via SDS
2. Internet-based CBT/MI-6= 7.31 (SD= 3.22),
internet-based written cannabis
information= 7.44 (SD= 3.56)
3. p= 0.49 (between groups), d= 0.10, both
groups p< 0.001 from baseline
4. NR
1. Severity of dependence via SDS
2. Internet-based CBT/MI-6= 5.70
(SD= 3.35), internet-based written
cannabis information= 6.82 (SD= 3.31)
3. p= 0.01 (between groups), d= 0.33,
both groups p< 0.001 from baseline
4. NR
4 months 16 months
Stephens 2000,50
Lozano 200678 and
DeMarce 200579
1. Mean number of dependence symptoms
via MDS
2. CBT/RP/social support-14= 1.96 (SD 2.73),
MI-2= 1.94 (SD 2.71), wait list= 4.63 (SD 2.59)
3. p< 0.001 (wait list VS MI-2 and CBT/RP/social
support-14), p=NS (CBT/RP/social support-14
vs. MI-2)
4. NR
1. Mean number of dependence symptoms
2. CBT/RP/social support-14= 2.83
(SD 3.27), MI-2= 2.75 (SD 3.18)
3. NS
4. NR
BL, baseline; CASUAS, Cannabis and Substance Use Assessment Schedule; MDS, Marijuana Dependence Scale;
MI-1, one-session MI; tele-CBT, telephone-delivered CBT.
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Author and
year
Cannabis problems (1) outcome measure, (2) absolute values (mean/median, SD/SE),
(3) p-values (groups/baseline), (4) between group difference and CI, (5) time point
4 months 9 months
Babor 200439
and Litt 200572
(secondary)
1. Cannabis problems (via MPS,
19 items)
2. Wait list= 7.77 (SD= 3.90), MET-
2= 8.35 (SD= 4.06), CBT/MET/
CaseM-9= 6.02 (SD= 4.85)
3. CBT/MET/CaseM-9 vs. wait
list= 0.41, MET-2 vs. CBT/MET/
CaseM-9= 0.53, both significant;
MET-2 vs. wait list=NS
4. NR
1. Cannabis problems
2. MET-2= 7.22 (SD= 4.21), CBT/MET/CaseM-9= 5.43
(SD= 4.31)
3. p=NS
4. NR
14 weeks
Budney 200040 1. Cannabis problems (via marijuana consequences questionnaire, 0–26 scale)
2. NR
3. NS between groups; significant change from baseline in all groups (p NR)
4. NR
14 weeks (post treatment) 12 months
Budney 200641 1. Cannabis problems (via MPS,
26 items)
2. CBT-14/vouchers mean= 3.6
(SD= 4.9); CBT-14 mean= 5.1
(SD= 4.7); voucher mean= 4.1
(SD= 4.5)
3. p=NS (between groups); p< 0.01
(for all groups from baseline)
4. NR
1. Cannabis problems (via MPS, 26 items)
2. NR
3. p=NS (between groups); p=NS (all groups over time
post treatment; no change after treatment ended)
4. NR
34 weeks (median)
Copeland 200153 1. Proportion of cannabis-related problems (via CPQ)
2. Final values: wait list mean 39.1 (SD 16.6), MI-1 mean 28.4 (SD 18.6), CBT-6 23.0 (SD= 16.8)
changes from baseline: wait list mean –6.3, MI-1 mean –14.0, CBT-6 –19.4 (SDs for change NR)
3. Adjusting for baseline: CBT-6 vs. wait list: p< 0.0001, MI-1 vs. wait list: p= 0.004. CBT-6 vs. MI-1:
p= 0.08 (all between group)
4. NR
4 weeks 12 weeks
Gates 201255 1. Cannabis problems via CPQ, of 22
2. Tele-CBT/MI-4= 3.6 (SD= 3.8), wait
list= 6.5 (SD= 4.7)
3. p< 0.001
4. NR
1. Cannabis problems
2. Tele-CBT/MI-4= 3.6 (SD= 4.4), wait list= 5.3 (SD= 4.5)
3. p= 0.006
4. NR
Post assessment
Hoch 201460 1. Mean number cannabis dependence symptoms
2. CBT/MET/PPS-10= 0.9 (SD= 1.6), wait list= 2.4 (SD= 2.1)
3. p< 0.001 (between groups)
4. d= –0.9, 95% CI –1.1 to –0.5 (between groups)
1. Mean CPQ scores
2. CBT/MET/PPS-10= 2.9 (SD= 3.8), wait list= 5.6 (SD= 4.4)
3. p< 0.001 (between groups)
4. d= –0.7, 95% CI –1.3 to 0.2 (between groups)
1. Mean CUPIT score
2. CBT/MET/PPS-10= 27.1 (SD= 14.1), wait list= 37.1 (SD= 14.7)
3. p< 0.001 (between groups)
4. d= –0.7, 95% CI –2.9 to 2.1
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Author and
year
Cannabis problems (1) outcome measure, (2) absolute values (mean/median, SD/SE),
(3) p-values (groups/baseline), (4) between group difference and CI, (5) time point
4 months
Jungerman 200763 1. Mean marijuana problems via MPS (19 items)
2. Wait list=8.92 (SE=0.64), CBT/MI/RP-4 (1 month)=9.54 (SE=0.61), CBT/MI/RP-4 (3 months)=8.52
(SE=0.63)
3. p= 0.5070 (between all groups)
4. NR
1. Change in mean marijuana problems
2. Wait list= 0.79 (SE= 0.46), CBT/MI/RP-4 (1 month)= 0.26 (SE= 0.43), CBT/MI/RP-4
(3 months)= 1.69 (SE= 0.45)
3. p= 0.0753 (between all groups)
4. NR
1. Mean ASI drug composite score
2. Wait list= 2.81 (SE= 0.21), CBT/MI/RP-4 (1 month)= 2.77 (SE= 0.20), CBT/MI/RP-4
(3 months)= 2.10 (SE= 0.21)
3. p= 0.0238 (between all groups)
4. NR
1. Change in mean ASI drug composite score
2. Wait list= 0.57 (SE= 0.23), CBT/MI/RP-4 (1 month)= 0.10 (SE= 0.22), CBT/MI/RP-4
(3 months)= 0.92 (SE= 0.23)
3. p= 0.0411 (between all groups), p= 0.0121 [CBT/MI/RP-4 (3 months) vs. CBT/MI/RP-4 (1 month)],
p= 0.2921 (wait list vs. 3 MIRP), p= 0.1460 [wait list vs. CBT/MI/RP-4 (1 month)]
4. NR
2 months (post treatment) and 14 months
Kadden 200744
and Litt 200877
1. Mean problem score
2. Across all groups: mean of 14 at baseline and < 8 post treatment (2 months) and throughout
14 months
3. No significant difference between groups, but decreased over time in all groups post treatment and
throughout 14 months (p< 0.001)
4. NR
3 months 6 months
Lee 201045 1. Marijuana-related problems (of 18)
2. Internet-based-personalised
feedback-1: baseline mean= 2.11,
3-month mean= 2.47 (SD 3.77).
AO: baseline mean= 1.86,
3-month mean= 1.99 (SD 2.76)
3. No time interactions; no time by
treatment interactions (BL to
3 month)
4. NR
1. Marijuana-related problems (of 18)
2. Internet-based-personalised feedback-1: 6-month
mean= 2.59 (SD 3.96). AO: 6-month mean= 2.19
(SD 2.95)
3. No time interactions; no time by treatment interactions
(BL to 6 month)
4. NR
3 months 6 months
Lee 201346 1. Number of cannabis-related
problems
2. Brief MI-1 mean= 7.84 (SD 5.0,
n= 87); AO mean= 8.67 (SD 6.0,
n= 90)
3. p< 0.10
4. RR for brief MI-1 vs. AO= 0.90
(95% CI 0.76, 1.07). 10% fewer
problems in intervention group
compared with control
1. Number of cannabis-related problems
2. brief MI-1 mean=6.54 (SD 5.3, n=82); AO mean=6.75
(SD 6.5, n=83)
3. NS (value NR)
4. RR for brief MI-1 vs. AO= 1.15 (95% CI 0.90 to 1.47)
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Author and
year
Cannabis problems (1) outcome measure, (2) absolute values (mean/median, SD/SE),
(3) p-values (groups/baseline), (4) between group difference and CI, (5) time point
End of treatment
Litt 201347 1. MPS score
2. NR
3. NS (F= 0.02) (treatment effect); p< 0.001 (all groups from baseline; maintained to 14 months)
4. NR
3 months 12 months
Stephens 199449 1. Mean number of problems via
modified DAST
2. CBT/RP-10= 2.11 (SD= 2.59), social
support group-10= 2.48 (SD= 3.53)
3. NS (between group), both groups
improved from baseline (p< 0.001)
4. NR
1. Mean number of problems
2. CBT/RP-10= 3.27 (SD= 3.41), social support
group-10= 2.97 (SD= 3.64)
3. NS (between group), both groups improved from baseline
(p<0.001)
4. NR
4 months 16 months
Stephens 200050
Lozano 200678
DeMarce 200579
1. Mean number of cannabis-related
problems via list of 19 problems
2. CBT/RP/social support-14 3.50
(SD= 4.23), MI-2 3.26 (SD= 3.99),
wait list 7.89 (SD= 4.23)
3. p< 0.001 (wait list vs. CBT/RP/social
support-14 and MI-2), p=NS (CBT/
RP/social support-14 vs. MI-2)
4. NR
1. Mean number of cannabis-related problems
2. CBT/RP/social support-14 4.21 (SD= 4.98), MI-2 4.71
(SD= 4.74)
3. NS
4. NR
7 weeks 6 months 12 months
Stephens 200751 1. Number of problems (scale 0–19
based on MPS) (7 week)
2. MI/personalised feedback-1
mean= 3.70 (SE= 0.41), cannabis
education-1 mean= 5.03 (SE= 0.41),
wait list mean= 5.01 (SE= 0.40)
3. NS (p> 0.05)
4. NR
1. Number of
problems
2. MI/personalised
feedback-1
mean=4.06
(SE=0.41), cannabis
education-1
mean=5.46
(SE=0.41)
3. NS (p> 0.05)
4. NR
1. Number of problems
2. MI/personalised feedback-1
mean=3.95 (SE=0.40),
cannabis education-1
mean=5.21 (SE=0.40)
3. NS (p> 0.05)
4. NR
BL, baseline; CUPIT, Cannabis Use Problems Identification Test; DAST, Drug Abuse Screening Test; DTC, delayed treatment
control; NR, not reported; NS, not significant; tele-CBT, telephone-delivered CBT; URICA, University of Rhode Island Change
Assessment Scale.
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Author and
year
Motivation to change (1) outcome measure, (2) absolute values (mean/median, SD/SE),
(3) p-values (groups/baseline), (4) between group difference and CI
3 months 6 months 12 months
Bonsack 201166 1. Readiness to
change
(scale 0–100)
2. CBT/MI-6+ TAU
median= 68.7,
TAU median= 50
3. p= 0.31
4. NR
1. Importance of
change
(scale 0–100)
2. CBT/MI-6+ TAU
median= 62.5,
TAU median= 37.5
3. p= 0.08
4. NR
1. Confidence to
change
(scale 0–100)
2. CBT/MI-6+ TAU
median= 75,
TAU median= 50
3. p= 0.02
4. NR
1. Readiness to
change
(scale 0–100)
2. CBT/MI-6+ TAU
median= 62.5,
TAU median= 50
3. p= 0.52
4. NR
1. Importance of
change
(scale 0–100)
2. CBT/MI-6+ TAU
median= 50,
TAU median= 50
3. p= 0.50
4. NR
1. Confidence to
change
(scale 0–100)
2. CBT/MI-6+ TAU
median= 75,
TAU median= 50
3. p= 0.05
4. NR
1. Readiness to change (scale 0–100)
2. CBT/MI-6+ TAU median=56.25, TAU median=50
3. p= 0.40
4. NR
1. Importance of change (scale 0–100)
2. CBT/MI-6+ TAU median= 50, TAU median= 50
3. p= 0.58
4. NR
1. Confidence to change (scale 0–100)
2. CBT/MI-6+ TAU median= 75, TAU median= 60
3. p= 0.12
4. NR
14 weeks
Budney 200040 1. URICA scores (least square means)
2. CBT/MET-14/vouchers= 8.5 (SE= 0.56), CBT/MET-14= 8.6 (SE= 0.45), MET-4= 6.6 (SE= 0.64)
3. p< 0.05 (M-4 group, change from baseline. All other changes from baseline NS)
4. NR
3 months 6 months
Edwards 200654 1. Change in readiness to change categories
2. NR
3. p= 0.68 (between group)
4. NR
1. Change in readiness to change categories
2. NR
3. p= 0.72
4. NR
2 months (post treatment) 14 months
Kadden 200744
and Litt 200877
1. (Reported by Litt77) mean readiness to
change score
2. Pre scores: CaseM= 13.84 (SD= 2.39), MET/
CBT= 14.76 (SD= 3.41), ContM= 14.32
(SD= 4.11), MET/CBT+ContM= 14.63
(SD= 3.50). post scores: CaseM= 14.29
(SD= 4.14), MET/CBT= 15.59 (SD= 4.44),
ContM= 15.82 (SD= 4.54),
MET/CBT+ContM= 15.71 (SD= 3.32)
3. F-value= 1.37 (NS) (between groups)
4. NR
1. (Reported by Litt77) mean coping strategies score
2. Pre scores: CaseM-9= 2.16 (SD= 0.47),
CBT/MET-9=2.05 (SD= 0.48), vouchers= 2.14
(SD=0.51), CBT/MET-9CBT/MET-9/vouchers=2.18
(SD=0.47). Post scores: CaseM-9=2.45
(SD=0.63), CBT/MET-9=2.50 (SD=0.61),
vouchers=2.46 (SD=0.61), CBT/MET-9CBT/MET-9/
vouchers=2.58 (SD=0.62)
3. F-value= 0.48 (NS) (between groups), significant
effect of time (p< 0.001, BL to 14 months)
4. NR
1. (Reported by Litt77) mean readiness to
change score
2. Pre scores: CaseM-9= 65.56 (SD= 25.14),
CBT/MET-9= 65.84 (SD= 26.1),
vouchers= 70.27 (SD= 24.54), CBT/MET-
9CBT/MET-9/vouchers= 65.29 (SD= 26.89).
Post scores: CaseM-9= 83.81 (SD= 36.19),
CBT/MET-9= 91.79 (SD= 33.38),
vouchers= 90.83 (SD= 30.49), CBT/MET-
9CBT/MET-9/vouchers= 81.02 (SD= 32.67)
3. F-value= 1.04 (NS) (between groups)
4. NR
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Author and
year
Motivation to change (1) outcome measure, (2) absolute values (mean/median, SD/SE),
(3) p-values (groups/baseline), (4) between group difference and CI
Post treatment
Litt 201347 1. Readiness to change action subscale
2. NR
3. p< 0.001 (BL to post treatment). NS differences by treatment
4. NR
7 weeks
Stephens 200751 1. RCQ (RTC)
2. NR
3. No significant difference between groups (p-values NR). Overall, greater efforts at making changes at
7 weeks than initial assessment on RTC action subscale (p=0.004)
4. NR
3 months
Tossmann 201161 1. Use-related self efficacy
2. Internet-based counselling= 51.1 (SD= 45.0), wait list= 43.3 (SD= 39.0)
3. p< 0.001 (between group)
4. NR
BL, baseline; CASUAS, Cannabis and Substance Use Assessment Schedule; ContM, contingency management;
MDS, Marijuana Dependence Scale; NR, not reported; NS, not significant; RTC, readiness to change; URICA, University of
Rhode Island Change Assessment Scale.
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Author and year
Attendance/compliance/dropout rates (1) outcome measure, (2) absolute
values (mean/median, SD/SE), (3) p-values (groups/baseline), (4) between
group difference and CI, (5) time point
Babor 200439 and Litt 200572
(secondary)
1. Mean number sessions attended
2. MET-2= 1.6 of 2. CBT/MET/CaseM-9= 6.5 of 9
3. NR
4. NR
5. End of treatment
1. % attending all sessions
2. MET-2= 71.9%, CBT/MET/CaseM–9= 47.0%
3. NR
4. NR
5. End of treatment
Baker 200652 Cannabis subgroup: NR all participants:
1. Number treatment sessions attended
2. CBT/MI-10+ TAU: 88% attended some or all, 71% attended all 10 (TAU: N/A)
3. N/A
4. N/A
5. 10 weeks
Bonsack 201166 1. Attendance at sessions
2. 5.13 of 6 CBT/MI-6+ TAU sessions over first 6 months; four participants received
between 7 and 12 sessions; two participants received only three sessions
3. NR
4. NR
5. 6 months
Budney 200040 1. Participants attending more than one session
2. CBT/MET-14/vouchers= 100%, CBT/MET-14= 95%, MET-4= 85%
3. Chi-squared statistic= 1.3 (NS)
4. NR
5. End of treatment
1. Treatment retention (participants attending > one sessions and providing one
urine sample during the final 2 weeks)
2. CBT/MET-14/vouchers= 55%, CBT/MET-14= 65%, MET-4= 45%
3. Chi-squared statistic= 1.6 (NS)
4. NR
5. End of treatment
Budney 200641 1. Number treatment sessions attended
2. CBT-14/vouchers= 9.6 of 14; CBT-14= 8.8 of 14
3. p= 0.50
4. NR
5. 14 weeks
1. Number of weeks retained in treatment
2. CBT-14/vouchers= 10.7 of 14; CBT-14= 9.3; vouchers= 9.5
3. p= 0.57
4. NR
5. 14 weeks
Copeland 200153 1. Likelihood in participating in follow-up
2. Overall 170/229 (74.2%) had follow-up data (% per group NR)
3. No difference between groups (p-values NR)
4. NR
5. Median 34 weeks after last treatment
1. Number treatment sessions attended
2. CBT-6=mean 4.2 out of 6, 50% attended all 6; MI-1, 87.8% attended the
session, overall 69.4% participants attended the sessions they were
randomised to
3. NR
4. NR
5. NR
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Author and year
Attendance/compliance/dropout rates (1) outcome measure, (2) absolute
values (mean/median, SD/SE), (3) p-values (groups/baseline), (4) between
group difference and CI, (5) time point
de Dios 201243 1. Attendance at sessions
2. 100% (n= 22) attended first session, 73% (n= 16) attended second session
3. NR
4. NR
5. End treatment
Edwards 200654 1. Number of sessions attended
2. CBT/MI-10+ TAU: mean= 7.6, SD= 2.8, psychoducation
(non-cannabis)–10+ TAU: mean= 8.4, SD= 2.5
3. p= 0.20 (between group)
4. NR
5. N/A
Gates 201255 1. Average sessions attended
2. 3.25 (SD= 1.2) of 4
3. NR
4. NR
5. End of treatment
Hjorthoj 201368 and Hjorthoj 201280 1. Attendance at sessions
2. Average attendance: 16/24 sessions. Attendance at zero sessions: n= 3 (5.8%),
attendance at least right sessions: 77% (n NR)
3. NR
4. NR
5. End treatment
Hoch 201259 and Hoch 200876 1. Retention in treatment
2. 86% retained in treatment
3. NR
4. NR
5. End treatment
Hoch 201460 1. Participants completing 10 sessions (not clear that completed all 10)
2. CBT/MET/PPS-10: 166/255 (65%)
3. NR
4. NR
5. End treatment
Humeniuk 201271 1. 100% received brief MI-1 or wait list
Jungerman 200763 1. Attendance at all four sessions
2. CBT/MI/RP-4 (1 month)= 86%, CBT/MI/RP-4 (3 months)= 67%
3. NR
4. NR
5. 4 months
Kadden 200744 and Litt 200877 1. Mean number sessions attended
2. 5.2 out of 9 (over all groups)
3. No difference (p> 0.36)
4. NR
5. Post treatment (2 months)
Kay-Lambkin 200957 1. Average number sessions attended (all participants)
2. CBT/MI-10=8.71 of 10 (SD=2.74), computer-delivered CBT/MI+brief therapist-10=
7.61 of 10 (SD=2.87)
3. p= 0.20 (between group)
4. NR
5. End treatment
1. Participants attending all allocated sessions (all participants)
2. CBT/MI-10= 78% (n=18), computer-delivered CBT/MI+brief therapist-10=52%
(n=12)
3. p= 0.122
4. NR
5. End treatment
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Author and year
Attendance/compliance/dropout rates (1) outcome measure, (2) absolute
values (mean/median, SD/SE), (3) p-values (groups/baseline), (4) between
group difference and CI, (5) time point
Kay-Lambkin 201158 1. Mean number sessions attended (all participants)
2. CBT/MI-10= 6.1, computer-delivered CBT/MI+ brief therapist-10= 5.3,
PCT-10= 5.4
3. p= 0.353
4. NR
5. End treatment
1. Percentage attending all sessions (all participants)
2. CBT/MI-10= 34% (30/88), computer-delivered CBT/MI+brief therapist-10=
30% (29/97), PCT-10=30% (27/89)
3. NR
4. NR
5. End treatment
Lee 201346 1. Attendance at session in person
2. 58/106 (55%)
3. N/A
4. N/A
5. Treatment
1. Attendance at session in person or mailed personalised feedback
2. 90/106 (85%)
3. N/A
4. N/A
5. Treatment
Litt 201347 and Litt 201347 1. Mean number attended sessions (of nine)
2. CBT/MET-9/vouchers (homework)= 5.7 (SD= 3.5), CBT/MET-9/vouchers
(abstinence)= 5.5 (SD= 3.8), CaseM-9= 6.0 (SD= 3.5)
3. p> 0.75
4. NR
5. End treatment
1. Completion of treatment assignments
2. CBT/MET-9/vouchers (homework)= 50.2%, CBT/MET-9/
vouchers (abstinence)= 31.7%
3. p< 0.01 (between groups)
4. NR
5. End treatment
Madigan 201369 1. Received intervention
2. CBT/MI-12 (group): 27/59 received intervention (remainder declined).
TAU: 100% received
3. NR
4. NR
5. 3 months
Rooke 201370 1. Number of modules completed
2. Internet-based CBT/MI-6: 3.5 of 6, internet-based written cannabis
information NR
3. NR
4. NR
5. End of treatment
Stein 201148 1. Attendance at MI sessions
2. Receiving two sessions= 131 (80%), receiving one session= 16 (10%), receiving
0 sessions= 16 (10%)
3. NR
4. NR
5. End of treatment
Stephens 199449 1. Difference in attendance rates
2. NR per group (across groups, mean number of sessions attended= 7.6 of 10;
attendance at >= seven sessions= 69%
3. NS
4. NR
5. End treatment
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Author and year
Attendance/compliance/dropout rates (1) outcome measure, (2) absolute
values (mean/median, SD/SE), (3) p-values (groups/baseline), (4) between
group difference and CI, (5) time point
Stephens 2000,50 Lozano 200678
and DeMarce 200579
1. Average sessions attended
2. CBT/RP/social support-14= 8.42 of 14
3. NR
4. NR
5. 18 weeks
1. Attendance at >= 10 OF 14 RPSG sessions
2. CBT/RP/social support-14; 50%
3. NR
4. NR
5. 18 weeks
1. Attendance at both IAI sessions
2. 86% (n= 76)
3. NR
4. NR
5. 1 month
Stephens 200751 1. Likelihood of attending single treatment session
2. MI/personalised feedback-1 89%, cannabis education-1 94%
3. NR
4. NR
5. 1 week
Tossmann 201161 1. Dropout of QTS group
2. 503/863 randomised but declined participation, 183/360 discontinued
intervention before end of 50-day period
3. NR
4. NR
5. NR
CaseM, case management; IAI, individualised assessment and intervention; N/A, not applicable; NR, not reported;
NS, not significant; QTS, quit the shit; RPSG, relapse prevention support group.
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Appendix 5 Patient and public involvement:
service user briefing document
 
CANNABIS PROJECT INTRODUCTORY DOCUMENT 
 
· What research are we undertaking? 
We are looking to see if psychotherapy treatments (like CBT) are good at treating people who 
are addicted to cannabis. 
 
· How are we doing the research? 
We are undertaking what is called a “systematic review”, which means that we are looking at 
all the research that has been undertaken in this area and summarising all the results. This 
allows us to say whether or not the treatment works.  We are not actually treating patients, we  
are just looking at research that has already been done. 
 
· Why are we doing this research? 
Currently there are lots of ways of treating people for cannabis addiction – we do not know 
which is best. This review will allow us to understand which treatment is the best at reducing,  
or stopping, cannabis usage for people who regularly use cannabis. 
 
· How is a systematic review undertaken? 
o First we develop a document which describes how we are undertaking the systematic 
review – this is called the ‘protocol’.  Because there has been so much research in 
this area, we have to narrow down what we are going to look at. In the protocol 
document, we describe the treatments we are going to look at and the measures by 
which the treatments will be assessed. We also describe how we are going to locate 
the previous research. 
o We then search for all the research that has been done in this area.  
o The research is summarised, and the results from all the different studies are bought 
together. 
o We then write up the research and describe what we have found, in a ‘report’. 
 
· What input will we need from you, the service user? 
We will show you sections of the protocol and report. We will describe what is written and 
ask you if you have any thoughts on it – don’t worry if you don’t have anything to say, just 
say so. We are looking for anything that you think is important to add – don’t worry if you are 
not sure if it is relevant or important - any input we receive will be useful.  
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